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General introduction 
Based on: Cardiac angiotensin II: an intracrine hormone? Am J Hypertens. 2002; in press 
Chapter I 
Clinical and experimental data obtained with renin-angiotensin system (RAS) blockers show 
that their beneficial effects on cardiac structure and function are independent, 1.2 at least in part, 
of their blood pressure lowering effects. It has therefore been suggested that 
angiotensin (Ang) II is synthesized locally in the heart, independently of its generation in the 
circulation. Such local synthesis may occur in the interstitial space, on the cell surface or 
within cardiac cells lf.igure I). It is still highly controversial to what degree all components 
required for local Ang II generation are actually produced in the heart. In this chapter we 
briefly describe the most important effects of Ang II in the heart and then focus on its 
synthesis at cardiac tissue sites, in order to unravel whether Ang IT in the heart acts as an 
para-, auto- and/or intracrine hormone. 
Cardiac angiotensin II: its function 
Ang II is believed to be an important modulator of cardiac growth and function. It induces 
cell growth via stimulation of Ang II type I (AT,) receptors-"' In agreement with this concept, 
myocardial hypertrophy was observed in transgenic animals overexpressing AT 1 receptors on 
cardiomyocytes,S-7 and diminished left ventricular remodeling occurred after myocardial 
infarction in AT1 receptor knockout mice.8 However, not all studies in transgenic animals 
agree on this matter. For instance, the pressure overload-induced cardiac hypertrophy in AT, 
receptor knockout mice was not different from that in wildtype mice/ indicating that in this 
model AT 1 receptor-mediated Ang IT signaling is not essential for the development of 
hypertrophy. Furthermore, in mice overexpressing AT1 receptors on cardiomyocytes, cardiac 
hypertrophy was either already present at birth, thereby resulting in prenatal lethality,' or 
started after 6 weeks only, and then led to early death due to development of heart failure.' A 
detailed analysis of the degree of AT1 receptor stimulation (i.e., of the cardiac Ang II levels) 
in utero and after birth, and of the efficiency of the Ang II-induced activation of signaling 
pathways in the two mice strains that were applied in these overexpression studies will help to 
explain why AT, receptor-dependent cardiac hypertrophy occurs either at an early or a late 
stage. 
Stimulation of Ang II type 2 (AT2) receptors is believed to inhibit cell growth,'"-'•" 
although a recent study in AT 2 receptor knockout mice demonstrated that AT 2 receptors are 
essential for the development ofleft ventricnlar hypertrophy in Ang II-induced hypertension." 
Similarly conflicting data have been obtained with regard to apoptosis. In cnitured vascular 
smooth muscle cells14 and fibroblasts15 AT2 receptor activation results in apoptosis, whereas in 
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cardiomyocytes apoptosis is attributed to AT 1 receptors. 16•17 In support of the latter, apoptosis 
was unaltered in hearts of mice overexpressing AT 2 receptors on cardiomyocytes,18 and AT 1 
receptor blockade reduced the number of apoptotic cells in spontaneously hypertensive rats.17 
Thus, the respective roles of AT1 and AT2 receptors with regard to the effects of Ang II on 
cardiac growth and apoptosis are at present not entirely clear and may differ both between 
cells and species. 
The receptor responsible for the effects of Ang II on cardiac contractility is less 
controversial. Both the positive and negative inotropic effects of Ang II are mediated via AT 1 
receptors,19"21 either directly or indirectly, via facilitation of norepinephrine release from 
noradrenergic nerve endings.Z2·z.~ Furthermore, the Ang IT-induced positive chronotropic 
effects are also mediated via AT1 receptors.25 AT2 receptors may counteract the latter effect, 
since Ang II infusion in transgenic mi,ce overexpressing AT 2 receptors on cardiomyocytes 
resulted in bradycardia," 
Finally, it is generally accepted that Ang II constricts coronary arteries exclusively via AT, 
receptors.27,:zg Although studies with coronary arteries29 did not support a role for AT2 
receptors in Ang IT-mediated vasoactive effects, recent in-vivo studies30,31 have shown that 
AT 2 receptors antagonize AT 1 receptor-dependent vasoconstriction, thus suggesting that AT 2 
receptors induce vasodilation in the coronary vascular bed. 
Cardiac angiotensin II: its generation 
Renin 
In agreement with the virtual absence of renin mRNA in the heart under normal and 
pathological conditions/2.33 renin could not be demonstrated in myocardial tissue of 
nephrectomized animals.34.35 Cardiac renin is therefore most likely kidney-derived.33"35 Renin 
diffuses into the interstitial space/6-38 and may bind to renin receptors on the cell surface.39 
These receptors, one of which is the mannose 6-phosphate/insulin-like growth factor II 
(M6PIIGFII) receptor, do not appear to make a distinction between renin and its inactive 
precursor, prorenin. Remarkably, (pro)renin binding to M6PIIGFII receptors on 
cardiomyocytes is followed by rapid internalization and, in the case of prorenin, proteolytic 
activation to renin,40 thus providing a basis for intracellular angiotensin generation. 
The above in-vivo data contrast with studies demonstrating renin by Western blot in 
cultured, serum-deprived cardiomyocytes.41 '42 There are several explanations for this 
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discrepancy. Cultured cardiac cells may not be representative for cardiac cells in vivo, the 
cells may have sequestered (pro )renin from the serum-containing medium during culturing," 
or the antibodies may have recognized renin-like enzymes like cathepsin. In support of the 
latter, using a specific rat renin inhlbitor, we were unable to demonstrate renin-dependent 
Ang !-generating activity in neonatal rat cardiomyocytes,43 while Katz et al.44 recently showed 
that cathepsin Dis fully responsible for Ang I generation in adult rat cardiomyocytes. Finally, 
the renin demonstrated by Western blot could represent a recently discovered second renin 
transcript that lacks the coding sequence for the prefragment" (i.e., that cannot be targeted to 
the secretory pathway and thus remains intracellular). This renin is expressed in rat hearts,45 
although it is currently not !mown whether it is catalytically active. 
Angiotensinogen 
The lack of angiotensinogen release from the isolated perfused rat heart"·" and the high 
correlation between myocardial and plasma angiotensinogen levels,4S both under normal and 
pathological conditions, strongly suggest that myocardial angiotensinogen is largely blood~ 
(and thus liver-) derived. Myocardial angiotensinogen levels, expressed per g tissue, are 
within the range expected based on the assumption that plasma angiotensinogen diffuses 
freely into the interstitial compartment.:>4·47.49 The rise in renin in the infarcted and failing heart 
may explain why cardiac angiotensinogen under these conditions decreases rather than 
increases. In vitro, cardiomyocytes have been reported to release angiotensinogen,41•42 
although not all investigators confirmed this finding.43.so Moreover, cardiac angiotensinogen 
mRNA levels are low or undetectable.51 Taken together therefore, local synthesis of 
angiotensinogen contributes marginally, if at all, to cardiac angiotensinogen levels. 
Unlike renin, angiotensinogen does not bind to cardiac membranes,34.39 nor has evidence 
been obtained to support angiotensinogen internalization." These findings, combined with the 
fact that angiotensinogen-synthesizing cells normally release angiotensinogen into the 
medium, without storing it intracellularly,53.54 suggest that angiotensinogen is restricted to the 
extracellular compartment. Without intracellular angiotensinogen, neither the alternative renin 
transcript mentioned above nor internalized activated prorenin may have a functional role. In 
support of this concept, evidence for intracellular Ang ll generation in rat hepatoma cells was 
only obtained following transfection of the cells with a mutated angiotensinogen eDNA that 
produces a nonsecreted form of angiotensinogen.55 
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Chapter I 
ACE and chymase 
Cardiac ACE is not limited to endothelial cells. Particularly under pathological conditions 
ACE has also been shown on cardiomyocytes, macrophages and fibroblasts." Although it is 
well accepted that ACE is a membrane-associated enzyme, the question arises whether ACE 
might also act intracellularly. Dostal et al.57 reported intensive staining for ACE protein in the 
perinuclear region of rat cardiomyocytes. This finding, however, does not necessarily imply 
that ACE contributes to intracellular Ang TI production; it may simply illustrate ACE 
synthesis in cardiomyocytes:t> Normally, ACE is directed to the ~ell membrane/8 where it is 
anchored with its active domain located extracellularly. Beldent et al.58 were unable to 
measure ACE activity in the cytosol. Furthermore, ACE inhibition did not affect stretch-
induced release of Ang IT from intracellular storage sites in cardiomyocytes,S0 suggesting that 
these Ang II storage sites do not depend on intra- (or even extra-) cellular ACE. In contrast, 
enalaprilat blocked the decrease of junctional conductance induced by intracellularly-applied 
Ang I in rat cardiomyocytes.59 However, the latter may have been due to a nonspecific effect 
of enalaprilat, since the ACE inhibitor also affected conductance in hamster cardiomyocytes 
in the absence of Ang I. 60 
Finally, in-vitro studies in cardiac homogenates have provided ample evidence for Ang I-II 
conversion by a serine protease, chymase.61 Remarkably, however, chymase is stored in mast 
cells and it is therefore unlikely that chymase is a contributor to Ang TI production by 
cardiomyocytes. Moreover, although its in-vivo importance still needs to be investigated, 
at-antitrypsin acts as an endogenous inhibitor of any chymase that is released into the 
interstitium.6~·63 Thus, it is not surprising that studies applying Ang I to the interstitium of 
intact dog and rat hearts observed ACE-dependent Ang I-II conversion only."·" 
Angiotensin I and II 
The presence of both renin and angiotensinogen in cardiac tissue allows local angiotensin 
production in the heart. Indeed, studies using systemic infusions of 125I-labeled Ang I to 
correct for uptake from plasma, have demonstrated that the majority of cardiac Ang I and II is 
not derived from the circulation, but is synthesized locally.34.66.67 The most likely site for 
cardiac Ang I production is the interstitial space. First, as discussed above, there is little 
evidence for the intracellular presence of angiotensinogen and ACE. Second, both in-vitro and 
in-vivo studies have shovm that cardiac Ang I, unlike cardiac Ang II, is present in 
extracellular fluid only.47•67 Thus, renin and angiotensinogen may either react in the interstitial 
fluid or, in the case of membrane-bound renin, on the cell surface. Membrane-associated renin 
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displays increased catalytic activity as compared to soluble renin.68 Ang I generated on the 
cell surface by renin may be rapidly converted to Ang II by membrane-bound ACE, and such 
efficient local Ang II generation might explain why similar Ang II-mediated effects are 
observed during application of Ang ll, Ang I or renin combined with angiotensinogen to 
coronary arteries and cardiomyocytes, despite the fact that the extracellular Ang ll levels 
required to induce effects during the latter two applications are 100-fold lower than during 
Ang n application.29•69 
Support for intracellular 
Ang II synthesis is derived 
from studies reporting that 
Angii is present in 
cardiomyocytes,57•70•71 that 
intracellularly applied Ang II 
exerts effects,59'60'72 and that 
eultured cardiomyocytes 
release Ang n into the 
medium. 42.so.73 How should 
this be reconciled with the 
above line of reasoning on 
extracellular Angl 
generation? First, Ang IT is 
internalized via AT r receptor-
mediated endocytosis74 and 
this may explain its 
intracellular presence. 1n fact, 
most or all tissue Ang II is 
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Figure 2. Angiotensin !I levels in whole heart in vivo (black bars) 
and in cultured myocytes (open bars) under control conditions. 
cell-associated, suggesting that if Ang n is generated extracellularly, it is immediately 
internalized via AT1 receptors,36·67•75 for instance because ACE and ATr receptors are 
colocalized." Second, at least part of the Ang II-mediated effects depend on internalization of 
the Ang ll-AT1 receptor complex17 and thus it is not surprising that cytosolic application of 
Ang n, via binding to internalized AT receptors, may exert effects. The mere fact that 
intracellularly applied Ang II exerts effects, of course, does not prove that Ang ll is 
synthesized in the cell. Third, the question arises whether internalized Ang II can be released 
again. This could explain the stretch-induced release of Ang II that has been demonstrated by 
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some/0'78 but not all investigators.43 In vivo, internalized Ang II disappears with a half-life of 
10-15 min, in full agreement with the concept of lysosomal degradation of internalized 
Ang IT." In cultured cardiomyocytes the Ang IT half-life is much longer' and thus, if the cells 
are loaded with Ang IT during their exposure to serum-containing (i.e. renin- and 
angiotensinogen-containing) medium this Ang IT might be released again in the absence of 
serum, in particular after stretch. However, Ang IT levels in serum43 are in the order of 
fmol/ml, and thus an argument against this concept are the exceptionally high Ang IT levels 
that have been demonstrated by some investigators71 ·78•79 in cardiomyocytes and 
cardiomyocyte-conditioned medium (Figure 2). Since the volume of a cardiomyocyte" is 
-25.000 J.Un3, it can be calculated, assuming that 1 ml volume corresponds with 
approximately 1 g weight," that cultured cardiomyocytes contain up to 250 pmol Ang IT 
per g"'-'"-'7•70·" (Figure 2) and secrete 0.2-15 pmol Ang ll!g per hour'"-" during basal conditions. 
This is several orders of magnitude higher than the Ang IT levels reported in myocardial tissue 
in vivo""'" (Figure 2). Not all studies, however, reported such high levels"·" and part of this 
discrepancy may be due to the fact that angiotensins were measured by direct 
radioimmunoassay (i.e., without prior purification and/or separation from material 
crossreacting with the Ang I and Ang IT antibodies applied in these assays). 
Transgenic experiments 
Male transgenic rats with liver-specific overexpression of rat prorenin (resulting in a 500-fold 
rise in plasma prorenin) displayed severe cardiac hypertrophy."' This hypertrophy occurred in 
the absence of hypertension or a rise in plasma renin activity, in agreement with the concept 
that circulating prorenin, following its uptake in the heart, is capable of exerting toxic effects 
locally. Unfortunately, this study did not address cardiac prorenin-renin conversion or 
circulating (pro)renin-induced angiotensin generation in cardiac tissue. Prescott et al.84 
investigated the latter by mating transgenic mice that release human active renin from the 
liver with transgenic mice expressing human angiotensinogen in the heart Double-transgenic 
mice displayed cardiac fibrosis and a substantial rise in the cardiac content of both Ang I 
and IT, without a change in the circulating levels of these peptides. These data are therefore 
direct evidence that circulating renin contributes to the synthesis of functionally important 
Ang IT in the heart. 
Further support for Ang n generation at cardiac tissue sites comes from studies in 
transgenic mice overexpressing rat angiotensinogen in cardiomyocytes. Hs Plasma angiotensin 
levels were not altered in these mice, whereas cardiac Ang I and n were 4- and 2-fold 
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elevate~ respectively, as compared to control mice. Importantly, both ACE inhibition and 
AT1 receptor blockade prevented or normalized ventricular hypertrophy in the transgenic 
mice, confirming that the angiotensinogen-induced effects depend on ATt receptor 
stimulation by Ang II. 
Finally, although transgenic rats overexpressing cardiac ACE 40-fold had normal Ang II 
levels,H6 such overexpression did result in cardiac hypertrophy and fibrosis.H7 These data 
therefore confirm that cardiac ACE is not rate-limiting for Ang II generation, and suggest that 
interference with other ACE substrates (e.g., bradykinin) may underlie the functional 
consequences of cardiac ACE overexpression. 
Remarkably, in contrast with the studies supporting a growth-stimulatory role for Ang II 
released from cultured cardiomyocytes,50•79 transgenic mice expressing an Ang IT-producing 
fusion protein in cardiomyocytes did not develop cardiac hypertrophy.'" Although 
intracellular cleavage of the fusion protein by furin led to Ang II secretion into the interstitial 
space, thereby raising cardiac Ang II 20- to 40-fold, the authors only observed a modest 
fibrosis in the hearts of these transgenic mice. Cardiac hypertrophy did occurr when replacing 
Ang II by a degradation-resistant analogue that resulted in much higher cardiac Ang II levels 
(>600-fold higher) and subsequent Ang II overflow into the circulation. These data suggest 
that extracellular production of Ang II, for instance on the cell surface in the innnediate 
vicinity of AT 1 receptors by membrane-bound renin and ACE, is much more efficient than 
intracellular Ang II synthesis, since Ang II-dependent cardiac remodeling in non-transgenic 
animals occurs at cardiac Ang II levels that are maximally 2- to 3-fold elevated as compared 
to control.H9-91 
References are presented in the general reference list. 
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Aim of the thesis 
Whether cardiac Ang IT generation occurs in an auto-, para-, or intracrine manner as well as 
whether Ang II stimulation of the AT 2 receptor mediates vasodilation, has not yet been 
thoroughly investigated. Therefore, we performed in-vivo studies in rats and pigs and in-vitro 
studies in porcine isolated vessels with the following aims: 
1. To study the vasoactive role of AT2 receptors under normal and pathological conditions, 
as well as to investigate which vasodilator compounds counterbalance Ang II -mediated 
vasoconstriction. 
2. To determine the site oflocal Ang II formation, and the enzyme(s) (ACE and/or chymase) 
involved in its generation. 
To address issue 1, we made use of the radioactive nricrosphere method under various 
conditions, which allowed us to measure blood flow in all organs of one animal. In normal 
anesthetized rats, blood flow was measured during Ang IT infusion in the absence or presence 
of antagonists at AT1 or ATz receptors (chapter 2) and following inhibition of nitric oxide 
synthase or cyclooxygenase (chapter 3 ). Shnilar studies were performed in rats 4 weeks after 
coronary artery ligation, i.e, at the time when ATz receptors are upregulated (chapter 4). To 
address issue 2, a detailed analysis of cardiac angiotensin generation was made in myocardial 
infarcted pigs with and without RAS blockade (chapter 5). Interstitial Ang I and Ang II levels 
were measured in porcine hearts in vivo, using the microdialysis technique, (chapter 6) and in 
isolated porcine arteries (chapters 7). Finally, the enzyme responsible for interstitial 
Ang I-to-Ang ll conversion was determined using a modified version of the rat Langendorff 
heart, which allows separate collection of coronary effluent and interstitial fluid (chapter 8). 
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No vasoactive role of the angiotensin II type 2 
receptor in normotensive Wistar rats 
J Hypertens. 1999; 17: 1879-1884 
Chapter 2 
Summary 
To investigate the vasoactive consequences of angiotensin (Ang) II type 2 (ATz) receptor 
stimulation in vivo, three consecutive 10-min intravenous infusion of Ang II (100, 300 and 
1000 ng/kg!min) were given to 20 pentobarbital-anesthesized normotensive Wistar rats 
(weight 330±6 g, mean±SEM). The rats bad been pretreated with saline (1F8), the 
Ang II type I (AT1) receptor antagonist, irbesartan (100 fig/kg/min for 30 min, 1F6), or the 
AT, receptor antagonist, PD123319 (20 fig/kg/min for 30 min followed by continuous 
infusion throughout the entire experiment, n=6). Regional hemodynamic effects of Ang II 
were studied using the radioactive microsphere method. Ang II increased mean arterial blood 
pressure (MAP) and heart rate by maximally 44±9 and 26±6%, respectively (P<O.OS 
compared with baseline), and decreased cardiac output and systemic vascular conductance 
(=cardiac outpuVMAP) by maximally 24±8 and 47±4%, respectively (P<O.OS compared with 
baseline). The Ang IT-induced decrease in systemic vascular conductance was caused by 
decreases in vascular conductances (regional flow/MAP) of the gastrointestinal tract (52±4%), 
JQdney (63±3%), skeletal muscle (39±8%), sJQn (63±4%), mesentery+pancreas (32±11%), 
adrenal (27±11 %) and spleen (57±6%) (all P<0.05 compared with baseline). lrbesartan 
increased baseline vascular conductances in adrenal, brain and JQdney, and inhibited all 
hemodynamic responses induced by Ang II. PD123319 affected neither baseline values, nor 
the Ang IT-induced hemodynamic responses. In conlusion, Ang II-induced systemic and 
regional hemodynamic effects in normotensive Wistar rats are mediated exclusively via AT 1 
receptors. No evidence for AT2receptor-mediated vasoactive responses was obtained. 
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Introduction 
Angiotensin (Ang) II, the active end-product of the renin-angiotensin system, is a potent 
vasoconstrictor with growth-promoting properties. Its effects are mediated by specific 
receptors, of which two major subtypes, termed AT 1 and AT 2 have been characterized to 
date." The AT1 receptor subtype appears to mediate essentially all of the known effects of 
Ang II, including the mentioned above; a physiological role for the AT 2 receptor has not yet 
been clearly established. Initially it was believed that this receptor existed in fetal tissue only 
and that it disappeared after birth.93-95 However, more recent studies support its existence in 
adult animals also. 96-101 On the basis of its abundant presence in fetal animals, it has been 
speculated that the AT2 receptor is involved in the regulation of growth and development. 
Indeed, in isolated cells, AT2 receptor stimulation results in growth inhibition and 
apoptosis/·15'102 thereby antagonizing the growth-stimulatory effects that are mediated via ATr 
receptors. 
AT2 receptor knockout mice display a significant increase in blood pressure or an 
increased sensitivity to the pressor action of Ang II, or both,103•104 which suggests that AT2 
receptors may cause vasodilation. In support of this concept, Arima et a/. 105 and Endo et a/. 106 
demonstrated AT2 receptor-dependent vasodilation in isolated microperfused rabbit afferent 
and efferent glomerular arterioles. In the intact rat however, AT2 receptor-mediated blood 
pressure decreasing effects have not been found by all investigators;107"111 indeed, in some 
cases, AT2 receptor-mediated increases in blood pressure were reported.w-113 These 
discrepancies may be explained by the short half-life of PD123319,'" (the AT2 receptor 
antagonist that was applied in most studies), in-vivo biotransformation of PD123319 to a 
metabolite with AT 1 receptor antagonist properties, 113 or displacement of non-specifically 
bound AT 1 receptor antagonist by AT 2 receptor antagonists in studies where both types of 
receptors were combined. 112 
It was our aim in the present study to investigate the systemic and regional hemodynamic 
effects of AT2 receptor stimulation in the rat, using the radiolabeled microsphere method. 115•116 
Injection of rad.iolabeled microspheres, which are trapped in end-arterioles because of their 
size, allows one to obtain detailed information on the regional hemodynamic effects of 
Ang II, both in the presence and absence of AT receptor antagonists. By using microspheres 
with different isotope labels it is possible to perform several measurements in one animal. Our 
working hypothesis was that Ang II causes vasorelaxation via AT2 receptors and 
vasoconstriction via AT1 receptors. Consequently, we expected enhanced vasoconstrictor 
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responses to Ang II in rats that were pretreated with the ATz receptor antagonist, PD123319, 
and vasodilator responses to Ang ll in animals that were pretreated with the AT 1 receptor 
antagonist, irbesartan. 
Materials and Methods 
General procedures 
All experiments were performed in accordance with the 'Guiding Principles in the Care and 
Use of Animals' approved by the American Physiological Society and under the regulation of 
the Animal Care Committee of the Erasmus University Rotterdam, Rotterdam, The 
Netherlands. Experiments were carried out in 28 male Wistar rats (body weight: 331±5g, 
mean±SEM) obtained from Harlan, Zeist, The Netherlands. Animals were anesthetized with 
an intraperitonial injection of sodium pentobarbital (60 mg/kg; Apharma, Amhem, The 
Netherlands). To maintain an adequate depth of anesthesia, intravenous bolus injections of 
sodium pentobarbital (5-1 0 mg/kg) were administered via the right external jugular vein every 
15 min during the stabilization period. A catheter was placed in the trachea for intermittent 
positive pressure ventilation with a mixture of oxygen and air, using a ventilatory pump 
(Small Animal Ventilator, Harvard Apparatus, Natick, MA, USA). The ventilatory rate was 
adjusted to keep arterial blood gases within the physiological range. Blood pressure and heart 
rate were recorded with a pressure transducer (Combitrans Disposable Pressure Transducer, 
Braun, Melsungen, Germany) in the left femoral artery. Radioactive microspheres were 
injected into the left ventricle via a catheter in the right carotid artery. Drugs were 
administered via the right external jugular vein. The right femoral artery was cannulated to 
allow the withdrawal of reference blood samples. 
Experimental protocol 
After a 1-h stabilization period after completion of instrumentation, the animals were given a 
30-min infusion of the AT1 receptor antagonist, irbesartan (100 fig/kg/min; n=6), the AT2 
receptor antagonist, PD123319 (20 fig/kg/min; n=6) or vehicle (saline, 0.1 ml/min; n=S). 
Next, three consecutive 10 min infusions of Aog II (100, 300 and 1000 ng/kg!min) were given 
to each animal. At the end of each Ang II infusion, when a steady state had been reached, 
hemodynamic parameters were measured and the distribution of aortic blood flow was 
determined by injecting radioactive microspheres (see below). In view of the short half-life of 
PD123319,'" the administration of this dmg (20 fig/kg/min) was continued during the Aog II 
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infusions. Hemodynamic parameters and the distribution of aortic blood flow were also 
measured in rats that were pretreated with a 30-min infusion of vehicle and then given three 
consecutive 1 0-min infusions of vehicle. The results revealed and excellent stability of the 
preparation (n=8, data not shown), in agreement with previous studies.115 
Angiotensin II (ng/kg/min): 
CJ baseline ~ 100 
saline irbesartan PD123319 
lml 300 
:5 § 
.§. 
0 
" 
-1000 
saline irbesartan PD123319 
Figure 1. Effects of 10-min intravenous infusions of Ang II on mean arterial blood pressure (MAP), 
cardiac output (CO), heart rate (HR) and systemic vascular conductance (SVC) in anesthesized rats 
pretreated with saline (0.1 ml/min; n=8), irbesartan (100 IJQ/kg/min; rr.=:6) or P0123319 (20 IJQ/kg/min; 
n=6). Values are mean±SEM. Significant differences (P<0.05): ., compared with baseline, t compared 
with corresponding dose in saline-pretreated animals. 
Distribution of cardiac output 
The distribution of aortic blood flow was determined with 15.5±0.1 ~m diameter (mean±SD) 
microspheres labeled with 141Ce, 103Ru, ''Nb or 46Sc (NEN Dupont, Boston, MA, USA). For 
each measurement about 200,000 microspheres, suspended in 0.2 ml saline and labeled with 
one of the isotopes, were mixed and injected into the left ventricle over a 15-s period. After 
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each injection, the catheter was flushed thoroughly with 0.5 ml saline. Starting 10 s before 
microsphere injection and lasting 70 s, an arterial reference blood sample was drawn from the 
left femoral artery at a constant rate of 0.5 ml/min, using a withdrawal pump (Model 55, 
Harvard Apparatus). At the end of the experiment, the animal was killed with an overdose of 
pentobarbital and all tissues and organs were removed, weighed and put into vials. The 
following tissues were dissected: gastrointestinal tract, kidney, skeletal muscle, skin, 
mesentery+pancreas (for practical reasons, these two tissues were not studied separately), 
adrenal, brain, liver, heart, spleen and lungs. Lungs were not evaluated further, because the 
amount of radioactivity in these organs represents microspheres that have bypassed the 
peripheral vascular beds (via arteriovenous anastomoses with a diameter larger than that of 
the microspheres), rather than pulmonary flow.116 The radioactivity in the reference blood 
samples and the tissues was counted for 5 min in a ')'-scintillation counter (Packard, Minaxi 
Auto-Gamma 5000 series, Downers Grove, IL, USA), using suitable windows discriminating 
the different isotopes C41Ce: 120-167 KeY; 103Ru: 450-548 KeY; 95Nb: 706-829 KeY; 46Sc: 
830-965 KeY). 
Drugs 
Irbesartan was a kind gift of Bristol-Myers Squibb, Princeton, NJ, USA. PD123319 was a 
kind gift of Parke-Davis, Natick, MA, USA. Irbesartan (330 )lg/ml) was dissolved in 1.2 mM 
KOH as described by Trippodo eta!."' PDI233!9 (70 )lg/ml) andAng II (0.33, 0.99 and 3.30 
)lg/ml) were dissolved in saline. 
Data presentation and statistical analysis 
Data were processed as described previously.118 Cardiac output and regional blood flow were 
calculated as follows: 
amount of radioactivity injected x withdrawal rate of arterial blood sample 
cardiacou~ut =-----------------------------------------------------
radioactivity of arterial blood sample 
tissue radioactivity x cardiac output 
regional blood flow= 
amount of radioactivity injected 
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Systemic and regional vascular conductances (i.e., cardiac output and regional blood flow 
corrected for mean arterial blood pressure) were calculated to quantify the vasoconstrictor 
effects of Ang II with or without its receptor antagonists. 
All data are presented as mean±SEM. Duncan's new multiple range test was used to test 
differences from baseline when two-way ANOV A had revealed that differences existed 
between the consecutive infusions. Student's unpaired !-test was used to evaluate the effects of 
the AT receptor antagonists when two-way repeated measures ANOVA followed by 
Bonferroni's correction had revealed differences between the groups. Statistical significance 
was accepted at P<0.05 (two-tailed). 
Results 
Systemic hemodynamic effects 
Mean arterial blood pressure, cardiac output, heart rate and systemic vascular conductance 
were not affected by acute administration of irbesartan or PD123319 (Figure 1). Ang II 
increased mean arterial blood pressure and heart rate by maximally 44±9 and 26±6%, 
respectively (P<0.05 compared with baseline), and decreased cardiac output and systemic 
vascular conductance by maximally 24±8 and 47±4%, respectively (P<0.05 compared with 
baseline). lrbesartan reduced or abolished the effects of Ang II, whereas PD123319 did not 
affect any of the Ang IT-induced systemic hemodynamic responses. 
Regional hemodynamic effects 
Acute administration of irbesartan increased the vascular conductance in adrenal, brain and 
kidney. Regional vascular conductances were not affected by acute administration of 
PD123319 (Figure 2). Ang II decreased vascular conductance in gastrointestinal tract, kidney, 
skeletal muscle, skin, mesentery+pancreas, adrenal and spleen (by maximally 52±4, 63±3, 
39±8, 63±4, 32±11, 27±11 and 57±6%, respectively; all P<0.05 compared with baseline). No 
Ang IT-induced effects on vascular conductance were observed in brain, liver and heart. This 
was most probably because of the effects of autoregulatory compensatory mechanisms in 
these organs. Irbesartan reduced or abolished the effects of Ang II, whereas PD123319 did not 
affect any of the Ang 11-induced regional hemodynamic responses. 
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Discussion 
The findings of the present 
study does not support a 
systemic or regional 
vasoactive role for AT 2 
receptors; all hemodynamic 
responses observed were 
mediated exclusively via AT 1 
receptors. We observed 
neither enhanced 
vasoconstriction in response 
to Ang II during AT, 
receptor blockade with 
PDl23319, nor Ang II-
induced vasorelaxation 
during AT, receptor 
blockade with irbesartan. 
Thus, our results are not in 
agreement with the concept 
of a vasodilatory AT 2 
receptor, which has been 
proposed on the basis of AT 2 
receptor lmockout 
experiments in mice.103.104 
We used the radiolabeled 
microsphere method, because 
it allows one to obtain 
detailed in-vivo information 
on the regional 
hemodynamic effects of a 
Angiotensin II (nglkg/min): 
D baseflne ~ 100 m 3oo -1000 
saline irbesartan PD123319 saline irbesartan PD123319 
Figure 2. Effects of 10 min intravenous infusions of Ang II on regional vascular conductance in 
anesthesized rats pretreated with saline (0.1 mllmin; n=8), irbesartan (100 ].Jg/kg/min; n;;;;;6) or PD123319 
(20 IJg/kg/min); rr-6). Values are mean±SEM. Significant differences ([<0.05): *compared with 
baseline, t compared with corresponding dose in saline-pretreated animals, compared with baseline of 
saline-pretreated animals. 
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vasoactive peptide such as Ang II. Until now, this information was not available, because 
previous investigations were limited either to the systemic hemodynamic effects of Ang II, 107-
110 or to its effects in one particular vascular bed. 105•106 
The dose of PD123319 that was applied in the present study was sufficient to result in 
micromolar blood plasma concentrations of the agent114 - that is, concentrations that 
selectively block AT2 receptors. Higher doses have been reported to lead to concentrations 
that also interfere with AT1 receptors.'" PD123319 was infused throughout the entire 
experiment in view of its short in-vivo half-life. Munzenmaier and Greene109 and Obkubo et 
a!." have demonstrated that PD123319, when given in doses similar to those applied in the 
present study, blocks the growth-inhibitory effects that are mediated by AT2 receptors. Thus it 
is unlikely that insufficient AT 2 receptor blockade was the cause of our failure to observe an 
AT 2 receptor-mediated response. 
Are AT 2 receptors present in adult rats? Originally, it was believed that AT 2 receptors 
disappeared after birth,93-95 to return only under pathological conditions. 119't!o However, 
numerous studies have now established that these receptors are also normally present in the 
brain,96 kidney,105•121 hea.rf7•98 and vascular walP01 of adult rats. Moreover, AT2 receptors have 
been demonstrated in the heart and kidney of adult humans.99•100•1:n.123 Stimulation of AT2 
receptors in the kidney and the vascular wall results in the release of bradykinin, nitric oxide 
and cGMP101 •121 •124 - a mechanism that may well explain the vasorelaxation ascribed to this 
receptor. Remarkably, however, and in agreement with the present study, the AT2 receptor-
mediated increase in aortic cGMP levels found in stroke-prone spontaneously hypertensive 
rats was not accompanied by a reduction in blood pressure. 
Pretreatment with the AT 1 receptor antagonist, irbesartan, in a dose that is selective for 
AT 1 receptors, 125- 127 increased vascular conductance in the kidney, adrenal, and brain. This 
demonstrates the importance of endogenous Ang II as a regulator of vascular tone in 
anesthesized rats. Interestingly, in the spleen Ang II increased vascular conductance (i.e., it 
caused vasorelaxation) in the presence of irbesartan. This effect was not mediated via AT2 
receptors, as the Ang IT-induced effects with PD123319 were indistinguishable from those 
without PD123319. Possibly, vasorelaxant Ang-(1-7) receptors, stimulated by either Ang II or 
its metabolite, Ang-(1-7), were involved in this effect. 1 ~~ 
In agreement with previous findings, 129 Ang II increased heart rate via AT 1 receptors. 
Masaki et aU6 reported that overexpression of AT2 receptors in the mouse heart attenuated 
this AT1 receptor-mediated chronotropic response. We were unable to confirm this finding in 
the present study. 
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In conclusion, the Ang ll-induced systemic and regional hemodynamic effects in 
normotensive Wistar rats are mediated exclusively via AT1 receptors. No evidence for AT2 
receptor-mediated vasoactive responses was obtained during Ang II infusion. 
References are presented in the general reference list. 
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Prostanoids, but not nitric oxide, counterregulate 
angiotensin II mediated vasoconstriction in vivo 
Eur J Pharmacal. 2001; 428: 331-336 
Chapter 3 
Summary 
To evaluate the modulating effects of nitric oxide and prostanoids during angiotensin 
(Ang) IT-mediated vasoconstriction, male Wistar rats (n=25) were infused with increasing 
doses of Ang II following pretreatment with the cyclooxygenase inhibitor indomethacin, the 
nitric oxide-synthase inhibitor N" -nitro-L-arginine methyl ester (L-NAME) plus sodium 
nitroprusside to restore mean arterial blood pressure, or saline. Hemodynamics were studied 
with the radioactive microsphere method. Indomethacin did not alter systemic or regional 
hemodynamics. L-NAME + sodium nitroprusside reduced cardiac output, as well as systemic 
and renal vascular conductance. Ang II increased mean arterial blood pressure and heart rate, 
and decreased systemic vascular conductance as well as vascular conductance in 
gastrointestinal tract, kidney, skeletal muscle, skin, mesentery+pancreas, spleen and adrenal. 
Indomethacin enhanced the Ang IT-mediated effects in all vascular beds, whereas L-NAME + 
sodium nitroprusside enhanced its effect in mesentery+pancreas only. In conclusion, 
vasodilator prostanoids, but not nitric oxide, counterregulate Ang IT-mediated 
vasoconstriction in vivo. 
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Introduction 
Angiotensin (Ang) II induces vasoconstriction via stimulation of Ang II type 1 (AT,) 
receptors. Simultaneous vasodilation via stimulation of the Ang II type 2 (AT,) receptor''" 
may counteract this effect, although not all studies agree on this matter.m·132 In addition, 
vasodilator factors, such as nitric oxide (NO) and vasodilator prostanoids, may oppose the 
vasoconstrictor effects of Ang II. These factors are either released in response to 
vasoconstriction or via stimulation of ATt and/or ATz receptors on endothelial and vascular 
smooth muscle cells.133' 137 
In support of this concept, NO-synthase (NOS) inhibition enhanced Ang II-induced 
vasoconstriction systemically as well as in the carotid artery and kidney.107• 13~ However, 
studies with NOS inhibitors have to be interpreted with care, because of the persistent rise in 
blood pressure which occurs during NOS inhibition. Indeed, an enhanced effect of Ang II was 
not observed in the kidney when NO was normalized by application of a NO donor during 
renal NOS inhibition139-141 Furthermore, Ang IT infusion is accompanied by a rise in the levels 
ofprostacyclin and/or prostaglandin E2 in blood plasma133 and interstitial fluid. 134' 142 Receptor-
mediated release of such vasodilator prostanoids may explain why Ang II induces 
vasodilation in cerebraP43 and mesenteric144 arteries. However, Ang II also stimulates the 
release of vasoconstrictor prostanoids (e.g. thromboxane A2). 145 Moreover, the 
cyclooxygenase inhibitor indomethacin attenuated the blood pressure lowering effects of both 
captopril and losartan, suggesting that blockade of Ang II synthesis or AT 1 receptors is also 
accompanied by release of vasodilator prostanoids. 146 
In view of these discrepancies, it was the aim of the present study to investigate the role of 
NO and cyclooxygenase products in the Ang II-induced systemic and regional hemodynamic 
effects in vivo, using the radiolabeled microsphere method. 132 By measuring radioactivity of 
microspheres trapped in end-arterioles detailed information on systemic hemodynamics as 
well as regional hemodynamics in all organs can be obtained, thereby extending previous 
studies on this isssue that were either limited to the systemic hemodynamic effects of Ang II, 
or its effect in one particular vascular bed. 
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Materials and Methods 
Instrumentation and hemodynamic measurements 
All experiments were pexfonned in accordance with the "Guiding principles in the care and 
use of animals' approved by the American Physiological Society aud under the regulation of 
the Animal Care Committee of the Erasmus University Rotterdam, Rotterdam, The 
Netherlands. Experiments were carried out in male Wistar rats (body weight: 364±7 g, 
mean±SEM: n=25) obtained from Harlan, Zeist, The Netherlands. 
Animals were anesthetized with au intraperitoneal injection of sodium pentobarbital (60 
mglkg). To maintain au adequate depth of anesthesia, intravenous bolus injections of sodium 
pentobarbital ( 5-l 0 mglkg) were administered via the right external jugular vein every 15 min 
during the stabilization period. A catheter was placed in the trachea for intermittent positive 
pressure ventilation with a mixture of oxygen and air, using a respiratory pump (Small 
Animal Ventilator, Harvard Apparatus, Natick, MA, USA). The ventilatory rate was adjusted 
to keep arterial blood gases within the physiological range. Blood pressure and heart rate were 
recorded with a pressure transducer (Combitrans Disposable Pressure Transducer, Braun, 
Melsungen, Germany) in the left femoral artery. Radioactive microspheres were injected into 
the left ventricle via a catheter in the right carotid artery. Drugs were administered via the 
right external jugular vein. The right femoral artery was caunulated to allow the withdrawal of 
reference blood samples. 
After a 1-h stabilization period following completion ofinsttumentation, the animals were 
given a 30-min infusion of the cyclooxygenase inhibitor indomethacin (5 mg/kg; n=S), the 
NOS inhibitor 11"'-nitro-L-arginine methyl ester (L-NAME; 10 mglkg; n~S) followed by a 
continuous infusion of sodium nitroprusside at a rate required (approximately 4 J.lg/kg/min) to 
restore mean arterial blood pressure to baseline, or vehicle (saline, 0.1 mllmin; n=9). 
Next, three consecutive 10-min infusions of Ang II (100, 300 aud 1000 ng/kg/min) were 
given to each animal. Prior to the Ang II infusions (baseline) aud at the end of each Ang II 
infusion, when a steady state had been reached, hemodynamic parameters were measured and 
the distribution of aortic blood flow was determined by injecting 15.5±0.1 (mean±SD) J.lm 
diameter microspheres labeled with 141Ce, 103Ru, 9~ or 113Sn (NEN Dupont, Boston, :rv1A, 
USA). For each measurement about 200,000 microspheres, suspended in 0.2 ml saline aud 
labeled with one of the isotopes, were mixed and injected into the left ventricle over a 15-s 
period. Following each injection, the catheter was thoroughly flushed with 0.5 ml saline. 
Starting 10 s before microsphere injection and lasting 70s, an arterial reference blood sample 
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was drawn from the right femoral artery at a constant rate of 0.5 ml/min, using a withdrawal 
pump (Model 55, Harvard Apparatus, Natick, MA, USA). At the end of the experiment the 
animal was sacrificed with an overdose of pentobarbital and all tissues were removed, 
weighed and put into vials. The radioactivity in the reference blood samples and the tissues 
was counted for 5 min in a y-scintillation counter (Packard, Minaxi Auto-Gamma 5000 series, 
Downers Grove, IL, USA), using suitable windows discriminating the different isotopes. 
Lungs and heart were not evaluated, because the amount of radioactivity in the lungs mainly 
represents accumulation of microspheres that have bypassed the peripheral vascular beds,11 ~ 
whereas radioactivity in the heart represents both coronary flow and microspheres entrapped 
in the trabeculae during injection into the left ventricle. The latter may lead to fulsely high 
values of coronary flow,'" but will only marginally affect cardiac output (the sum of all tissue 
radioactivities) since it accounts for less than 2% oftotal body radioactivity. 
Drugs 
Indomethacin, L-NAME and sodium nitroprusside were obtained from Sigma (St. Louis, MO, 
USA) and Ang II was from Bachern Feinchemikalien AG (Bubendorf, Switzerland). 
Indomethacin (4 mg/ml) was dissolved in phosphate buffered saline (140 mM NaCl, 2.6 mM 
KCl, 1.4 mM KH,P04 and 8.2 mM Na,HPO•) containing 7 mM NaOH and titrated to pH 7.4 
with 6 M HCI. L-NAME (27 mg/ml), sodium nitroprusside (40 J.Lg/ml) and Ang II (0.33, 0.99 
and 3.30 J.Lg/ml) were dissolved in saline. 
Data presentation and statistical analysis 
Data were processed as described previously.118 Cardiac output and regional blood flow were 
calculated as follows: 
amount of radioactivity injected x withdrawal rate of arterial blood sample 
cardiac output~------------------------------------------------------
radioactivity of arterial blood sample 
tissue radioactivity x cardiac output 
regional blood flow ~ 
amount of radioactivity injected 
Systemic and regional vascular conductances (i.e., cardiac output and regional blood flow 
corrected for mean arterial blood pressure) were calculated to quantify the vasoconstrictor 
effects of Ang II with or without inhibition of NOS or cyclooxygenase. 
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All data are presented as mean±SEM. Duncan's new multiple range test was used to test 
differences from baseline, once a two-way analysis of variance (ANOV A) had revealed that 
differences existed between the consecutive infusions. Student's unpaired t-test was used to 
evaluate the effects of the inhibitors, once two-way repeated measures AN OVA followed by 
Bonferroni's correction had revealed differences between the groups. Statistical significance 
was accepted at P<0.05 (two-tailed). 
Mean Arterial Heart Rate 
160 Pressure 500 
C) 140 r, I:: 450 ~: :>: :§ E • E 120 . ~ 400 • 
" • -"
100 350 • 
80 300 
Cardiac Output Systemic Vascular 
100 1.00 Conductance 
~: "' ~: 75 J: 0.75 " E .E .E :=. 50 " 0.50 E E :=. 
25 E 0.25 
0 0.00 
0 100 300 1000 0 100 300 1000 
Angiotensin II (ng/kg/min) 
Figure 1. Effects of 10-min intravenous infusions of angiotensin II on systemic hemodynamic 
parameters in rats pretreated with vehicle (0.1 ml/min; n=9; open circles). indomethacin (5 mglkg; n=B; 
closed squares) or L-NAME (10 mg/kg; followed by a continuous infusion of sodium nitroprusside to 
restore mean arterial blood pressure to pre-L-NAME level; n=B; closed triangles). Values are 
mean±SEM. * P<O.OS vs. baseline, t P<O.OS vs. vehicle. 
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Results 
Systemic hemodynamic effects (Figure 1) 
Mean arterial blood pressure, cardiac output, heart rate and systemic vascular conductance 
were not affected by indomethacin. L-NAME + sodium nitroprusside reduced cardiac output 
and systemic vascular conductance by 26% and 28%, respectively (P<0.05), but did not affect 
mean arterial blood pressure and heart rate. Ang IT increased mean arterial blood pressure and 
heart rate by maximally 35±7% and 18±3%, respectively, and decreased systemic vascular 
conductance by maximally 36±7%. Cardiac output was not affected by Ang II. Neither 
indomethacin nor L-NAME + sodium nitroprusside affected any of the Ang 11-induced 
systemic hemodynamic effects on mean arterial blood pressure, heart rate or cardiac output. 
Indomethacin, but not L-NAME + sodium nitroprusside, augmented the Ang IT-induced 
decrease in systemic vascular conductance. 
Figure 2. Effects of pretreatment with vehicle (0.1 ml/min; n=9; open bar), L-NAME (1 0 mg/kg; 
followed by a continuous infusion of sodium nitroprusside to restore mean arterial blood pressure to 
pre-blockade level; n=B; black bar), or indomethacin (5 mg/kg; n=B; hatched bar) on basal regional 
vascular conductance in rats. Values are mean±SEM. GIT: gastrointestinal tract t P<O.OS vs. vehicle. 
Regional hemodynamic effects 
Basal blood flow values in adrenal, brain, gastrointestinal tract, kidney, liver, 
mesentery+pancreas, skeletal muscle, skin and spleen were 3.36 ±0.70, 0.76±0.05, 1.27±0.13, 
4.52±0.36, 0.23±0.04, 0.23±0.03, 0.06±0.01, 0.10±0.01 and 2.3±0.37 ml/min per g, 
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respectively. L-NA.Iv.IE +sodium nitroprusside reduced renal and brain vascular conductance 
and increased vascular conductance in mesentery+pancreas. No significant changes were 
observed in the vascular conductance of other organs after L-NAME + sodium nitroprusside, 
nor did indomethacin alter the vascular conductances in any of the organs that were studied 
(Figure 2). 
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Figure 3. Changes in regional vascular conductance during 1 0-min intravenous infusions of 
angiotensin II in rats, pretreated with vehicle (0.1 ml/min; n=9; open circles), indomethacin (5 mg/kg; 
n=B; closed squares) or L-NAME (10 mg/kg; followed by a continuous infusion of sodium nitroprusside 
to restore mean arterial blood pressure to .pre-blockade level; n=8; closed triangles). Values are 
mean±SEM. * P<O.OS vs. baseline, t P<O.OS vs. vehicle. 
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Ang II decreased vascular conductance in gastrointestinal tract, kidney, skeletal muscle, skin, 
mesentery+pancreas, spleen and adrenal by maximally 37±8%, 56±5%, 26±7%, 55±7%, 
28±9%, 54±6% and 33±11 %, respectively (Figure 3). No effects of Ang II were observed on 
vascular conductance in brain and liver, which is most likely due to autoregulatory 
compensatory mechanisms in these organs. The effects of Ang II were augmented by 
indomethacin in all organs, although the differences were significant in skin, kidney and 
mesentery+pancreas ouly. L-NAME + sodium nitroprusside did not augment the Ang II-
induced effects in any of the organs studied, with the exception of the mesentery+pancreas. 
Discussion 
The present study demonstrates that vasodilator prostanoids, but not NO, counterregulate the 
acutely induced systemic and regional vasoconstrictor effects of Ang II in vivo. The absence 
of NO-mediated counterregnlatory effects in virtually all organs is in full agreement with 
previous studies in the kidney, where endogenous NO also did not counteract the 
vasoconstrictor effects of Ang II.139•141 In these renal studies, like in our in-vivo study, NO 
levels were normalized during NOS inhibition via application of sodium nitroprusside or 
S-nitroso-N-acetylpenicillamine. The dose of sodium nitroprusside administered during 
L-NAME application in our study was high enough to restore mean arterial blood pressure to 
preblockade level, although it did not restore cardiac output and vascular conductance in 
every vascular bed. The reduction in cardiac output might either be the consequence of the 
increase in systemic vascular resistance or it may reflect NO saturation in the heart and a 
subsequent decrease in cardiac inotropy. 148-150 
NO normalization was not applied by Champion et a!., 107 and this may explain why these 
authors did observe au enhanced effect of Ang II in the renal vascular bed with NOS 
inhibition. Furthermore, our data do not argue against the concept that the renal 
vasoconstriction observed during NO inhibition, particularly during high renin states, is the 
consequence of unopposed Ang II-mediated effects.150•151 They merely demonstrate that Ang II 
infusion per se does not mediate NO release, neither directly (via angiotensin receptors) nor 
indirectly (i.e., as a consequence of shear stress). 
The absence of NO-mediated effects during Ang II infusion opposes previous reports on 
Ang IT-induced NO release via endothelial ATt or AT2 receptors. 107•134•138 In an earlier study, 
using the same approach (Ang II infusions and regional blood flow measurements with 
microspheres), we were also unable to demonstrate AT2 receptor mediated hypotensive 
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effects132 and similar in-vivo data were obtained by others.l 07•111 Moreover, the initial reports on 
ATz receptor-mediated vasorelaxation in AT2 receptor knockout mice103.J04 were disputed by 
subsequent studies131 •152 demonstrating that the enhanced Ang IT-mediated vasoconstriction in 
AT 2 receptor knockout mice is due to and upregulation of AT 1 receptors rather than the 
absence of vasodilator AT2 receptors. Furthermore, removal of the endothelium as well as 
preincubation with L-NAME did not affect the AT1 receptor-mediated contractions in human 
subcutaneous arteries, 153 thereby supporting our data on the absence of endothelial 
AT 1 receptor-mediated NO release. 
Prostacyclin is kno'WD. to counteract Ang IT-induced vasoconstriction.154 Moreover, 
stimulation of both AT 1 and AT 2 receptors on endothelial and vascular smooth muscle cells 
has been reported to result in the release of vasodilator and vasoconstrictor prostanoids, 
including prostacyclin, prostaglandin E2 136 and tbromboxane A2 •145 A recent study in human 
isolated subcutaneous resistance arteries/53 however, does not support the latter concept, 
suggesting that if prostanoids are released during Ang II infusion, this is due to the rise in 
blood pressure. Based on the present study, it cannot be concluded whether the release of 
prostanoids is a direct consequence of angiotensin receptor stimulation or occurs in response 
to the regional and systemic vasoconstrictor effects of Ang II (i.e., occurs as a consequence of 
shear stress). Although the Ang IT-induced release of prostanoids differs depending on the 
vascular bed, resulting in both vasodilator143.1 44 and vasoconstrictor145 effects in vitro, our data 
indicate a predominance of vasodilator prostanoids during Ang II infusion in virtually all 
vascular beds. Our study, using the radio labeled microsphere method, is the first to investigate 
the role ofNO and prostanoids in all regional vascular beds at the same time. 
The dose of indomethacin used in the present study has been reported to attenuate the 
responses mediated by the prostanoid precursor, arachidonic acid. 155•156 Indomethacin did not 
alter systemic and regional hemodynamics, thereby indicating that, normally, prostanoids do 
not play a major regulatory hemodynamic role. Furthermore, the rise in blood pressure 
occuring during L-NAME administration in this study confirms its NOS-inhibitory effect at 
the dose applied. In conclusion, vasodilator prostanoids are more important than NO in 
counterregulating the Ang IT-mediated systemic and regional hemodynamic effects in Wistar 
rats. 
References are presented in the general reference list. 
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AT2 receptor-mediated vasodilation in the heart: 
effect of myocardial infarction 
Am J Physiol. 2001; 281: H2590-H2596 
Chapter4 
Summary 
To investigate the functional consequences of postinfarct cardiac angiotensin (Ang) type 2 
(AT,) receptor upregulation, rats underwent coronary artery ligation or sham operation and 
were infused with Ang IT 3-4 weeks later, when scar formation is complete. Ang II increased 
mean arterial pressure (MAP) more modestly in infarcted than in sham animals. The AT 1 
receptor antagonist irbesartan, but not the AT z receptor antagonist PD 123319, decreased MAP 
and antagonized the Ang IT-mediated systemic hemodynamic effects. Myocardial (MVC), but 
not renal vascular conductance (RVC) was diminished in infarcted versus sham rats. Ang II 
did not affect MVC and reduced RVC in all rats. MVC was unaffected by irbesartan and 
PD123319 in all animals. However, with PD123319, Ang II reduced MVC in sham but not 
infurcted animals, and, with irbesartan, Ang II increased MVC in infarcted but not sham 
animals. lrbesartan increased RVC and antagonized the Ang IT-mediated renal effects in all 
animals. RVC, at baseline or with Ang II, was not affected by PD123319 in infarcted and 
sham animals. In conclusion, coronary but not renal AT 2 receptor stimulation results in 
vasodilation, and this effect is enhanced in infarcted rats. 
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Introduction 
The effects of angiotensin (Ang) II are mediated by specific receptors, of which two major 
receptor subtypes, termed AT 1 and AT,, have been characterized to date. AT 1 receptors 
mediate essentially all of the known effects of Ang II, including vasoconstriction and cell 
proliferation.157 Much less is known about the physiological role of AT2 receptors. On the 
basis of its high expression in fetal tissues, it has been speculated that AT2 receptors are 
involved in cell growth and differentiation.119 Indeed, AT2 receptor stimulation in isolated 
cells results in growth inhibition and apoptosis/·15• 10~ thereby antagonizing the AT1 receptor-
mediated growth-stimulatory effects. AT 2 receptor knockout mice are more sensitive to the 
pressor action of Ang II than wildtype mice, 103•104 suggesting that AT 2 receptors antagonize the 
AT1 receptor-mediated rise in blood pressure. However, this increase in sensitivity may also 
be explained on the basis of the increased vascular AT 1 receptor expression in AT 2 receptor 
knockout mice. 131 Moreover, AT2 receptor-mediated blood pressure decreases have not been 
found consistently in normal animals.107•109•132 
Although initially it was thought that cardiac AT 2 receptors disappear after birth, it is now 
widely accepted that both AT 1 and AT 2 receptors are expressed in the normal adult heart, 
either at equal levels or with AT 1 receptors predominating.n1ss-162 Pathophysiological 
conditions such as postinfarct remodeling and heart failure are accompanied by increased AT 2 
receptor expression120•16 u 63"165 and/or decreased AT1 receptor expression,99•166 resulting in a 
relative AT 2 receptor upregulation. 158'167 Stimulation of cardiac AT 2 receptors results in 
inhibition of cell growth and fibrillar collagen metabolism, thereby counteracting the 
AT1 receptor-mediated effects on cardiac remodeling after myocardial infarction (MI)."·"' The 
contribution of AT, receptors to coronary blood flow regulation is currently unknown. A 
recent study168 in dogs that underwent a 15-min coronary artery occlusion followed by 4-h 
reper:fusion, observed an increase in myocardial blood flow after pretreatment the the AT1 
receptor antagonist candesartan. This finding is in agreement with the concept that AT 1 and 
AT2 receptors mediate vasoconstriction and vasodilation, respectively. 
In the present study, we investigated Ang ll-mediated effects in the rat coronary circulation 
in vivo using the radiolabeled microsphere method. Microspheres are trapped in 
end-arterioles, thus allowing one to obtain information on regional hemodynamics by 
measuring tissue radioactivity. In view of the relative upregulation of AT2 receptors after MJ, 
we also studied the effects of Ang II on coronary blood flow in MI rats. These studies were 
performed at 3-4 wk after coronary ligation, when scar formation is complete, 169 i.e., at the 
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compensated stage of cardiac remodeling. 17° Finally, for comparison we investigated the 
Ang IT-mediated effects on renal hemodynamics in sham and MI rats in view of the AT2 
receptor-mediated vasodilation that has been reported in glomerular arterioles.105 All studies 
were performed with and without the AT 1 receptor antagonist irbesartan or the AT 2 receptor 
antagonist PD123319. The effect of combined AT, receptor and AT2 receptor blockade was 
not investigated, because PD123319 displaces AT, receptor antagonists from their plasma 
protein-binding sites. 11z.113•171 Non-specific displacement of irbesartan would increase its free 
(effective) plasma concentration, thereby making the interpretation of such combination 
stndies highly complex. 
Methods 
The investigation conforms with the Nationallnstitntes of Health 'Guide for the Care and Use 
of Laboratory Animals' (NIH publication No. 85-23, revised 1996). Experiments were carried 
out in male Wistar rats (260-280 g body wt) obtained from Harlan (Zeist, The Netherlands). 
Rats were housed with a 12:12-h light-dark cycle with standard rat chow and water available 
ad libitum. 
Myocardial infarction 
Rats were subjected to either coronary artery ligation (n=64) or sham operation (n=28). Under 
sodium pentobarbital (60 mg/kg ip, Apharma; Amhem, The Netherlands) anesthesia, the left 
anterior descending coronary artery (LADCA) was ligated.'" Briefly, after the trachea had 
been intubated, an incision was made in the skin and the muscles overlying the fourth 
intercostal space were placed aside. The animals were put on positive pressure ventilation 
(frequency, 65 breaths/min; tidal volume, 3 ml), and the thoracic cavity was opened by 
cutting the intercostal muscles. The heart was then carefully pushed to the left and a 6-0 silk 
suture was looped under the LADCA -2 nun from its origin. After the heart was returned to 
its normal position, the suture was tied. The intercostal space was closed by pulling the ribs 
together with 2-0 silk. Subsequently, the muscles were returned to their normal position, and 
the skin was sutured. Sham-operated animals underwent the same surgical procedure, without 
the aetna! LADCA ligation. Proper occlusion of the LADCA resulted in an extensive 
transmural infarction comprising a major part of the left ventricular tissue, with small 
variations in size. 170 
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Systemic and regional hemodynamics 
At 3-4 wk after surgery, animals were anesthetized with an intraperitoneal injection of 
sodium pentobarbital ( 60 mglkg). To maintain an adequate depth of anesthesia, intravenous 
bolus injections of sodium pentobarbital (5-10 mglkg) were administered via the right 
external jugular vein every 15 min during the stabilization period. A catheter was placed in 
the trachea for intermittent positive pressure ventilation with a mixture of oxygen and air, 
using a respiratory pump (Small Animal Ventilator, Harvard Apparatus; Natick, MA). The 
ventilatory rate was adjusted to keep arterial blood gases within the physiological range. 
Blood pressure and heart rate (HR.) were recorded with a pressure transducer (Combitrans 
Disposable Pressure Transducer, Braun; Melsungen, Germany) in the left femoral artery. 
Radioactive m.icrospheres were injected into the left ventricle via a catheter in the right 
carotid artery. Drugs were administered via the right external jugular vein. The right femoral 
artery was cannulated to allow the withdrawal of reference blood samples. 
After a 1-h stabilization period after completion of instrumentation, animals were given a 
30-min infusion of the AT1 receptor antagonist irbesartan (100 fig/kg/min), the AT2 receptor 
antagonist PD123319 (20 fig/kg/min, continued throughout the experiment to ensure 
blockade)"' or vehicle (saline, 0.1 mllmin). Two consecutive 10-min infusions of Ang II (100 
and 300 nglkg/min) were then given to each animal. At the end of each Ang II infusion, when 
a steady state had been reached, hemodynamic parameters were measured and the distribution 
of aortic blood flow was determined by injecting 15.5±0.1 (mean±SD) fim diameter 
m.icrospheres labeled with 141Ce, 103Ru or 9~ (NEN Dupont; Boston, MA). For each 
measurement, -200,000 microspheres, suspended in 0.2 ml of saline and labeled with one of 
the isotopes, were mixed, and injected into the left ventricle over a 15-s period. After each 
injection, the catheter was thoroughly flushed with 0.5 ml saline. Starting 10 s before 
m.icrosphere injection and lasting 70 s, an arterial reference blood sample was drawn from the 
right femoral artery at a constant rate of 0.5 mllmin, using a withdrawal pump (Model 55, 
Harvard Apparatus). At the end of the experiment the animal was euthanized with an 
overdose of pentobarbital, and the heart and kidneys were removed. The ventricles were 
separated from atria and large vessels, and subsequently divided into right and left ventricular 
tissue and interventricular septum tissue. The left ventricular tissue of :rvn hearts were further 
divided into viable tissue and scar tissue based upon macroscopic appearance. Tissues were 
washed thoroughly, to remove radioactive m.icrospheres not trapped in arterioles, weighed, 
and put into vials. The radioactivity in the reference blood samples and the tissues was 
counted for 5 min in a y-scintillation counter (Minaxi Auto-Gamma 5000 series, Packard; 
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Dov.rners Grove, IL), using suitable windows, discriminating the different isotopes. Tissues 
other than heart and kidney were also removed and counted, but since the findings in these 
tissues resembled those in the kidney, they will not be discussed here. 
Drugs 
!rbesartan was a kind gift of Bristol-Myers Squibb (Princeton, NJ). PD123319 was a kind gift 
of Parke-Davis (Natick, MA). Irbesartan (330 ~g/ml) was dissolved in 1.2 mM KOH as 
described by Trippodo et a!."' PD123319 (70 ~g/ml) and ANG II (033 and 0.99 ~g/ml, 
respectively) were dissolved in saline. 
Data presentation and statistical analysis 
Data were processed as described previously."" Cardiac output (CO) and regional bl0od flow 
were calculated as follows: 
amount of radioactivity injected x withdrawal rate of arterial blood sample 
co= (I) 
radioactivity of arterial blood sample 
and 
tissue radioactivity x CO 
regional blood flow= (2) 
amount of radioactivity injected 
Systemic and regional vascular conductances [i.e., CO and regional blood flow corrected for 
mean arterial blood pressure (MAP)] were calculated to quantify the vasoconstrictor effects of 
Ang n with or without its receptor antagonists. 
All data are presented as mean±SEM. Duncan's new multiple-range test was used to test 
differences from baseline once a two-way ANOV A had revealed that differences existed 
between the consecutive infusions. Student's unpaired t-test was used to evaluate the effects of 
the AT receptor antagonists once two-way repeated-measures ANOVA followed by 
Bonferroni's correction had revealed differences between the groups. To evaluate differences 
between sham and MI animals Stndent's unpaired t-test was used. Statistical significance was 
accepted at P<0.05 (two-tailed). 
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Sham Myocardial Infarction 
Mortality 
-o-vehicle _,_irbesartan --e-PD123319 
All 28 sham animals survived the follow-up 
period. Three sham animals were excluded 
from analysis due to technical failure during 
microsphere injection. Of the 64 MI 
animals, 32 animals died within 24 h after 
LADCA ligation and 8 animals died due to 
technical failure during microsphere 
injection. Three MI animals were excluded 
from analysis because the infarcted area 
comprised only a minor part ( <20%) of the 
left ventricular free wall. 
Systemic hemodynamic effects 
Acute administration of irbesartan or 
PD123319 did not affect CO or HR in sham 
and MI animals (Figure I). Irbesartan, but 
not PD1233!9, reduced MAP and tended to 
increase (P=not significant) systemic 
vascular conductance in sham and MI rats. 
Angll reduced systemic vascular 
conductance similarly in sham and MI 
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reduced CO in MI animals only. The Ang IT-induced rise in MAP was larger in sham (44±6 
mmHg) than in MI (26±5 mmHg) animals (P<0.05). In both sham and MI rats, irbesartan 
reduced or abolished the systemic hemodynamic effects of Ang II, while PD123319 did not 
affect these effects. 
Cardiac hemodynamic effects 
MI reduced left ventricular blood flow by 35%, but did not significantly affect right 
ventricular, interventricular septal, or atrial blood flow (Figure 2). As a consequence, 
myocardial blood flow (i.e., the sum of left and right ventricular, interventricular septal, and 
atrial blood flow) and myocardial vascular conductance were lower (P<0.05) in MI than in 
sham animals (Figures. 2 and 3). Irbesartan and PD123319 did not affect myocardial vascular 
conductance. In sham animals Ang II, with or without irbesartan, did not affect myocardial 
vascular conductance. Only in the presence of PD1233!9 did Ang II infusions decrease 
myocardial vascular conductance (i.e., caused coronary vasoconstriction) in sham animals. 
This effect was due to vasoconstriction in the left ventricle (Table !). In MI animals, Ang II 
also did not affect myocardial vascular conductance, nor did PD123319 affect the myocardial 
vascular response to Ang II. In the presence of irbesartan, however, Ang II increased 
myocardial vascular conductance (i.e., caused vasodilation) in rvrr animals. These vasodilatory 
effects were limited to the right ventricle and the viable part of the left ventricle (Table I). 
Fig. 2. Baseline regional 
myocardial blood flow 
values in sham-operated 
(n=9) and Ml rats (n=?). 
Myocardium represents 
the sum of interventricular 
septum, left and right 
ventricles, and atria. 
Values are mean±SEM. 
"'P<0.05 vs. sham. 
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The present study supports the concept of AT2 receptor-mediated vasodilation in the rat 
coronary vascular bed. No such vasodilation was observed in the renal vascular bed or the 
systemic circulation, in either normal animals or in :MJ animals. 
Ang II infusion into sham-operated rats did not affect myocardial vascular conductance 
despite its significant pressor effects, thereby indicating either a balance between AT 1 and 
AT 2 receptors in the coronary circulation in the normal heart or autoregulatory mechanisms 
overruling any Ang IT-mediated coronary effects. In support of the first concept, myocardial 
vascular conductance did decrease (i.e., vasoconstriction occurred) when Ang II was infused 
in the presence of the AT2 receptor antagonist PD123319. These data are in agreement with 
studies providing evidence for the presence of both AT, and AT 2 receptors in coronary 
arteries of normal hearts.123•162 Remarkably, however, coronary vasodilation did not occur 
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during Ang II infusion in the presence of the AT 1 receptor antagonist irbesartan, at a dose that 
fully prevented the systemic pressor effects of Ang II. This indicates that, normally, AT2 
receptor-mediated coronary vasodilation is of limited importance, and mainly serves to 
counteract AT1 receptor-mediated effects. This may be different under pathological 
conditions, when AT2 receptors are upregulated164'167 relative to ATt receptors either because 
AT2 receptor density increases and/or because AT1 receptor density decreases.99•120•1sM,l 61 •163•16s-167 
Indeed, 3-4 wk after Ml, we observed Ang IT-mediated coronary vasodilation in the presence 
of irbesartan. In agreement with a reduced density of AT 1 receptors in the infarcted heart, 
Ang II did not cause coronary vasoconstriction in the presence ofPD123319. An alternative, 
less likely, explanation for this lack of Ang IT-mediated vasoconstriction in the presence of 
PD123319 is that, due to the upregulation of AT2 receptors in the infarcted heart, the applied 
dose ofPD123319 was insufficient to obtain full blockade of cardiac AT2 receptors. Previous 
studies, however, have demonstrated that this dose of PD123319 is sufficient to result in 
micromolar blood plasma concentrations (i.e., concentrations that selectively block AT2 
receptors) and that higher doses will lead to concentrations that also interfere with AT1 
receptors. 114 Moreover, the previously described increases in AT2 receptor density are 
relatively modest, i.e., less than three- to fourfold. 12•167 
We were unable to demonstrate a vasodilator role for AT2 receptors in the systemic 
circulation and the kidney. The irbesartan-induced increases in systemic and renal vascular 
conductance in sham and 1vli rats are suggestive for AT 1 receptor-mediated vasoconstriction 
by endogenous Ang II in anesthetized animals. No PD123319-induced decreases in systemic 
or renal vascular conductance were observed in normal or :rvn rats, nor did the AT2 receptor 
antagonist affect the Ang IT-induced systemic and renal hemodynamic responses in these rats. 
Thus MI does not appear to result in AT2 receptor upregulation in organs other than the heart, 
including the kidney, at least at 3-4 wk after coronary ligation, i.e., at the compensated stage 
of cardiac remodeling.170 
Our in-vivo data showing no AT2 receptor-mediated vasodilation in the rat kidney contrast 
with in-vitro data demonstrating AT2 receptor-dependent vasodilation in microperfused rabbit 
glomerular afferent and efferent arterioles105 One explanation for this discrepancy might be a 
difference in shunting in the kidney as compared to the heart, as a consequence of the use of 
microspheres of a single size (15.5 J.l..Dl in the present study). However, we172 demonstrated 
earlier that for the measurement of regional blood flow, for the vast majority of tissues 
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Table 1. Regional myocardial conductances during 10-min intravenous infusions of Ang II in sham-
operated and Ml rats pretreated with vehicle, irbesartan, or P0123319. 
Sham-operated (ng Ang 11/kg/min) Ml (ng Ang 11/kg/min) 
0 100 300 0 100 300 
Interventricular Septum 
Vehicle 45± 5 44±3 48± 3 34±4 33± 4 37± 3 
lrbesartan 38± 5 43± 3 46± 4 44±10 47± 6 56± 7 
PD123319 38± 6 33± 4 33± 3 33± 2 37± 5 40± 6 
Right Ventricle 
Vehicle 47± 7 49± 6 52± 6 34±3 39± 4 42± 6"" 
lrbesartan 48±13 48±10. 47± 8 42± 4 45± 4 54±3 
PD123319 52± 6 42± 5 44±6 45± 5 49±10 49± 9 
Left Ventricle 
Viable Tissue 
Vehicle 47± 5 43± 3 55± 3 32± 2 33± 3 34± 3"" 
lrbesartan 44±2 49± 5t 53± 5t 36± 4 40± 3 48± 4 
PD123319 41± 6 34±2 35± 2 34±3 38± 6 38± 5 
Infarct Area 
Vehicle 11± 3 11± 3 9± 2 
lrbesartan 13± 4 13± 4 16± 3 
PD123319 11± 3 14± 6 10± 3 
Atria 
Vehicle 12± 1 10± 1 10± 1 16± 3 13± 2 13± 1 
lrbesartan 15± 3 15± 3 14± 2 14± 3 14± 2 16± 3 
PD123319 11± 3 9± 2 10± 3 15± 3 13± 4 11± 3 
Values are mean±SEM; n=9 sham-operated and 7 myocardial infarcted {MI) rats pretreated with vehicle (0.1 
ml/min), 8 sham-operated and 7 Ml rats pretreated with irbesartan {100 IJQ/kg/min), and 8 sham-operated and 
7 Ml rats pretreated with PD123319 {20 IJQ/kg/min). Values of myocardial conductance are IJI/min/mmHg per g . 
.. P<O.OS vs. baseline. t P<O.OS vs. vehicle. 
(including the kidney) it does not matter whether one uses microspheres of I 0, !5, 25 or 35 
J.llll diameter!" It is also unlikely that drawing the reference blood sample from a relatively 
distal vessel such as the femoral artery and/or non-appropriate admixture of microspheres 
with blood after their injection into the left ventricle underlie this phenomenon. First, 
although using femoral arterial blood as a reference may result in a modest overestimation of 
C0,147 this will not affect regional blood flow or mask regional AT2 receptor-mediated effects. 
Second,. in this study, as in many previous studies, 115•173•174 we observed similar blood flow 
values in the left and right kidney, both in sham-operated and infurcted animals (data not 
shown), thereby supporting the concept of appropriate admixture. A more likely explanation 
for the lack of renal AT2 receptor-mediated vasodilation is therefore that ATr receptors 
predominate in renal blood vessels other than the glomerular arterioles. Indeed, our results 
obtained in whole kidney do not rule out the possibility of regional hemodynamic changes 
with no change in total renal hemodynamic blood flow. 
The MI model used in the present study is well-established,'" and results in extensive 
transmural infarction comprising >20% of the left ventricle. As a consequence, and in full 
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agreement with previous studies, m baseline left ventricular blood flow was found to be 
reduced by 35% in :rvrr animals as compared to sham-operated rats. No flow reductions were 
observed in other parts of the heart. The Ang IT-induced effects on myocardial vascular 
conductance were limited to the left ventricle in sham-operated animals and to the right 
ventricle and viable left ventricle in the :rv1I animals, indicating that the :rv1I-induced changes in 
AT receptor density were most prominent in these areas of the heart. Such changes, which 
need to be confirmed in future stndies. most likely relate to the vascular growth and 
remodeling process that occurs in the noninfarcted myocardium.10•12.175•176 
Ang II reduced systemic vascular conductance similarly in sham-operated and MI rats. 
However, in :rvrr rats, this increase in systemic vascular conductance was accompanied by a 
reduction in CO, thereby attenuating the rise in blood pressure in these rats. 
In conclusion, this stndy is the first to demonstrate the counteracting effect of AT 2 
receptors on AT1 receptor-mediated coronary vasoconstriction. This effect appears to be 
enhanced after MI and parallels similar findings on AT2 receptor-mediated growth inhibition 
opposing AT 1 receptor-mediated growth stimulation. 3•15•102 
References are presented in the general reference list. 
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Angiotensin-converting enzyme inhibition and 
angiotensin II type 1 receptor blockade prevent 
cardiac remodeling in pigs after myocardial 
infarction 
Role of tissue angiotensin II 
Circulation. 2000; 102: 1556-1563 
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Summary 
The mechanisms behind the beneficial effects of renin-angiotensin system blockade after 
myocardial infarction (l\1!) are not fully elucidated but may include interference with tissue 
angiotensin (Ang) II. Forty-nine pigs underwent coronary artery ligation or sham operation 
and were studied up to 6 weeks. To determine coronary Ang I to Ang ll conversion and to 
distingoish plasma-derived Ang II from locally synthesized Ang II, 125!-labeled and 
endogenous Ang I and II were measured in plasma and in infarcted and in noninfarcted left 
ventricle <L;;?, during 1251-Ang I infusion. Ang II type l (AT1) receptor-mediated uptake of 
circulating 12 l-Ang II was increased at l and 3 weeks in noninfarcted LV, and this uptake 
was the main cause of the transient elevation in Ang II levels in the noninfarcted LV at 
1 week. Ang II levels and AT1 receptor-mediated uptake of c:irculating Ang II were reduced in 
the infarct area at all time points. Coronary Ang I to Ang II conversion was unaffected by MJ. 
Captopril and the AT 1 receptor antagonist eprosartan attenuated postinfarct remodeling, 
although both drugs increased cardiac Ang II production. Captopril blocked coronary 
conversion by >80% and normalized Ang II uptake in the noninfarcted LV. Eprosartan did 
not affect coronary conversion and blocked cardiac Ang II uptake by >90%. In conlusion, 
both circulating and locally generated Ang II contribute to remodeling after MI. The rise in 
tissue Ang II production during angiotensin-converting enzyme inhibition and AT 1 receptor 
blockade suggests that the antihypertrophic effects of these drugs do not only result from 
diminished AT1 receptor stimulation, but also from increased stimulation of growth-inhibitory 
Ang II type 2 receptors. 
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Introduction 
Angiotensin-converting enzyme (ACE) inhibitors prevent cardiac remodeling (i.e., ventricular 
hypertrophy and chamber dilatation) following myocardial infarction (MI). This occurs, in 
part, independent of their blood pressure-lowering effect, 177 suggesting interference with 
tissue angiotensin (Ang) II. However, ACE inhibitors do not always lower cardiac Ang II66·so.9o 
because of (l) their pharmacokinetic properties (short half-life, lack of tissue penetration),""·" 
(2) ACE upregulation during prolonged ACE inhibition,'" or (3) alternative converting 
enzymes such as chymase. 61 Furthermore, previous Ang II measurements in infarcted 
hearts90•91•179 have not taken into account that cardiac Ang II is partly derived from the 
circulation. Plasma Ang IT accumulates in the heart through Ang IT type I (AT,) receptor-
mediated endocytosis,66.74 and changes in AT1 receptor density following :Ml167•180 may 
influence this process. 
AT 1 receptor antagonists have opened new avenues to investigate the importance of 
cardiac Ang II after :MI. In general, these drugs increase rather than decrease Ang II levels,1 ~ 1 
and this may lead to activation of unoccupied, growth-inhibitory' Ang II type 2 (AT2) 
receptors. Currently, the effect of AT, receptor antagonism on the Ang II content of the 
infarcted heart is unknown. Furthermore, it is still controversial whether AT 1 receptor 
antagonism prevents the development of cardiac hypertrophy and increases survival following 
:MJ.182.18J 
Therefore, the aim of the present study was to investigate changes in cardiac Ang II content 
and origin (local synthesis versus uptake from plasma) after :MJ in pigs, to compare the effects 
of ACE inhibition and AT 1 receptor antagonism on these changes, and to evaluate whether the 
effects of both renin-angiotensin system (RAS) blockers on cardiac angiotensin content are 
related to their effects on postinfarct remodeling. 
Methods 
Animals 
Experiments were performed in accordance with the 'Guide for the Care and Use of 
Laboratory Animals' (NIH Publication 86-23, revised 1985). Forty-nine 2-3 month-old 
Yorkshire><Landrace pigs of either sex entered the study. Adaptation of animals to laboratory 
conditions started 1 week before surgery. 
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Surgical procedure 
Animals were sedated with ketamine (30 mglkg IM), anesthetized with thiopental (10 mglkg, 
iv), intubated and ventilated with a nlixture of O, and N10 to which 0.2 to 1.0% (voVvol) 
isoflurane was added.'"' Anesthesia was maintained with midazolam (2 mglkg + l mglkg per 
hour IV) and fentanyl (10 ~glkg per hour IV). The chest was opened via a left intercostal 
space and a fluid-filled polyvinylchloride catheter was inserted into the aortic arch for 
hemodynamic monitoring and blood sampling. 1M Subsequently, the pericardium was opened, 
the proximal left circumflex coronary artery (LCXCA) dissected out, and a suture placed 
around the LCXCA. In 35 animals, the LCXCA was permanently ligated (MI group), whereas 
in 14 animals the suture was removed (sham group). The pericardium was closed and the 
aortic catheter tunneled subcutaneously to the back. The chest was closed and animals were 
allowed to recover. Animals received analgesia (0.3 mg buprenorphine 1M) for 2 days and 
antibiotic prophylaxis (25 mglkg amoxicillin and 5 mglkg gentamycin IV) for 5 days.'"' 
Experimental groups 
Animals were followed for I, 3 or 6 weeks. Of the 3-week Ml animals, 6 received captopril 
(25 mg PO BID), and 7 received the AT1 receptor antagonist eprosartan (400 mg PO BID, a 
gift of Dr. P.K. Week, SmithKlineBeecham, Collegeville, PA). This dose of eprosartan blocks 
Ang IT-induced pressor responses by >95% (n=3). Treatment started 12 to 24 hours after 
LCXCA ligation and was continued for 3 weeks. 
Echocardiography 
At the end of the follow-up period, animals were sedated with ketamine, and 2D 
echocardiographic recordings of the left ventricular (LV) short axis at midpapillary level were 
obtained (Sonos 5500, Hewlett-Packard) and stored for off-line analysis. LV end-diastolic 
cross-sectional areas (EDA) and end-systolic cross-sectional areas (ESA) were determined 
and ejection fraction (EF) was calculated as (EDA-ESA)IEDA x I 00%. 
Infusion of 1251-Angiotensin I 
After echocardiography, pigs were anesthetized and prepared for hemodynamic monitoring, 
administration of 125!-Ang I, and blood and tissue sampling.74.1 29 After baseline measurements 
were collected, the animals were subjected to a 60-minute infusion of 125I-Ang I (= 4 x 106 
c. p.m./min) into the LV cavity. 125I-Ang I and II reach steady-state levels in plasma and 
cardiac tissue within 10 and 60 min, respectively.74 
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Blood and tissue sampling 
During follow-up, arterial blood samples were collected in the morning from awake animals, 
for measurement of norepinephrine, epinephrine, atrial natriuretic peptide (ANP), N-terminal 
ANP, Ang I and Ang II.66•185 .186 During 125I-Ang I infusion, arterial and coronary venous blood 
samples were collected from anesthetized animals for measurement of endogenous and 
125I-labeled Ang I and II."·" With the 125I-Ang I infusion still rurming, the heart was stopped 
by fibrillation, the LV and right ventricle (RV) were separated and weighed, and 0.5- to 1-g 
samples were rapidly obtained from noninfarcted anterior LV wall, lateral LV wall 
(containing the infarct area and borderzone after NIT), interventricular septum, and RV wall. 
Samples were immediately frozen in liquid nitrogen and stored at -70°C. 
Biochemical measurements 
Norepinephrine, epinephrine, ANP, and N-terminal ANP were measured as described 
before.1Hs,Ju Endogenous and 125I-labeled Ang I and II were measured, after SepPak extraction 
and high-performance liquid chromatography separation, by y-counting and 
radiommunoassay, respectively.66•74 
Data analysis 
Fractional conversion and degradation of 125I-Ang I in the coronary vascular bed, i.e., the 
percentage of arterially delivered 125I-Ang I that is converted to 125I-Ang II or degraded to 
other angiotensin metabolites during coronary passage, were calculated as described 
previously."' To quantify cardiac Ang I and II synthesis, tissue levels of Ang I and II were 
corrected for uptake from plasma by using the steady-state plasma and tissue levels of 125I-
Ang I and II.66 Cardiac tissue 12'r-Ang I was undetectable in nearly all animals. To prevent 
underestimation of the contribution of plasma Ang I to tissue Ang I, in-situ synthesized tissue 
Ang I was quantified under the assumption that tissue 125I-Ang I equals 5% of the steady-state 
plasma levels of 1251-Ang 1.66 Differences between sham and 1v1I animals and differences 
between treated and untreated animals were tested by 2-way ANOV A or multivariate 
ANOV A, followed by Student t test. Statistical significance was accepted at P<0.05. Data are 
expressed as mean±SEM. 
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~I Table 1. Hemodynamics and morphology g 
{l 
1 wk 3wk 6wk 'l 
v, 
Sham Ml Sham Ml MI+Captopril MI+Eprosartan Sham Ml 
Parameter (n=4) (n=4) (n=5) (n=6) (n=6) (n=5) (n=3) (n=4) 
MAP,mmHg 95±4 90±3 93±4 96±6 85±4 89±2 94±6 100±3 
Heart rate, bpm 115±5 124±11 101±6 103±8 103±5 113±8 118±9 130±8 
Cardiac output, Umin 2.2±0.1 1.9±0.2 3.0±0.2 2.7±0.1 2.8±0.3 2.2±0.3 2.8±02 3.5±0.2 
LV dP/dlmax• mm Hgls 2343±214 2221±301 2053±138 1706±78 1872±162 1690±127 1940±104 2053±99 
LVEDP, mm Hg 7±2 10±2 8±2 14±2. 11±1 11±3 7±1 9±2 
PAP, mm Hg 21±4 31±1 16±3 28±2" 25±4 24±3 23±5 31±3 
EDA, cm2 8.1±0.1 13.6±0.3' 9.7±1.4 12.8±1.5 11.8±1.2 11.6±0.7 10.0±0.3 15.8±4.2 
ESA, cm2 4.1±0.5 10.4±0.6' 4.6±0.8 8.6±1.6' 6.9±1.0 7.0±1.3 5.7±0.8 9.7±2.8 
EF,% 50±6 24±3' 53±4 33±9' 42±3* 42±8 43±6 40±4 
BW,kg 23.7±0.5 23.5±1.2 30.0±1.4 28.7±1.1 28.3±1.4 28.4±0.6 36.5±1.5 40.1±1.5 
LVW,g 75.1±1.4 90.6±1.1' 82.7±6.2 102.2±5.2' 88.2±3.2t 82.5±4.4t 102.1±1.0 131.3±12.2' 
RVW,g 30.7±2.7 32.5±2.8 27.3±1.0 40.1±3.1' 31.9±1.5't 30.3±2.7t 27.8±2.5 52.9±4.7' 
L VW/BW, g/kg 3.17±0.11 3.90±0.22' 2.75±0.16 3.57±0.14' 3.17±0.25t 2.91±0.16t 2.80±0.09 3.32±0.42 
RVW/BW, g/kg 1.30±0.10 1.39±0.12 0.91±0.04 1.39±0.06' 1.14±0.06't 1.06±0.0Bt 0.77±0.10 1.34±0.16' 
Values are mean±SEM. MAP indicates mean arterial pressure; LVEDP, LV end-diastolic pressure; PAP, pulmonary arterial pressure; EDA, end-diastolic cross-
sectional area; ESA, end-systolic cross-sectional area; EF, ejection fraction; BW, body weight; L VW, LV weight; and RVW, RV weigh!. * P<0.05 vs sham; t P<0.05 vs 
untreated MI. 
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Results 
Mortality 
All sham animals survived the follow-up period, but 2 sham anll:nals died during 1251-Ang I 
infusion because of technical failure. Eight MI animals died within 12 hours after induction of 
MI, and 2 during eprosartan treatment on days 7 and 15. 
Hemodynamic and neurohumoral characteristics 
One day after surgery, mean arterial pressure was lower and heart rate was higher in MI pigs 
than in sham pigs (Figure 1). Mean arterial pressure partially recovered in the MI group 
during the first week but remained below sham levels during follow-up. Plasma 
norepinephrine and epinephrine levels were similar in MI and sham animals, wherease plasma 
ANP and N-terminal ANP were higher in MI anll:nals during the entire follow-up period. 
Captopril and eprosartan did not affect any of the hemodynamic or neurohumoral parameters 
(data not shown). 
Remodeling 
LV EDA and ESA were increased at 1 week after Ml, so that EF was lower in MI anll:nals 
(Table 1). EF recovered during the follow-up period, although LV EDA and ESA remained 
increased compared to sham values. Captopril and eprosartan blunted the increases in LV 
dimension, thereby slightly increasing EF. 
After MI, the surviving myocardium hypertrophied, as reflected by the increased LV and RV 
weight and the ratios of LV and RV weight to body weight (Table 1). Captopril and 
eprosartan attenuated LV and RV hypertrophy. 
Hemodynamics during anesthesia 
Hemodynamics did not differ between MI and sham animals, except for LV end-diastolic 
pressure and pulmonary arterial pressure, which were higher (P<0.05) in MI pigs at 3 weeks 
(Table 1). Neither captopril nor eprosartan affected hemodynamics. 
Angiotensin levels in plasma 
In anll:nals in the awake state, plasma Ang I and II levels (Figure 1) were somewhat higher 
than those levels in anesthetized anll:nals (Table 2). However, the changes produced by MI 
and RAS blockade in anll:nals in the awake state parallelled those in anesthetized anll:nals. The 
Ang I and II levels in arterial and coronary venous plasma in MI animals were marginally 
higher (P=NS) than those in corresponding sham animals at 1 week. At 3 and 6 weeks, the 
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levels were similar in both groups. Captopril increased plasma Ang I 5- to!O-fold, but did not 
alter plasma Ang IT in MI animals. The plasma Ang II!Ang I ratio decreased by ~sO% during 
captopril treatment. indicating effective ACE inhibition. Eprosartan increased plasma Ang I 
and II in Nil animals 5- to 1 0-fold, without altering the plasma Ang IV Ang I ratio. Neither the 
steady-state 125I-Ang I and II levels nor the 125I-Ang WAng I ratios in arterial and coronary 
venous plasma differed between sham and MI animals at any time point. Captopril reduced 
the 125I-Ang II levels and the 125I-Ang WAng I ratio at both sampling sites, whereas 
eprosartan did not alter the steady-state plasma 1251-Ang I and IT levels. 
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Figure 1. Mean arterial blood pressure, heart rate, and arterial plasma levels of neurohormones in sham 
(o) and Ml (•) animals. N-artrial natriuretic peptide indicates N-terminal atrial natriuretic peptide." P<O.OS 
vs sham. 
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Angiotensin I metabolism in the coronary vascular bed 
Coronary 1251-Ang l-Ang II conversion and 125!-Ang I degradation in sham animals (Table 2) 
were not different from those reported in noninstrumented normal pigs.!S1 MI did not alter 
Ang I conversion or degradation at any time point. Captopril inhibited conversion but did not 
affect degradation. Eprosartan affected neither conversion nor degradation. 
Non-Infarcted Myocardium 
1 week 3weeks 6weeks 
--
•• 
Infarcted Myocardium 
1 week 3weeks 
Ml: myocardial infarction 
capt: captopril 
epro: eprosartan 
LV: left ventricle 
!VS: interventricular septum 
6weeks 
i 
Figure 2. Cardiac Ang 1 levels. Black area in bar represents amount of locally synthesized Ang 1. * P<0.05 
vs sham; t P<0.05 vs untreated MI. 
Angiotensin levels in tissue 
Ang I and II levels in the noninfarcted myocardium were higher in MI animals than in sham 
animals at 1 week but not at 3 and 6 weeks (Figures 2 and 3). In sham animals. Ang II levels 
were similar at all myocardial sites, whereas in MI animals, Ang ll levels were lowest in the 
center of the infarct region and intermediate in the borderzone. Both captopril and eprosartan 
increased Ang I and II 2- to 3-fold at all tissue sites in MI animals (Figures 2 and 3), without 
altering the tissue Ang II/Ang I ratios significantly (data not shown). 
125!-Ang I was undetectable in all regions, indicating that virtually all tissue Ang I had been 
produced in situ (Figure 2). 125!-Ang II accumulated in cardiac tissue, reaching steady-state 
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levels in the noninfarcted myocardium that were comparable to or higher than those in arterial 
plasma (Figure 4). 125!-Ang II levels in the infarcted and border-zone lateral LV wall were 
~20% to 30% and ~60% to 70% of those in arterial plasma. Blockade of cardiac 125!-Ang II 
accumulation by eprosartan (Figure 4) indicates that this process is AT1 receptor-mediated. 
There were no changes in 1251-Ang II accumulation in the RV wall or in the infarcted or 
border-zone lateral LV wall dnring the follow-up period. In sham animals compared with 
normal noninstrumented animals, 1251-Ang IT accumulation in the noninfarcted anterior LV 
wall and the interventricular septum was increased at 1 week but not at 3 and 6 weeks,74 
whereas it was elevated in Jv1I animals at 1 week and 3 weeks but not at 6 weeks. Captopril 
abolished the increased 125!-Ang II accumulation in the noninfarcted myocardium of MI 
animals at 3 weeks. After the tissue 1251-Ang TI levels were used to correct for uptake of 
circulating Ang ll, it appeared that the increase in cardiac Ang II levels in MI animals at 
1 week was mainly due to uptake from plasma, whereas the increases in cardiac Ang II levels 
in captopril- and eprosartan-treated animals were due to Ang II generated in situ from locally 
synthesized Ang I (Figure 3). 
Non-Infarcted Myocardium 
1week 3weeks 6 weeks 
Infarcted Myocardium 
1 week 3weeks 
Ml: myocardial infarction 
capt captopri! 
epro: eprosartan 
l V: left ventricle 
IVS: interventricular septum 
6 weeks 
Figure 3. Cardiac Ang II levels. Black area in bar represents amount of locally synthesized Ang II. "' P<0.05 
vs sham; t P<0.05 vs untreated MI. 
60 
RAS blockade in post-infarct remodeling 
Discussion 
The present study demonstrates that after MI, the Ang II levels in the noninfarcted LV are 
transiently increased because of enhanced AT1 receptor-mediated uptake of circulating 
Ang II, Captopril and eprosartan normalized or blocked this uptake and attenuated postinfarct 
remodeling but increased local cardiac Ang II production. These results suggest that the 
antihypertropbic effects of RAS blockade results not only from diminished AT1 receptor 
stimulation but also from increased stimulation of growth-inhibitory AT 2 receptors. 
LCXCA ligation caused LV and RV hypertrophy within I to 3 weeks, MI was 
accompanied by a transient but severe decrease in mean arterial pressure, which, via 
stimulation of renal renin release, may have caused the modest (nonsignificant) rise in plasma 
angiotensin levels in the first week. The hemodynamic and neurohumoral profile of the MI 
animals indicates that permanent LCXCA occlusion, which results in 15% to 25% infarction 
of the porcine LV, was associated with mild-to-moderate LV dysfunction, requiring minimal 
sympathetic activation to maintain cardiovascular homeostasis. This contrasts with an atrial 
pacing model in pigs, which led to severe heart failure and significant neurohumoral 
activation within 3 weeks.'u Interestingly, in the latter model, LV AT1 receptor density was 
decreased, whereas after :r-.11, LV AT1 receptors are usually upregulated}67•189 The present 
findings are in agreement with such upregulation, inasmuch as the amount of plasma-derived 
125!-Ang II sequestered by the noninfarcted LV myocardium via AT1 receptor-mediated 
internalization at 1 week and 3 weeks after :MI was twice as high as that in a previous study in 
normal pigs.74 However, similar increases were observed in sham animals at 1 week after 
surgery, suggesting that this procedure, possibly through the induction of a fibrogenic 
response, 1 ~9 is partly responsible for the increase in AT1 receptor density. It must be realized 
that 125!-Ang II uptake in the heart is mediated exclusively via AT1 receptors, because AT, 
receptors do not internalize Ang II.74' 119 Furthermore, 1251-Ang II formation from 125!-Ang I 
that has diffused into the interstitial space does not contribute significantly to the steady-state 
tissue levels of 125!-Ang II.36•74 
The increase in ATr receptor-mediated uptake of circulating Ang II is responsible for the 
transient rise in Ang II levels in the noninfarcted LV myocardium, suggesting that circulating 
Ang II is among the factors initiating the development of LV hypertrophy, even when plasma 
Ang II is only marginally increased. This observation extends previous studies demonstrating 
that elevation of circulating Ang II, either through infusion of Ang II or through renovascular 
hypertension, induces biventricular hypertrophy within 2 weeks.190 Increased 1251-Ang II 
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.g 
1 wk 3wk 6wk ii; ~ 
"" Sham Ml Sham Ml MI+Captopril MI+Eprosartan Sham Ml 
Parameter (n=4) (n=4) (n=5) (n=6) (n=6) (n=5) (n=3) (n=4) 
Aorta 
Ang I, pmoi/L 4.5±1.7 8.4±4.3 4.9±1.6 2.9±1.0 24.7±8.5't 19.0±4.7't 2.1±0.3 3.0±1.0 
Ang II, pmoi/L 1.4±0.1 6.6±2.9 3.6±1.2 1.9±0.5 4.2±1.6 16.5±3.4't 1.1±0.1 2.1±0.7 
Ang 1111 ratio 0.54±0.22 0.82±0.08 0.62±0.08 0.73±0.04 0.16±0.05't 0.92±0.09 0.50±0.12 0.49±0.20 
1251-Ang I, 103 cpm/L 546±76 501±52 420±28 545±106 620±63 563±73 369±28 459±50 
1251-Ang II, 103 cpm/L 263±19 255±33 232±46 286±62 100±15't 385±15 186±12 352±81 
1251-Ang 11/1 ratio 0.50±0.05 0.51±0.05 0.56±0.12 0.57±0.14 0.17±0.03't 0.73±0.09 0.51±0.01 0.74±0.13 
Coronary vein 
Ang I, pmoi/L 2.6±0.8 7.1±3.2 4.7±1.1 2.5±1.0 21.8±7.6't 15.8±3.9't 1.9±0.3 3.1±0.8 
Ang II, pmoi/L 1.1±0.2 4.8±2.0 2.8±0.8 1.4±0.3 4.5±1.4 18.0±3.2't 1.3±0.2 1.9±0.6 
Ang 1111 ratio 0.58±0.22 0.63±0.0.8 0.49±0.08 0.66±0.10 0.18±0.06't 0.96±0.16 0.65±0.25 0.59±0.13 
1251-Ang I, 103 cpm/L 257±35 323±35 203±31 267±74 455±50 225±28 193±25 250±26 
1251-Ang II, 103 cpm!L 277±23 268±38 223±48 289±52 97±11't 346±16 223±33 349±58 
1 :~_51-Ang Ill! ratio 1.12±0.08 0.82±0.05 1.14±0.16 1.22±0.20 0.21±0.04't 1.67±0.26 1.17±0.17 1.21±0.17 
Coronary 1251-Ang I metabolism 
Fractional conversion, % 24±1 17±1 20±4 25±2 4±1't 26±4 26±4 24±1 
Fractional degradation, % 29±2 20±4 31±6 31±4 23±1 31±5 22±4 22±2 
Values are mean±SEM. • P<O.OS vs sham; t P<0.05 vs untreated MI. 
RAS blockade in post-infarct remodeling 
levels in the noninfarcted LV myocardium were no longer observed at 6 weeks, nor were they 
present in captopril-treated animals at 3 weeks. This, in combination with the notion that 
eprosartan fully blocked the uptake of circulating 1251-Ang II at all myocardial locations, 
suggests that RAS blockade prevents the development of LV hypertrophy, at least in part, by 
attenuating or blocking the AT1 receptor-mediated uptake of circulating Ang II. 
In addition to their effects on cardiac 125I-Ang IT uptake, both captopril and eprosartan 
increased plasma and cardiac Ang I. Because cardiac renin is derived from the circulatio~ 
both under normal circumstances and after J\11,34.38.49 these increases most likely reflect the rise 
in renal renin release that normally accompanies RAS blockade. It is currently unknov.rn 
whether enzymes other than renin (e.g., cathepsin D191) contribute to Ang I generation in 
infarcted hearts. Similarly, the origin of cardiac angiotensinogen after MI has not been fully 
elucidate~ although recent data suggest that most angiotensinogen in infarcted hearts,38 like in 
normal hearts,34 is plasma-derived. 
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Figure 4. Tissue/plasma concentration ratios of 1251-Ang II. .. P<O.OS vs sham; t P<O.OS vs untreated MI. 
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In the eprosartan-treated pigs, plasma and cardiac Ang II rose in parallel with Ang I, 
whereas in the captopril-treated pigs, Ang II did not change in the circulation but increased in 
the heart. Consequently, the Ang III Ang I ratio, a measure of ACE activity, was decreased in 
plasma but not in the heart after captopril treatment. 
The rise in cardiac Ang II synthesis with captopril may have several causes. First, captopril 
may not have entered the heart in sufficient quantities. This seems unlikely, because in an 
earlier study, we observed a clear reduction in the cardiac Ang Il!Ang I ratio after 3 days of 
treatment with the same dose of captopril.66 It is also unlikely in view of the favorable cardiac 
effects of captopril in humans following N11. 177 Second, cardiac Ang II synthesis might occur 
at intracellular sites" that cannot be reached by ACE inhibitors. Third, the initial captopril-
induced blockade of cardiac tissue Ang l-Ang II conversion66 may have been compensated 
for during long-term treatment with this drug, either through an upregulation of ACE1n or 
because alternative converting enzymes such as chymase61 have come into play. Our findings 
do not provide evidence for changes in cardiac or coronary ACE activity, because neither the 
cardiac Ang WAng I ratio nor coronary Ang l-Ang II conversion were altered in MI animals. 
Although Nfl-induced ACE upregulation has been described,S(;,l~9 transgenic rats 
overexpressing cardiac ACE 40-fold have normal cardiac Ang n levels.86 Moreover, we failed 
to observe ACE gene insertion/deletion polymorphism-related differences in vascular Ang l-
Ang II conversion despite profound effects of this polymorphism on plasma and tissue ACE 
levels.192 Thus, elevated cardiac ACE levels, if present in Iv1I pigs, do not necessarily result in 
elevated Ang II levels or Ang III Ang I ratios but may explain why captopril decreases the 
cardiac Ang Ill Ang I ratio less effectively. Furthermore, chymase is present in the porcine 
heart/93 and its concentration increases following Ivli.194 
Does the rise in cardiac Ang II production during RAS blockade have a physiological 
function? If caused by chymase, one must realize that chymase is present in the cytosol of 
mast cells and in the extracellular matrix,61 whereas ACE is located on the cell membrane, in 
proximity to AT1 receptors.76• 1 ~9 Consequently, Ang II generated by chymase may couple less 
efficiently to AT1 receptors than Ang II generated by ACE." 
AT2 receptor antagonism abolishes the beneficial effects of AT1 receptor blockade in Iv1I 
rats. 10 This raises the possibility that the rise in Ang II in the present study results in 
stimulation of grov.rth-inhibitory AT2 receptors.3•119 The AT2 receptor density is increased in 
infarcted and failing hearts, 167•1 ~0 and because the net effect of Ang II depends on the AT1/AT2 
receptor ratio/ it is indeed conceivable that growth inhibition occurs, not only during AT1 
receptor antagonism, but also during ACE inhibition, because the latter prevents the rise in 
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AT1 receptor density following MI (the present study), and is possibly accompanied by 
chymase-dependent Ang I~Ang II conversion at sites distant from AT1 receptors.29•76 
Enhanced AT 2 receptor stimulation, together with diminished AT 1 receptor stimulation, 
might also explain why captopril and eprosartan prevented RV hypertrophy in MI animals. 
Both drugs minimally affected the increase in pulmonary arterial pressure that, in 
combination with the elevated RV Ang II levels at 1 week after MI, may have contributed to 
this hypertrophy. 
Interestingly, the lowest 125!-Ang IT accumulation and local Ang II production were 
observed in the infarct area. The latter finding could indicate that in this area, possibly 
secondary to the reduced blood flow, renin uptake was diminished in parallel with the 
diminished 1251-Ang II uptake. Alternatively, and perhaps more likely in view of the unaltered 
local Ang I production in this area, the low 1251-Ang IT and Ang IT levels might be the 
consequence of increased local Ang II degradation. 
In summary, MI results in a transient upregulation of AT 1 receptors in spared noninfarcted 
myoeardimn, which will cause enhanced sequestration of plasma Ang II even in the absence 
of changes in the circulating RAS. RAS inhibitors prevent the rise in plasma Ang II 
sequestration, either by interfering with myocardial AT 1 receptor up regulation or by blocking 
these receptors. Furthermore, these inhibitors increase tissue Ang IT production, which 
through stimulation of cardiac AT 2 receptors may minimize postinfarct remodeling. 
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Cardiac interstitial fluid levels of angiotensin I and II 
in the pig 
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Summary 
To study whether cardiac interstitial fluid levels of angiotensin (An g) I and II can be 
monitored in vivo, using the microdialysis technique, and to assess the contribution of plasma-
derived angiotensins to the interstitial fluid levels of these peptides, microdialysis probes were 
placed in the left ventricular (LV) myocardium of eight anesthesized pigs, three of which 
were untreated and five treated with the Ang II type l (AT 1) receptor antagonist L-158,809 
(10 mg intracoronary). All pigs were given a 1-h intracoronary infusion of 125I-Ang II. Aortic 
and coronary venous blood samples were taken under steady-state conditions, and interstitial 
dialysate was collected during the entire infusion period. Immediately after stopping the 
infusion, LV tissue pieces were obtained at various time points. L-158,809 did not affect the 
levels of endogenous Ang I and II or the levels of plasma 125I-Ang II. Aortic Ang I and II 
(22 and 16 fmoVml; geometric mean of eight pigs) were comparable to coronary venous Ang 
I and II levels, whereas the coronary venous 125I-Ang II levels (6650 c.p.m./ml) were 
approximately 30 times higher than those in the aorta. Tissue Ang I and II were 5 and 17 
fmoVg, respectively. In untreated animals, the 125!-Ang II levels per g LV tissue were similar 
to the levels per ml coronary venous ~lasma, and the ex-vivo half-life of tissue 125!-Ang II was 
>30 min. In treated animals, tissue 1 5!-Ang II was <5% of coronary venous 125!-Ang II and 
became undetectable within 15 min. 125I-Ang II, Ang I and Ang II in interstitial fluid were 
close to or below the detection limit (200 c. p.m., 60 fino) and 20 fino! per ml, respectively) in 
all animals. In conclusion, plasma and myocardial interstitial fluid angiotensin levels arc of 
the same order of magnitude. Plasma Ang II does not contribute to the interstitial fluid level 
of Ang II, most likely because of its rapid metabolism in the vascular wall. Binding to AT1 
receptors protects Ang II against metabolism. 
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Introduction 
It is now generally accepted that angiotensin (Ang) I and II are not only produced in 
circulating blood, but also at tissue sites. Using systemic infusions of 125!-labeled Ang I and II 
we have recently demonstrated that, in the heart, the majority of tissue Ang I and II is 
produced locally and not derived from the circulation.66 Uptake of circulating Ang II, which 
occurs predominantly via AT1 receptor-mediated endocytosis/4•19$ accounts for less than 20% 
of cardiac tissue Ang II. 
It is not yet known where tissue angiotensin production occurs. Renin and angiotensinogen 
diffuse into the interstitial space/5.37.47 and thus angiotensin generation might occur in cardiac 
interstitial fluid. In a modified version of the isolated perfused rat Langendorff heart, which 
allows separate collection of interstitial fluid and coronary effluent. Ang I and II are generated 
in interstitial fluid if renin and angiotensinogen are provided via the perfusion buffer.36.47 The 
angiotensin levels in interstitial fluid during perfusion of the isolated rat heart with renin and 
angiotensinogen were only marginally higher than in coronary effluent. In contrast, using the 
microdialysis technique, Dell'Italia et a/.196 demonstrated that the angiotensin levels in 
interstitial fluid, obtained from the dog heart in vivo, are 100 times higher than in plasma. 
Such high angiotensin levels have also been found in interstitial fluid obtained from rat 
kidneys 197• In general, the angiotensin levels in the cardiac atria and ventricles, unlike those in 
the kidney, are not several orders of magnitude higher than the angiotensin levels in 
plasma.66•8° Consequently, high cardiac interstitial fluid angiotensin levels do not appear to be 
in accordance with the reported angiotensin levels in the heart. 
The present study aimed to compare the in-vivo angiotensin levels in blood plasma, cardiac 
interstitial fluid and cardiac tissue in the pig, in order to investigate whether tissue Ang I 
and II are restricted to extracellular fluid or cell-associated. Interstitial fluid was collected 
during intracoronary infusion of 125!-Ang II to quantify the contribution of circulating Ang II 
to the interstitial fluid levels of this peptide. To address the possibility that binding to AT 1 
receptors contributes to the interstitial clearance of Ang II, we infused both untreated pigs and 
pigs treated with the AT 1 receptor antagonist L-158,809. 
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Methods 
In-vivo studies 
All experiments were performed under the regulations of the Animal Care Committee of the 
Erasmus University Rotterdam, Rotterdam, The Netherlands, in accordance with the 'Guiding 
Principles in the Care and Use of Animals' approved by the American Physiological Society. 
Eight female pigs (crossbred Yorkshire x Dutch Landrace) with a body weight of 25-30 kg 
were included in the study. Two of these pigs had been used, immediately prior to the present 
experiments, in acute pharmacological studies investigating the effects of the calcium 
sensitizer El\ID 57033. All animals were prepared for hemodynamic measurements, 
administration of anaesthetic and 125!-labeled Ang II, and for blood and tissue sampling as 
described previously."·'" After a stabilization period of 30-45 minutes following completion 
of instrumentation, baseline hemodynamic measurements were made. Subsequently, five 
animals were given a 10-min infusion of the AT, receptor antagonist L-158,809 into the left 
anterior descending coronary artery (LADCA), at a dose (I mg/min) previously shown to 
block the Ang II-mediated effects in the area perfused by the LADCA'". The other three 
animals were not pretreated. Thirty minutes later, a 1-h infusion of 125!-Ang II (approximately 
7 x 105 c. p.m./min) into the LADCA was started in all eight auimals. 
Blood, interstitial fluid and tissue sampling 
Blood samples (10 ml) were taken from the aorta and great cardiac vein 20 and 55 min after 
the start of the infusion of 125!-Ang II, i.e., under steady-state conditions.74·187 The blood was 
rapidly drawn with a plastic syringe containing the following inhibitors (0.5 m1 inhibitor 
solution in 10 m1 blood): 0.2 mM of the renin inhibitor remikiren, 125 mM disodium EDTA 
and 25 mM 1,10-ortho-phenanthroline. The blood was immediately transferred into prechilled 
polystyrene tubes and centrifuged at 3000 g for 10 min at 4°C. Plasma was stored at -70°C 
and assayed within 3 days. 
To collect interstitial fluid, microdialysis probes (CMN20, Carnegie Medicine AB, 
Sweden; cut-off value 20 kDa) were inserted into the left ventricular myocardium in the 
region perfused by the LADCA (i.e., the area exposed to 125!-Ang II) and in the region 
perfused by the left circumflex coronary artery (LCXCA; control area), as described 
before.'%·"' The probes were perfused by a microinjection pump (CMNIOO, Carnegie 
Medicine AB) at a flow rate of 2 f!l/min with isotonic Ringer's solution. The dialysate was 
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collected over the entire 60-min infusion period in chilled polystyrene tubes containing 10 ~1 
of the above inhibitor solution and 10 ~1 0.1% bovine serum albumin in saline. 
The heart was removed immediately after the infusion of 1251-Ang II had been stopped. 
Prior to its removal from the body, the heart was stopped by fibrillation, while the infusion 
was still running. Immediately after the heart had been removed from the body, pieces of left 
ventricular free wall tissue (1-2 g) from the areas perfused by the LADCA and the LCXCA 
were excised and transferred into liquid nitrogen. The tissues were frozen within 15 s after the 
heart had been stopped. To study the ex-vivo degradation of 1251-Ang II in tissue, further parts 
of left ventricular wall tissue from the LADCA area were cut off and rapidly frozen in liquid 
nitrogen at various time points after the heart had been stopped. The frozen tissues were 
stored at -70'C and assayed within 3 days. 
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Figure 1. Recovery of angiotensin I and II in dialysate collected with microdialysis probes perfused at 
varying flow rates in Eppendorf cups containing 2 (o), 5 (•) and 10 (o) pmol angiotensin/mi. Data are 
means±SEM of three experiments. 
In-vitro studies 
Microdialysis is based on the principle that, as the dialysate solution passes through the 
microdialysis fibre, diffusion occurs between the fluid within the fibre and the interstitial fluid 
surrounding the fibre. Since it is unlikely that complete equilibration occurs bet\veen the 
solution within the fibre and the interstitial fluid in the vicinity of the fibre, we estimated the 
recovery from our microdialysis probes by perfusing microdialysis probes at I, 2 and 4 ~Vmin 
with Ringer's solution in an Eppendorf cup containing Ang I and II in Ringer's solution 
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(maintained at 37°C) at concentrations ranging from 2-10 pmol/ml. Recovery was determined 
by comparing the concentration in the dialysis probe effluent to that of the solution in the 
Eppendorf cup. Figure 1 shows the recovery of Ang I and Ang II at different concentrations 
and flow rates. Recovery was unrelated to angiotensin concentration, but diminished rapidly 
at high flow rates. At 2 j..Lllmin, the rate that was used for the present in-vivo experiments, the 
recovery was 13±2% (mean±SEM of all experiments, 1F9) for Ang I and 23±1% for Ang II. 
Recent studies on noradrenaline kinetics in the porcine heart have shown that in-vitro probe 
recoveries are in good agreement with those in vivo. 19~ The in-vitro recovery percentages for 
Ang I and Ang II were therefore used to correct the angiotensin concentrations measured in 
the dialysate collected during the 125I-Ang II infusions. We assumed the recovery of 125I-Ang 
II to be similar to that of Ang II, although in reality it may have been somewhat lower 
because the presence of the 125I-label will increase the molecular weight of Ang II by about 
10%. 
Measurement of angiotensins 
Frozen tissue samples were homogenized in 20 m1 ice-cold 0.1 M HCL/80% ethanol as 
previously described34•74• The homogenate was centrifuged at 20,000 g for 25 minutes at 4°C. 
Ethanol in the supernatant was evaporated under constant air flow and the remainder of the 
supernatant was diluted in 20 mll% ortho-phosphoric acid and centrifuged again at 20,000 g. 
The supernatant was diluted with an equal volume of 1% ortho-phosphoric acid and then 
concentrated on SepPak cartridges. Plasma was directly applied to the SepPak cartridges. The 
preparation of the SepPak extracts for high-performance liquid chromatographic (HPLC) 
separation of the angiotensins and the HPLC procedure have been described elsewhere34·74·187• 
Interstitial fluid dialysates were applied directly to the HPLC. The concentration of intact 
125I-Ang II and the concentrations of intact Ang I and II in the HPLC eluate fractions were 
measured by gamma counting and radioimmunoassay, respectively. Data were not corrected 
for losses occurring during extraction and separation. These losses were less than 10% in 
plasma, and maximally 20-30% in tissue extracts. The lowest Ang I levels that could be 
measured were 1 frnollml in plasma, 60 frnol/ml in interstitial fluid and 2 frnollg in tissue. The 
lowest Ang II levels that could be measured were 0.5 frnol/ml in plasma, 20 frnollml in 
interstitial fluid and I frnol/g in tissue. The lowest 125I-Ang II levels that could be measured 
were 5 c.p.m./ml in plasma, 200 c.p.m/ml in interstitial fluid and 10 c.p.m./g tissue. 
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Statistics 
Hemodynamic data and data from the in-vitro experiments are expressed as mean±SEM. All 
other data are expressed as geometric mean and range, because of non-normal distribution. 
Angiotensin levels that were below the detection limit were taken to be equal to the lower 
limit of detection in order to allow statistical calculations. Differences in angiotensin levels 
between untreated and L-158,809-treated animals were tested by Mann-Whitney U test. A 
P value of0.05 was taken to indicate statistical significance. 
We calculated the predicted cardiac tissue levels of Ang I, Ang II or 1251-Ang II in the area 
perfused by the LADCA, assuming that angiotensins are restricted to extracellular fluid (i.e., 
blood plasma and interstitial fluid, accounting for 5 and 15% of tissue weigbt, 
respectively)/5.37'47•199.200 as follows: 
predicted [Ang]tissuc = 0.05 X [Ang]coronaryvcin + 0.15 X [Ang]interstit:bl fluld 
in which [Ang] represents the level of Ang I, Ang II or 1251-Ang II per g tissue or per ml fluid. 
Predicted tissue levels were compared with measured tissue levels. Higher measured tissue 
levels were taken as evidence for the presence of angiotensins outside the extracellular fluid 
compartment (i.e., as evidence for their localization on or in cells). 
Table 1. Endogenous angiotensin I and II levels and angiotensin 11/1 ratios in aortic blood plasma, 
coronary venous blood plasma, cardiac interstitial fluid and cardiac tissue obtained from eight pigs. 
Interstitial fluid and tissue were obtained from the left ventricular free wall regions perfused by the 
LADCA and the LCXCA. Predicted cardiac tissue angiotensin levels in the lADCA area were 
calculated based upon the assumption that angiotensins are restricted to extracellular fluid 
Blood Interstitial Fluid Cardiac Tissue 
Great LADCAarea LADCAarea LCXCAarea 
Parameter Aorta Cardiac Vein LADCAarea LCXCAarea (measured) (predicted) (measured) 
Angl 22 24 <129 <120 4.9 2,- 3.4 
(fmo!lm! or fmol/g) (1.0-281) (1.0-251) (ND-1236) (ND-1785) (2.0-21) (9.0-189) (2.0-19) 
Ang I! 16 22 <30 <37 17 6.6~ 27 (fmo!lm! or fmol/g) (1.0-283) (3.0-158) (ND-262) (ND-819) (7.0-195) (32-45) (9.0-210) 
Ang 1!/1 ratio 0.72 0.95 3.5* s.o· (0.09-6.8) (0.39-3.0) (1.0-14) (4.5--17) 
Data are geometric mean and range in parentheses; ND=not detectable; • P<O.OS versus aorta and coronary 
vein; ...... P<O.OS versus measured tissue !eve! in the LADCA area. 
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Results 
The baseline mean arterial pressure, heart rate and cardiac output were 74±5 mmHg, 128±11 
beats/min and 2.4±0.2 1/min. These hemodynamic parameters were not affected by acute 
intracoronary administration ofL-158,809 or by the infusion of 1251-Ang II (data not shown). 
In agreement with previous findings,129 the levels of endogenous Ang I and II did not differ 
between untreated and L-158,809-treated animals. Table I summarizes the findings in all 
animals. Aortic Ang I and II levels were comparable to coronary venous Ang I and II levels. 
Tissue Ang I and II levels in the area perfused by the LADCA and the LCXCA, measured in 
tissue that was frozen within 15 s of the heart being stopped, did not differ. Measurements in 
tissue pieces that had been frozen at later time points did not differ from those in tissue pieces 
that were frozen within 15 s (data not shown). The Ang IVI ratio in cardiac tissue was five- to 
ten-fold higher than in plasma. The angiotensin levels in interstitial fluid were close to or 
below the detection limit of our assay. This is not due to rapid metabolism in interstitial 
dialysate prior to its mixture with angiotensinase inhibitors, since the addition of Ang I and ll 
(2 pmollml) to freshly obtained dialysate at 3TC revealed no detectable breakdown over a 
1-h period in the absence of inhibitors (n=3, data not shown). 
Table 2. Levels of 1251-Ang II in aortic blood plasma, cardiac interstitial fluid and cardiac tissue 
obtained from three untreated pigs and five pigs pretreated with the AT1 receptor antagonist 
L-158,809. Interstitial fluid and tissue were obtained from the left ventricular free wall regions perfused 
by the LADCA and the LCXCA. Predicted cardiac tissue 1251-Ang II levels in the LADCA area were 
calculated based upon the assumption that angiotensins are restricted to extracellular fluid. 
Blood Interstitial Fluid cardiac Tissue 
Great lADCAarea LADCA area LCXCA area 
Parameter Aorta Gardiac Vein lADCAarea LCXCAarea (measured) (predicted) (measured) 
'~&l-Ang II (c.p.mJml 263 7094- <200 <200 3303 sas- 122 orc.p.m./g) without AT, (94-1174) (4870-14685) (NO) (ND) (603-12602) (274-764) (27-580) 
receptor blockade 
1251-Ang II (c.p.mJml 201 6330* <279 <247 240 ...... 251 19-* orc.p.m./g) with AT, (138-256) (3299-13842) (ND-642) (ND-575) (86-693) (49-722) (ND-85) 
receptor blockade 
Data are geometric mean and range in parentheses: ND=not detectable: .. P<0.01 versus aorta and coronary 
vein; - P<0.01 versus measured tissue level in the LADCA area; .......,. P<0.01 without versus AT1 receptor 
blockade 
In untreated animals, the steady-state 1251-Ang II levels in the coronary vein were 
approximately 30 times higher than in the aorta (Table 2). The tissue 125!-Ang II levels in the 
area exposed to 1251-Ang II (LADCA area) were comparable to or somewhat lower than the 
levels in coronary venous plasma, whereas the tissue 125I~Ang ll levels in the control area 
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Figure 2. Ex-vivo decrease in 1251-Ang 11 in 
cardiac tissue obtained from the LADCA area in 
three untreated pigs (o) and five pigs pretreated 
with the AT1 antagonist L-158,809 (10 mg 
intracoronary; •). Values (mean±SEM) are 
expressed as a percentage of the levels 
measured immediately after removal of the heart 
from the body 
Cardiac interstitial angiotensin levels 
(LCXCA area) were in the same range as 
the aortic 125I-Ang II levels. L-158,809 did 
not affect the plasma levels of 125I~Ang II, 
but greatly reduced the tissue levels of the 
radiolabeled peptide. The ex vivo half-life of 
tissue 1251-Ang II in the LADCA area was 
>30 min in untreated animals (Figure 2). Iu 
L-158,809-treated animals, tissue 1251-Ang 
II in the LADCA area decreased rapidly, 
aud becarue undetectable within 15 min. 
Iuterstitial dialysate collected during the 
course of the experiment contained 
radioactivity (2,570 c.p.m./ml; range 1,137-
8,524 c.p.m./ml). After correction for 
recovery, on the basis of the recoveries for 
Ang I and II, this concentration is 
comparable to the concentration of 
radioactivity in coronary venous plasma 
(19,413 c.p.m./ml; range 1,137-60,259 
c.p.m./ml). Thus, radiolabeled angiotensins 
had reached a steady state in the interstitium after 1 h of 1251-Ang ll infusion. HPLC 
separation showed that the majority of the radioactivity in interstitial dialysate eluted in a 
peak corresponding with 125I-tyrosine (Figure 3). Iutact 125I-Ang II could be demonstrated in 
two samples from the LADCA area and in one sample from the LCXCA area. It was below 
the detection limit in all other dialysates. 
The predicted tissue Ang I levels in the LADCA area were comparable to or higher than 
the measured Ang I levels, whereas the predicted tissue Ang II levels were at least three-fold 
lower than the measured Ang ll levels. This suggests that tissue Ang I is predominantly 
extracellular, whereas tissue Ang II is largely cell-associated. In untreated animals, the 
predicted tissue 1251-Ang II levels were also much lower than the measured tissue levels, 
while in lr 158,809-treated animals the predicted and measured tissue 1251-Ang n levels were 
similar. Thus, in pigs treated with ATr receptor blocker, but not in untreated pigs, tissue 
125I-Ang II is located extracellularly. 
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Discussion 
The use of the microdialysis technique in the present study, which allows the collection of 
interstitial dialysate under in-vivo circumstances, shows that the interstitial fluid levels of 
Ang I and II in the pig heart are of the same order of magnitude as the plasma levels of these 
peptides. These data are in accordance with previous in-vitro studies in a modified version of 
the rat Langendorff heart, where, during perfusion of the heart with renin and 
angiotensinogen, the angiotensin levels in interstitial transudate were t:\vo- to three-fold higher 
than those in coronary effluent.36.47 
Comparison of the tissue, interstitial fluid and plasma levels of Ang I reveals that tissue 
Ang I is largely extracellular. In fact, the level of Ang I expected per g of tissue based upon 
the assumption that Ang I is restricted to trapped blood plasma and interstitial fluid (the 
'predicted tissue level')/5'37.-~7 was higher than the tissue level that was actually measured. The 
reason for this discrepancy is either an underestimation of tissue Ang I because of ex vivo 
metabolism of extracellular angiotensin, or the fact that in some cases the actual Ang I level 
in interstitial fluid was below the detection limit of our assay. In such cases we assumed 
interstitial Ang I to be equal to the detection limit in order to predict the tissue leveL Since 
tissue Ang I levels remain constant for at least 1 h after removal of the heart from the body," 
the second possibility is the most likely. 
Interestingly, the measured tissue levels of Ang II were three-fold higher than the predicted 
tissue levels of this peptide. Thus, Ang II, in contrast with Ang I, is largely cell-associated, 
either due to AT 1 receptor-dependent intemalization36'74 or intracellular generation. Our 
findings with 1251-Ang IT support the first possibility. Experimental evidence demonstrating 
binding and internalization of renin and prorenin and intracellular activation of prorenin by 
cardiac and endothelial cells40.2°1 supports the second possibility. Additional studies involving 
long-term treatment with AT1 receptor antagonists are needed to solve this issue. 
The low levels of 125I-Ang II in interstitial fluid suggest that circulating Ang II only 
marginally contributes to the interstitial fluid levels of Ang II. This is most likely due to rapid 
metabolism in the vascular walPM7 by angiotensinases such as aminopeptidases A and M,202 
prolyl endopeptidase203 and carboxypeptidases.204 Consequently, and in agreement with our in-
vitro observations in the rat Langendorff heart,36 the majority of Ang ll pre~ent in interstitial 
fluid must have been synthesized locally. These results therefore fully support the concept of 
tissue Ang n generation as opposed to Ang n generation in the circulation. They are also in 
agreement with recent studies showing that tissue angiotensin-converting enzyme (ACE) 
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Figure 3. HPLC elution profile of endogenous (hatched bars) and 1251-labelled (lines) angiotensins in 
coronary venous blood plasma, cardiac tissue and interstitial fluid (!SF) from the area perfused by the 
LADCA in an untreated pig (left panels) and a pig pretreated with the AT1 receptor antagonist L-
158,809 (right panels). The retention times of 1251-labeled standards are indicated by arrows at the top 
of the figure: 1, 1251-tyrosine; 2, 1251-angiotensin-(1-7); 3, 1251-angiotensin-(4-8); 4, 1251-angiotensin II. 
77 
[ 
Chapter6 
knockout mice, despite the fact that ACE is present in the plasma of these animals, display the 
same hemodynamic and vascular abnormalities as mice that are completely ACE 
deficient. 205.206 
Treatment with the AT1 receptor antagonist L-158,809 did not result in elevated interstitial 
fluid levels of 1251-Ang II. Moreover, the ex vivo half-life of tissue 1251-Ang IT in the presence 
of this drug was in the order of I min or less, which is comparable to the half-life of 
angiotensins in the circulation. 11" Since 1251-Ang II is restricted to the extracellular fluid 
compartment during AT 1 receptor blockade, these data suggest that the clearance of Ang II in 
the interstitial space is comparable to its clearance in the circulation, and that receptor binding 
does not make an important contribution importantly to the disappearance of Aog II from 
extracellular fluid. 
Why do the in-vivo interstitial fluid levels of Aog I and II resemble the plasma levels of 
these peptides? Clearly, this is not due to the fact that angiotensins diffuse freely from the 
circulation into the interstitial space and vice versa, because such diffusion is accompanied by 
rapid metabolism. 36.47 The most likely reason for these similar angiotensin levels is the fact 
that circulating renin and angiotensinogen also diffuse into the interstitial space, and that, 
under steady-state conditions, their levels in cardiac interstitial fluid are similar to those in 
plasma.35.37•47 Thus, in tissues where local angiotensin production synthesis depends on uptake 
of renin and angiotensinogen from the circulation (such as the heart and the vascular 
wal), 191:\.2°7 the Ang !-generating capacity will be similar in plasma and interstitial fluid. High 
interstitial fluid angiotensin levels might only be expected under conditions where interstitial 
angiotensin clearance is reduced as compared to clearance in the vascular compartment (e.g., 
in vitro, in the isolated perfused heart)/6.47 or when renin and/or angiotensinogen are produced 
locally (e.g., in the kidney).'" The high interstitial fluid levels reported in the dog heart'" 
suggest that in this animal, in contrast with humans, pigs and rats,47.49•1&7 renin is synthesized at 
cardiac tissue sites. 
References are presented in the general reference list. 
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Vasoconstriction is determined by interstitial rather 
than circulating angiotensin II 
Br J Pharmacal. 2002; 135; 275-283 
Chapter 7 
Summary 
We investigate why angiotensin (Ang) I and II induce vasoconstriction with sintilar potencies, 
although Ang I-II conversion is limited. Construction of concentration-response curves to 
Ang I and II in porcine femoral arteries, in the absence or presence of the AT 1 or AT 2 receptor 
antagonists irbesartan and PD123319, revealed that the ~2-fold difference in potency between 
Ang I and II was not due to stimulation of different AT receptor populations by exogenous 
and locally generated Ang II. Measurement of Ang I and II and their metabolites at the time 
of vasoconstriction confirmed that, at equimolar application of Ang I and II, bath fluid Ang II 
during Ang I was ~18 times lower than during Ang II and that Ang II was by far the most 
iruportaut metabolite of Ang I. Tissue Ang II was 2.9±1.5% and 12.2±2.4% of the 
corresponding Ang I and II bath fluid levels, and was not affected by irbesartan or PDI23319, 
suggesting that it was located extracellularly. Since ~15% of tissue weight consists of 
interstitial fluid, it can be calculated that interstitial Ang II levels during Ang II resemble bath 
fluid Ang II levels, whereas during Ang I, they are 8.8-27 fold higher. Consequently at 
equiruolar application of Ang I and II, the interstitial Ang II levels differ only 2-4 fold. In 
conclusion, interstitial, rather than circulating Ang IT determines vasoconstriction. Arterial 
Ang I, resulting in high interstitial Ang II levels via its local conversion by ACE, may be of 
greater physiological iruportauce than arterial Ang II. 
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Introduction 
Angiotensin (Ang) I and II both induce vasoconstriction via stimulation of AT 1 receptors, the 
former following its conversion to Ang II by ACE and/or chymase.64.2°~ In healthy volunteers, 
during intrabrachial Ang I infusion, one third of arterially delivered Ang I is converted to 
Ang II in the forearm vascular bed,209 whereas in isolated human coronary arteries mounted in 
organ baths, the Ang II levels reached in the organ bath at the time of contraction are <1% of 
the levels of Ang 1.29 Yet, despite the relatively low Ang II levels during Ang I administration, 
the potencies of Ang I and Ang II in vivo as well as in vitro are sim.ilar_29.2°9•211 Likewise, in 
isolated perfused rat hindquarters, renin infusion causes equal increases in perfusion pressure 
as Ang II infusion, although the Ang II levels during renin perfusion are five times lower than 
during Ang II perfusion."' 
Several explanations may solve these discrepancies. Firstly, in view of the vasodilator 
effects of AT2 receptors,213.214 it is possible that locally generated Ang II reaches different AT 
receptors than exogenously applied Ang II. For instance, exogenous Ang II may stimulate 
both endothelial (vasodilatory) AT2 receptors and AT1 receptors on smooth muscle cells, 
whereas locally generated Ang II might stimulate the latter predominantly. Secondly, Ang I 
and Ang II are degraded to vasoconstrictor (Ang-(2-8) and Ang-(3-8), also known as Ang III 
and Ang IV) and vasodilator (Ang-(1-7)) metabolites,"')"-'" and this may affect their 
vasoconstrictor potency. Thirdly, the Ang II levels in the circulation and organ bath may not 
be representative for the tissue (interstitial fluid) levels in the irmnediate vicinity of the AT 
receptors that actually cause vasoconstriction. This theory has also been put forward to 
explain the beneficial effects of ACE inhibitors on blood pressure and cardiac remodelling in 
the absence of clear reductions in circulating Ang ll.89.z17 Fourthly, results obtained with Ang I 
and Ang II in organ baths, as well as during systemic infusion in vivo, may be of little 
physiological relevance~ since normally vascular Ang IT (i.e., the Ang II that is responsible for 
vasoconstriction) is largely derived from local synthesis by renin and converting enzymes 
from angiotensinogen.21 s.220 In this respect, it is of interest to note that the majority of vascular 
Ang I-II conversion, at least in vitro, is mediated by chymase, a converting enzyme that is 
located in the adventitia.29•61 .210 
To investigate these issues, we constructed Ang I _and Ang ll concentration-response 
curves (CRCs) in porcine femoral and carotid arteries mounted in organ baths. Ang I and 
Ang IT-mediated effects were also studied following preconstriction, to facilitate the detection 
of vasodilator effects, and in the presence of ATt and AT2 receptor antagonists. Additional 
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studies with Ang I were performed in the presence of the ACE inhibitor qninaprilat, to 
investigate the importance of ACE versus chymase. Subsequently, we compared the tissue 
and bath fluid levels of Ang I and Ang II and their metabolites at the time of maximal 
vasoconstriction. The amount of vascular Ang II present in interstitial fluid was estimated 
after correction of the tissue levels for Ang IT bound to AT receptors.7'1 Finally, we studied the 
vasoconstrictor effects of Ang I and Ang II applied to the adventitial side of perfused carotid 
arteries, thereby mimicking the vascular origin of Ang IT mediating vasoconstriction. 
Methods 
Chemicals 
Angiotensin I and II, prostaglandin Fza (PGFza), 9,11-dideoxy-lla,9a-epoxymethano-
prostaglandin Fza (U46619) and substance P (acetate salt) were purchased from Sigma 
(Zwijndrecht, The Netherlands). Irbesartan was a kind gift of Bristol-Myers Squibb 
(Princeton, NJ, U.S.A,), PD123319 and qninaprilat were a kind gift of Parke Davis 
(Hoofddorp, The Netherlands). Irbesartan was dissolved in ethanol and qninaprilat in 
dimethylsulphoxide. All other chenticals were dissolved in distilled water. 
Tissue collection 
Porcine femoral and carotid arteries were obtained from 33 2-3 month-old pigs (Yorkshire x 
Landrace, weight 10-15 kg). The pigs had been used in in-vivo experiments studying the 
effects of a-adrenoceptor and serotonin receptor (ant)agonists under pentobarbital (600 mg, 
i.v.) anesthesia."' The Ethics Comntittee of the Erasmus University Rotterdam dealing with 
the use of animals for scientific experiments approved the protocol for this investigation. 
After sacrificing the animal with an overdosis of pentobarbital, the right femoral artery and 
both carotid arteries were removed and stored overnight in a cold, oxygenated Krebs 
bicarbonate solution of the following composition (mM): NaCl 118, KCl 4.7, CaC12 2.5, 
Mgso. 1.2, KH2PO. 1.2, NaHC03 25 and glucose 8.3; pH 7.4. 
Organ bath studies with femoral arteries 
To study Ang I- and II-induced vasoconstriction and/or vasodilatation, femoral arteries were 
cut into segments of approximately 3-4 mm length, suspended on stainless steel hooks in 
15-ml organ baths containing Krebs bicarbonate solution, aerated with 95% 0 2/5% C02, and 
maintained at 37°C. All vessel rings were allowed to equilibrate for at least 30 min and the 
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organ bath fluid was refreshed every 15 min during this period. Changes in tissue contractile 
force were recorded with a Harvard isometric transducer (South Natick, MA, U.S.A,), The 
vessel rings, stretched to a stable force of about 50 mN, were exposed to 30 mM K+ twice. 
Subsequently, the tissue was exposed to I 00 mM K+ to determine the maximal contractile 
response to K+. The rings were then allowed to equilibrate in fresh organ bath fluid for 
30 min. Next, the vessel rings were pre-incubated for 30 min with or without the AT, 
antagonist irbesartan (I ~M). the AT, antagonist PD123319 (1 ~M) or the ACE inhibitor 
quinaprilat (10 ~·Thereafter, Ang I orAng II (0.3 nM-10 ~M) CRCs were constructed. To 
facilitate detection of vasodilation due to AT2 receptor stimulation, Ang I orAng II CRCs 
were also constructed following preconstriction with 1 ~M PGFza or 10 nM U466!9. 
Preconstrictions amounted to approximately 40-50% of the maximal contraction induced by 
100 mM K+. In the presence ofirbesartan, the amount ofPGF2a or U46619 required to obtain 
such preconstrictions was approximately 5-6 times higher, because, at a concentration of 
I ~-tM, irbesartan acts as an antagonist of the thromboxane A2/prostaglandin endoperoxide 
receptor.222 After the addition of Ang I or II, it took 10-15 min to reach a stable contraction. 
Subsequent angiotensin concentrations were applied as soon as a stable contraction had been 
reached. Construction of the CRC was discontinued when desensitisation occurred, i.e., when 
subsequent angiotensin doses elicited no response or decreased contraction. At the end of the 
experiment the functional integrity of the endothelium was verified by observing relaxation to 
1 nM substance P or 100 nM bradykinin after pre-constriction with PGF2a or U46619. To 
measure the release of newly formed Ang II into the organ bath fluid during Ang I CRCs, 
bath fluid samples (150 ~1) for Ang II measurements were taken as soon as a stable 
contraction had been reached. All samples were collected in chilled tubes containing 15 ~1 
inhibitor solution (125 mM disodium EDTA and 25 mM 1,10-ortho-phenanthroline) and 
15 ~1 0.1% bovine serum alburuin (BSA) in distilled water. The samples were stored at -80'C 
until analysis. 
Metabolism studies with femoral arteries 
To study vascular Ang I-II conversion and Ang I and II metabolism in further detail, femoral 
arteries were cut into segments of approximately 3-4 mm length (weight 10-45 mg; mean 22 
mg), put into test tubes containing 1.0 ml Krebs bicarbonate solution ('incubation fluid'), 
aerated with 95% 0,!5% C02, and maintained at 37'C. After a 10-min equilibration period, 
vessel rings were pre-incubated for 30 min with or without irbesartan (1 ~M), PD123319 
(1 ~M) or quinaprilat (10 ~M). Next, Ang 1 (10 or 100 pmol) orAng II (10 pmol), randomly 
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combined with 125!-Ang I (100,000 c,p.m.) or 125!-Ang II (100,000 c.p.m.), were added to the 
incubation fluid. The use of radio1abe1ed angiotensins facilitates the detection of the various 
angiotenin metabolites, by gamma-counting after their high-petformance liquid 
chromatographic (HPLC) separation (see below). After either 15 or 60 min the vessel 
segments were removed, washed in fresh Krebs solution and dried on tissue paper. The 
remaining incubation fluid (=1 ml) as well as the dried segment were rapidly frozen in liquid 
nitrogen and stored at -80°C until analysis. 
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Figure 1. Contractions of femoral arteries, at baseline and after preconstriction with 1 !JM PGF2a or 
10 nM U46619, to Ang 11 (upper panels; n=8) orAng r (lower panels; n::;5) in the absence or presence 
of 11JM irbesartan, 11JM PD123319 or 10 ).JM quinaprilat. Data are expressed as a percentage 
(mean±SEM) of the response to 100 mM K". 
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Perfusion and organ bath studies with carotid arteries 
To study whether adventitial application of Ang I and II elicits a response that is different 
from the combined luminal and adventitial application obtained after addition of Ang I or II to 
the organ bath in the above set-up, carotid arteries (diameter 2-3 mm) were divided in 3-4 mm 
rings as well as 1-1.5 em sections. The rings were mounted in organ baths as described above. 
The vessels sections, which did not contain side branches, were mounted horizontally in a 
double-jacketed 4-ml bath containing a carbogenated Krebs bicarbonate solution and 
maintained at 37°C, as described by Hulsmann et a!."' Krebs solution was perfused through 
the vessels using a roller pump (Ismatec IPS, ZUrich, Switzerland). This approach allows the 
adventitial application (i.e., into the bath) of drugs. Fluids were refreshed every 15 min. 
Changes in pressure were recorded with a Viggo-spectramed disposable pressure transducer 
(Bilthoven, The Netherlands). The vessel sections and rings, at a stable force of 44 nun Hg 
and 20 mN, respectively, were exposed to 30 mM K+ twice. Subsequently the tissues were 
exposed to 100 mM K+ to determine the maximal contractile response to K+. The vessels were 
then allowed to equilibrate in fresh organ bath fluid for 30 min. Thereafter, Ang I or Ang II 
(I nM-1 f!M ) CRCs were constructed as described above. At the end of the experiment the 
functional integrity of the endothelium of the vessel rings was verified by observing 
relaxation to 100 nM bradykinin after pre-constriction with 10 nM U46619. 
Measurements of angiotensins 
In the metabolism studies, Ang I and Ang II and radiolabeled Ang I and Ang II in vascular 
tissue and incubation fluid were measured as described previously,74.187 using SepPak 
extraction and HPLC separation. In short, frozen vessel segments were homogenised in 4 ml 
ice-cold 0.1 M HCl/80% ethanol. The homogenate was centrifuged at 20,000xg for I 0 min at 
4°C. Ethanol in the supernatant was evaporated under constant air flow. The remainder of the 
supernatant was diluted in 8 rn.l 1% ortho-phosphoric acid and concentrated on SepPak 
cartridges. SepPak extracts were dissolved in 100 f!l HPLC elution buffer and injected into 
the HPLC column. Incubation fluid was directly applied to the column without prior SepPak 
extraction. The concentrations of Ang I and Ang IT and of radio labeled Ang I and Ang IT in 
the HPLC eluate fractions were measured by radioimmunoassays and gamma counting, 
respectively. Measurements were not corrected for losses occurring during extraction. These 
losses were maximally 20-30 %.74 The lowest Ang I levels that could be measured were 
50 frnol/g tissue and 10 frnol/ml incubation fluid. The lowest Ang II levels that could be 
measured were 25 frnollg tissue and 5 frnol!ml incubation fluid. The lowest 1251-Ang I and 
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125I~Ang II levels that could be measured were 500 c.p.m./g tissue and 100 c.p.m./ml 
incubation fluid. 
In the organ bath studies, Ang I and Ang II in organ bath fluid were measured by 
radioimmunoassay without prior SepPak extraction or HPLC separation.29 The lowest Ang I 
and Ang II levels that could be measured in these experiments were 20 and 10 fmoVml bath 
fluid, respectively. 
Data presentation and statistical analysis 
Data are given as mean±SEM. Data of the functional studies are expressed as a percentage of 
the maximal contraction to 100 mM K+ (88±5 mN in the organ bath studies with femoral 
arteries (n=l5); 220±20 mmHg in the perfusion studies with carotid arteries (n=7) and 
111±8 mN in the organ bath studies with the carotid arteries (n=7)). Data of metabolism 
experiments are expressed as percentage of the angiotensin concentration in the bath fluid at 
the start (t=O) of the experiment, assuming that 1 g of tissue equals 1 mi of fluid." To allow 
statistical evaluation, angiotensin levels that were below the detection limit were taken to be 
equal to this limit. 
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Figure 2. Contractile responses of femoral arteries versus organ bath fluid Ang II levels (left panel) or 
interstitial fluid Ang II levels (right panel), during Ang I ('endogenous') or Ang II ('exogenous') 
application. Contractions are expressed as a percentage (mean±SEM; n=S) of the response to 
100 mM K'·. Interstitial fluid levels of endogenous and exogenous Ang II were calculated by multiplying 
the Ang ll levels in the organ bath with the interstitial fluid/incubation fluid Ang II concentration ratios 
obtained 15 min following Ang I (8.5±4.4) orAng II (1.1±0.2) administration in the metabolism studies. 
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CRCs were analysed using the logistic function described by de Lean et al."' to obtain 
pECso e'logECso) values. Statistical analysis was by ANOV A, followed by post hoc 
evaluation according to Dunnett. P values <0.05 were considered significant. Statistics were 
performed using the software package SigmaStat. 
Results 
Organ bath studies with femoral arteries 
In non~preconstricted femoral arteries (Figure 1 ), Ang I and Ang IT displayed similar maximal 
effects CE=x 31±2% and 37±7%, respectively, n=5). Ang I was 2 fold less potent than Ang IT 
(pECso 8.21±0.13 and 8.59±0.09, respectively; P<0.05). In femoral arteries that had been 
preconstricted with PGFza or U46619 to 34±4 mN (or =45% of the maximal contraction 
induced by 100 mM K+; n=13), Ang I and Ang II increased contraction further to 63±9% and 
62±6% (Figure 1). The potencies of Ang I and Ang II in the preconstricted vessels (pECso 
8.08±0.11 and 8.51±0.05, respectively) were not different from those in the 
non~preconstricted vessels. 
The ATt receptor antagonist irbesartan abolished all contractile responses to both Ang I 
and Ang IT, whereas the AT2 receptor antagonist PD123319 was ineffective under all 
circumstances. In non~preconstricted vessels, the ACE inhibitor quinaprilat shifted the Ang I 
CRC approximately 10 fold to the right (pECso 7.12±0.10, n=5; P<O.OOl vs control). 
Despite the small difference in potency between Ang I and Ang II, the Ang IT levels 
measured in the organ bath fluid during the Ang I CRC, at the time a stable contraction had 
been reached, were <3% of the levels of Ang !. Figure 2 (left panel) relates the organ bath 
fluid levels of Ang II measured during the Ang I CRC ('endogenous Ang II') to the 
contractile response. For comparison the CRC obtained with exogenous Ang IT is also shown 
in this Figure. The pECso value of endogenous Ang II (9.84±0.14) illustrates that, for a given 
contractile response, the organ bath fluid levels of endogenous Ang II are ~ 18-fold lower than 
for exogenous Ang II. 
Metabolism studies with femoral arteries 
Incubation fluid. Femoral artery segments slowly metabolized 125I~Ang I and Ang I 
(Figure 3). After 1 h of incubation at 37°C, 56±6% (n=4) and 64±9% (n~6) of the incubation 
fluid levels at t=O was still present as intact 125I~Ang I and Ang I, respectively. Metabolism 
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was partly due to Ang I-II conversion, as evidenced by the rise in the 125I-Ang II and Ang II 
levels over time (Figure 3). After I h, the incubation fluid levels of 125I-Ang II and Ang II 
were 4.5±2.6 and 5.4±2.0% of the respective 125I-Ang I and Ang I levels at t=O. HPLC 
separation of the incubation fluid samples revealed that 125I-Ang II was by far the most 
important metabolite of 125I-Ang I (Figure 4). The metabolism of 125I-Ang II and Ang II 
occurred at a similarly slow rate as the metabolism of 125I-Ang I and Ang I, resulting in 
incubation fluid 125I-Ang II and Ang II levels after I h that were >60% of the levels at t=O 
(data not shown). Metabolites that could be detected in the incubation fluid during incubation 
with 125I-Ang II were 125I-Ang-(4-8) and 125I-tyrosine. Irbesartan and PD\23319 did not affect 
the metabolism of 125I-Ang I, 125I-Ang II, Ang I or Ang II (Figure 3). Quinaprilat virtually 
completely prevented the appearance of 125I-Ang IT and Ang IT in the incubation fluid during 
incubation of the vessel segments with 125I-Ang I and Ang I, but did not significantly affect 
the decrease in 125I-Ang I or Ang I over time (Figure 3), thereby indicating that Ang I-II 
conversion is not the only metabolic pathway which results in destruction of Ang I. 
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Figure 3. Metabolism of 1251-Ang 1 and generation of 1251-Ang II (left panel) and metabolism of Ang I 
and generation of Ang II (right panel) by femoral artery rings incubated 1n 1 ml incubation fluid 
containing 1251-Ang I (100,000 c.p.m.) orAng I (10 or 100 pmol) in the absence or presence of 1 ].JM 
irbesartan, 1 ].JM PD123319 or 10 ].JM quinaprilat. Incubation fluid levels are expressed as a 
percentage (mean±SEM, n=4-6) of the 1251-Ang I and Ang l levels at t=O. 
Vessel segment. Under all conditions that were investigated, the angiotensin levels 
measured in the vessel segment at t= 15 min were not different from those at t=60 min. 
Therefore, the data in Figure 5 represent the average of the measurements at these two time 
points ('steady-state' levels). The 125I-Ang I and Ang I levels in the vessel segments 
(expressed per g tissue) were 3-6 times lower than the concomitant levels in the incubation 
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fluid (expressed per mi fluid). In contrast, the tissue 125I-Ang II and Ang II levels, measured 
after the addition of 1251-Ang I and Ang I to the incubation fluid, were as high as (or slightly 
higher than) the incubation fluid 125I-Ang II and Ang II levels. Quinaprilat reduced these 
levels by >75% (data not showo). 
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Figure 4. HPLC elution profile of 1251-labeled angiotensins in femoral artery tissue (22 mg) and 
incubation fluid (100 J.JI) obtained after incubation of femoral art~ rings at 37"C for 60 min in 1 ml 
incubation medium containing 100,000 c.p.m. 1251-Ang I or 1 l-Ang II. The retention times of 
1251-labeled standards are indicated by arrows at the top (1, 1251-tyrosine; 2, 1251-Ang-(1-7); 3, 
1251-Ang Ill; 4, 1251-Ang-(4-8); 5. 1251-Ang II; 6, 1251-Ang IV; 7, 1251-Ang-(2-10); 8. 1251-Ang 1). 
The tissue 125I-Ang II and Ang II levels, measured after the addition of 125I-Ang II and 
Ang ll to the incubation fluid were 5-6 times lower than the concomitant levels in the 
incubation fluid. Other metabolites that could be detected in the vessel segments during 
125!-Ang I or 125!-Ang ll application were 125!-Ang-(2-10), 125!-Ang-(4-8) and 125!-tyrosine 
(Figure 4). 
Neither irbesartan nor PDl233l9 affected the tissue 125I-Ang II and Ang II levels under 
any of the conditions studied, thereby indicating that the majority of tissue 125!-Ang IT and 
Ang ll was not bound to cell surface - or internalized AT receptors. Assuming therefore that 
all tissue 125I-Ang II and Ang II is located extracellularly (i.e., present in vascular interstitial 
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fluid, which accounts for =15% of tissue weigb.t/5•199.225226 it can be calculated that during 
125I-Ang I and Ang I application, the interstitial 125I-Ang II and Ang II levels are 49±17 and 
19±10%, respectively, of the initial 125I-Ang I and Ang I levels in the incubation fluid. 
Moreover, during 125I-Ang II and Ang II application, the interstitial 125I-Ang II and Ang II 
levels are 103±23 and 81±16%, respectively, of the initial 1251-Ang II and Ang IT levels in the 
incubation fluid. In other words, 15 min after the application of 125I-Ang I and Ang I, the 
interstitial fluid 125I-Ang II and Ang II levels are, respectively, 27±13 and 8.8±4.4 times 
higher than the 125I-Ang II and Ang II levels in the incubation fluid (the latter levels are 
shown in figure 3), whereas 15 min after the application of 125I-Ang II and Ang II, the 
interstitial fluid 1251-Ang IT and Ang IT levels equal the levels in the incubation fluid. 
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~igure 5. S~ea1~-state tissue 1251-Ang I, 1251-Ang II, Ang I and Ang II levels in femoral artery rings 
mcubated w1th l-Ang I (100,000 c.p.m.) orAng I (10 or 100 pmol) (left panels) or with 1251-Ang 11 
(100,000 c.p.m.) orAng II (10 pmol) (right panels) in the absence or presence of 1 [.JM irbesartan or 
1 IJM PD123319. Data are expressed as a percentage of the radiolabeled and endogenous Ang I or II 
levels in incubation fluid at t=O (mean±SEM, n--4-6). 
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Perfusion and organ bath studies with carotid arteries 
Ang I and Ang II displayed similar maximal effects, both in the organ bath studies and the 
perfusion experiments (Figure 6). Under both conditions, Ang I tended to be less potent than 
Ang II (pECso 7.53±0.11 vs 7.76±0.08 in the organ bath studies and 7.73±0.07 vs 8.00±0.11 
in the perfusion experiments), but the difference did not reach statistical significance. Ang II, 
but not Ang I, was more potent after adventitial application (perfusion experiment) than after 
application to the organ bath (P<0.05). 
Discussion 
In the present in-vitro study, in agreement with previous studies measuring Ang II following 
Ang I administration,"0"'"'7 the levels of Ang II in the organ bath during the construction of 
the Ang I CRC in femoral artery rings were <3% of the Ang I levels at the time of maximal 
vasoconstriction. Yet, in femoral, as well as in carotid arteries, the potency of Ang I was only 
2 fold lower than that of Ang II. 
The results obtained with the AT 1 receptor antagonist irbesartan and the AT 2 receptor 
antagonist PD123319 do not support the possibility that exogenous Ang II and locally 
generated Ang II stimulate different AT receptors. Neither at baseline, nor following 
preconstriction, we were able to demonstrate Ang I- orAng II-induced vasodilation via ATz 
receptors in femoral arteries. Thus, either such receptors do not exist in porcine femoral 
arteries, or ATz receptors in these vessels mediate other, non-blood pressure-related effects in 
this vessel (e.g., effects on vascular grovvth and remodeling. 3•15•102 Measurement of 
radio labeled angiotensin metabolites during incubation of femoral artery rings with 125I-Ang I 
and 125I-Ang II, revealed that the metabolism of Ang I and Ang II by these rings is relatively 
slow (half-life > 1 h), and that Ang II is by far the most important metabolite of Ang I. The 
enzyme responsible for Ang I-II conversion is ACE, since the ACE inhibitor quinaprilat 
shifted the Ang I CRC 10 fold to the right and prevented the appearance of Ang II in the 
organ bath. The latter contrasts with previous findings in human vessels, 29.210 where chymase 
was by far the most important converting enzyme. Neither the vasoconstrictor metabolites 
Ang III and Ang IV,216 nor the vasodilator metabolite Ang-(1-7)128.215 were present in 
detectable amounts. Thus, the similar potencies of Ang I and Ang II are not related to the 
generation of different vasoconstrictor and/or vasodilator metabolites from Ang I and Ang II, 
nor to differences in the rapidity of their metabolism. Moreover, the rightward shift of Ang I 
CRC caused by quinaprilat, and the similar potencies of Ang I and Ang II despite the >I 00 
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fold lower affinity of Ang I for the AT, receptor,"'"" exclude the possibility that Ang I 
mediated its vasoconstrictor effects directly, independent of its conversion to Ang IT. 
During adventitial application to perfused carotid arteries, Ang I and Ang II were 
equipotent, thereby showing that their similar potency in organ bath studies29.2'0.2'' or 
following arterial infusion in vivo209 is not a consequence of the experimental set-up. The 
perfusion studies in the present investigation were performed with carotid arteries, since the 
many sidebranches of femoral arteries did not allow such studies with these vessels. The 
slightly higher potency of Ang II following adventitial application as compared to combined 
adventitial + luminal application (i.e., into the organ bath) is in agreement with earlier studies 
showing a higher metabolic clearance rate of angiotensins after luminal application than after 
adventitial application.227 Apparently, the majority of the vascular angiotensin metabolizing 
enzymes is located on endothelial cells. 
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Figure 5. Contractions of carotid arteries to Ang I or Ang II added adventitially to perfused vessel 
sections (left panel) or into the bath fluid of vessel rings mounted in organ baths (right panel). Data are 
expressed as a percentage (mean±SEM; n=7) of the response to 100 mM K'". 
Based on the above findings, we reasoned that Ang I administration results in high tissue 
Ang II levels with limited Ang II release into the surrounding bath fluid, and that these high 
tissue Ang II levels might explain why the potency of Ang I is similar to that of Ang II. We 
therefore expected the vascular Ang ll levels during Ang I administration to be much higher 
than the organ bath fluid Ang IT levels. As shown in Figures 3 and 5, this was not the case. 
Fifteen minutes after Ang I administration (i.e., at the time maximal vasoconstriction had 
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occurred), the vascular Ang II levels were approximately as high as the bath fluid levels. The 
tissue concentrations at 15 min represented steady~state levels, since similar concentrations 
were measured after 60 min. Tissue Ang II, however, is localized in one or more different 
compartments, and a low tissue level therefore does not argue against the possibility that 
Ang II is present at high concentrations in a specific tissue compartment. For instance, 
previous in~vivo196• 191 and in-vitrd6.41 studies have shown that interstitial fluid Ang II may be 
higher than circulating Ang II. In addition, tissue Ang II is, at least partly, localized 
intracellularly, because of its internalization via AT1 receptors.74•75 Such internalization does 
not appear to occur after binding to AT2 receptors/4•119 nor via non~ATt, non-AT2 receptor-
mediated mechanisms.75 Finally, Ang II may be bound to AT receptors on the cell surface. 
Receptor binding protects Ang II against rapid metabolism by degrading enzymes." Since in 
pigs, like in humans, there is currently no evidence for the existence of AT receptors other 
than the AT, and AT, receptor, we distinguished cellular (membrane bound or internalized) 
and extracellular Ang II by measuring tissue Ang ll in the presence of irbesartan and 
PD123319. No siguificant differences were found in comparison with the control situation. 
This suggests that only a small fraction of tissue Ang II in femoral artery tings is bound to cell 
surface~ and/or internalized ATt receptors, and, thus, that the majority of vascular Ang II is 
localized in interstitial fluid. Assuming therefore that all vascular Ang II is present in the 
interstitial space, and taking into account that this compartment represents =15% of tissue 
weight,"·"'-"'-"' it follows that interstitial Ang II duting Ang I administration is 8.8-27 times 
higher than bath fluid Ang II. 
The latter was not the case duting Ang II administration. Tissue Ang II following Ang II 
administration was also restricted to the interstitial fluid compartment (i.e., not affected by 
irbesartan or PD123319), and the interstitial Ang II fluid levels duting Ang II administration 
were not different from the bath fluid Ang ll levels. The latter contrasts with earlier findings 
in isolated perfused rat Langendorf£' hearts, where interstitial Ang II during Ang II infusion 
was <35% of arterial Ang II/6 and with in-vivo studies in pigs67 and dogs, 196 where interstitial 
fluid Ang II during Ang II infusion was <5% of arterial Ang ll. These differences are most 
likely related to the amount of metabolizing enzymes present under the various experimental 
conditions. In addition, chronic exposure to Ang ll is lmown to affect the level of angiotensin-
metabolizing enzymes, including ACE. 178 
Why are the interstitial Ang II levels duting Ang I administration higher than the bath fluid 
Ang II levels? In porcine arteries, Ang I~ll conversion occurs both after luminal and after 
adventitial Ang I administration,"' suggesting that ACE is present both in the endothelium 
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and the adventitia. In addition, ACE has been demonstrated on rat and human vascular 
smooth muscle cells.'" Most likely therefore, Ang I-II conversion occurs by ACE within the 
interstitial space. This does not exclude Ang I-ll conversion on either the endothelial or 
adventitial surface. In fact, in view of the much larger volume of the organ bath (15 ml) as 
compared to the interstitial fluid volume of a 22 mg vessel segment (~3 J.ll), it can be 
calculated that the majority (>95%) of Ang II is present in the organ bath, and thus is 
probably generated on the vascular surface. In the artecy segment, the interstitial space is 
continuously supplied, via diffusion," with Ang I from the bath fluid, and this Ang I will be 
converted by ACE into Ang II in close proximity of the AT1 receptors. The small volume of 
the interstitial space allows a rapid rise in the interstitial Ang n levels, resulting in a steady 
state within 15 minutes. The rate-limiting factor in this process is most likely the diffusion of 
Ang I into the interstitial space.65 Although the bath fluid Ang II levels continue to rise over 
time, previous studies29.n7 have shown that it is unlikely that these levels will become as high 
as the interstitial Ang ll levels. This is due to the small volume of the interstitial space, 
thereby allowing interstitial Ang ll to contribute only marginally to the organ bath levels of 
Ang ll. Indeed, in previous perfusion studies with porcine carotid arteries, we found no Ang ll 
in the perfusion fluid upon adventitial Ang I administration, nor was Ang II detectable in bath 
fluid upon huninal Ang I administration.227 Moreover, we were also unable to demonstrate 
significant release of Ang II from tissue sites into the circulation.219.22o 
Taken together, the similar potencies of Ang I and Ang II in the present and previous 
studies,29.209.227 can be fully explained on the basis of the interstitial Ang II levels that are 
reached in the vessel wall during Ang I and Ang II application. During Ang I application, at 
the time of vasoconstriction, these levels are almost one order of magnitude higher than the 
levels in the organ bath, whereas during Ang II application the interstitial and bath fluid 
Ang II levels are virtually equal. The right panel of Figure 2 illustrates the consequences of 
this concept. Our results not only explain why circulating Ang ll does not always represent 
tissue (interstitial) Ang II,"'"""" but they also raise the possibility that circulating Ang I, 
through its local conversion into Ang II, is of greater physiological importance than 
circulating Ang II. When considering the latter, it should be kept in mind that the circulating 
Ang I levels are higher than those of Ang II.'"-"0 
References are presented in the general reference list. 
94 
Chapter 8 
Angiotensin-converting enzyme is the main 
contributor to angiotensin 1-11 conversion in the 
interstitium of the isolated perfused rat heart 
J Hypertens. 2001; 19: 959-965 
ChapterS 
Summary 
Recent studies in homogenized hearts suggest that chymase rather than angiotensin-
converting enzyme (ACE) is responsible for cardiac angiotensin (Ang) I to Ang II conversion. 
We investigated in intact rat hearts whether (i) enzymes other than ACE contribute to Ang I to 
Ang IT conversion, and (ii) the localization (endothelial/extra-endothelial) of converting 
enzymes. We used a modified version of the rat Langendorff heart, allowing separate 
collection of coronary effluent and interstitial fluid. Hearts were perfused with Ang I (arterial 
concentration 5-l 0 pmoVml) under control conditions, in the presence of captopril (l !1M) or 
after endothelium removal with 0.2% triton X-100. Endothelium removal was verified as the 
absence of a coronary vasodilator response to 10 nmol bradykinin. Ang I and Ang II were 
measured in coronary effluent and interstitial fluid with sensitive radioimmunoassays. In 
control hearts, 45% of arterial Ang I was metabolized during coronary passage, partly through 
conversion to Ang IT. At steady-state, the Ang I concentration in interstitial fluid was three to 
four-fold lower than in coronary effluent, while the Ang IT concentrations in both fluids were 
similar. Captopril and endothelium removal did not affect coronary Ang I extraction, but 
increased the interstitial fluid levels of Ang I two- and three-fold, respectively, thereby 
demonstrating that metabolism (by ACE) as well as the physical presence of the endothelium 
normally prevent arterial Ang I from reaching similar levels in coronary effluent and 
interstitial fluid. Captopril, but not endothelium removal, greatly reduced the Ang II levels in 
coronary effluent and interstitial fluid. With the ACE inhibitor, the .A.ng WI ratios in coronary 
effluent and interstitial fluid were 83 and 93% lower, while after endothelium removal, the 
ratios were 33 and 71% lower. In conclusion, in the intact rat heart, ACE is the main 
contributor to Ang I to Ang II conversion, both in the coronary vascular bed and the 
interstitium. Cardiac ACE is not limited to the coronary vascular endothelium. 
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Introduction 
Recent evidence suggests that angiotensin~converting enzyme (ACE) is not the only enzyme 
capable of converting angiotensin (Ang) I into Ang II. An important alternative candidate is a 
serine protease, chymase.2os.:n1 Chymase is located in the adventitia, in the cytosol of mast 
cells, and in the extracellular matrix.61 In-vitro studies in human blood vessels and tissue 
homogenates clearly support its functional importance.29.z10.z11 In contrast, the results of in-vivo 
studies, consisting of systemic or regional infusions of Ang I or 1251-Ang I with simultaneous 
administration of an ACE inhlbitor, are less convincing.1tr7.zw.n2 It has been suggested that this 
is due to the fact that chymase converts Ang I predominantly at tissue sites, e.g., in the 
interstitial space, rather than in the circulation.231 Indeed, a study by Wei et a/.64 in dogs 
elegantly provided evidence for chymase-dependent Ang I to Ang II conversion in the cardiac 
interstitial space. 
Furthermore, mammalian chymases are biochemically heterogenous, in that primate, dog 
and hamster chymase highly efficiently convert Ang I into Ang II, whereas rat chymase also 
degrades Ang IVn3.234 Despite the latter observation, Akasu et al. 193 demonstrated that virtually 
all Ang I to Ang II conversion in rat heart homogenates is due to chymase. Similarly, Mil!ler 
et a/.28 were unable to block Ang I to Ang II conversion in rat left ventricular membranes with 
an ACE inhibitor. In view of the widespread use of the rat in cardiovascular studies, it is 
important to know (i) whether chymase contributes to Ang I to Ang II conversion in intact rat 
tissues, and (ii) whether this occurs in the circulation, in the interstitium or elsewhere. A 
unique model to address these issues is a modified version of the Langendorff heart, which 
enables the investigator to separately collect the coronary effluent and the transudate derived 
from the interstitial fluid compartment.36.47 We report here on the use of this model to study 
the generation of Ang II during infusion of Ang I in the presence or absence of the ACE 
inhibitor captopril. In addition, we investigated the importance of extra-endothelial converting 
enzymes by infusing Ang I into de-endothelialized hearts. 
Materials and methods 
Chemicals 
[Ile']-Ang-(1-10) decapeptide (Ang I) and [Ue']-Ang-(1-8) octapeptide (Ang II) were 
obtained from Bachem (Bubendorf, Switzerland). Bovine serum albumin (BSA), captopril 
and bradykinin were from Sigma (St. Louis, MO, USA). 1,10-Phenanthroline was from 
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Merck (Darmstadt, Germany). Sodium pentobarbital was obtained from Apharma (Arnhem, 
The Netherlands). Endothelin-1 was obtained from Neosystem Laboratoire (Strassbourg, 
France). 
Preparation of the modified Langendorff heart 
All experiments were performed under the regulation of the Animal Care Committee of the 
Erasmus University Rotterdsm, Rotterdsm, The Netherlands, in accordance with the 'Guiding 
principles in the care and use of animals' as approved by the American Physiological Society. 
Male Wistar rats (Harlan, Zeist, The Netherlands; 280-400 g) were anesthesized with 
pentobarbital (60 mg!kg, intraperitoneally), and heparinized (5,000 U/kg, intravenously). The 
hearts were rapidly excised, cooled in ice-cold Tyrode's buffer (125 mM NaCl, 4.7 mM KCl, 
1.4 mM CaCh, 20 mM NaHCO,, 0.4 mM NaH,P04, 1.0 mM MgC12, 10 mM D-glucose, pH 
7.4) until contractions stopped, and prepared for Langendorf[ perfusion. Carbogen-gassed 
(95% Oz/5% C02) Tyrode's buffer at 37°C was continuously perfused innnediately after 
carmulation of the aorta, at a constant perfusion pressure of 80 mmHg. Subsequently the 
pulmonary artery was cannulated and the caval and pulmonary veins were carefully ligated. 
After the ligation procedure, which took 30-45 minutes, the hearts were allowed to stabilize 
for30min. 
With this modified Langendorff heart preparation it is possible to collect separately 
coronary effluent and interstitial fluid?M7 Coronary effluent, ejected by the right ventricle, 
was collected via the carmulated pulmonary attery. Interstitial fluid, which keeps dripping 
from the heart, was collected at the apex. An interstitial fluid flow >2% of the coronary flow 
was considered to be an indication of leakage, e.g., from veins that were not properly 
ligated.47 Hearts with such high interstitial fluid flow were therefore not used. 
Removal of the coronary endothelium 
In some Langendorf[ heatts, the coronary endothelium was disrupted with a single bolus 
injection (0.1 ml) of triton X-100 (0.2% in Tyrode's buffer, v/v) into the aortic carmula. This 
approach has been reported previously to selectively destroy the endothelium of the isolated 
heart, without affecting the smooth muscle layer. ~35 Endothelium disruption was verified in 
each heart by comparing the vasodilatory, endothelium-dependent effects of 10 nmol 
bradykinin"' before triton X-100 with its effects after treatment. The viability of the 
underlying smooth muscle cells was tested by comparing the vasoconstrictor effects of 30 
pmol endothelin-1 before and after treatment. 
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Perfusion with angiotensin I 
After the 30-min stabilization period, Ang I was infused, via a T -connection, into the 
cannulated aorta at a speed of 40 pmoVmin for a period of 15 min, either with or without 
captopril (1 flM in the perfusion buffer). In previous studies we have shown that the Ang II-
mediated reduction in coronary flow at this infusion rate is transient, and that coronary flow 
returns to baseline within 2-3 min after the start of the Ang I infusion.36.47 At the end of the 
infusion period, the hearts were rapidly frozen in liquid nitrogen for the measurement of 
tissue Ang I and Ang II. Coronary effluent and interstitial fluid were collected during the 
infusion over two time periods (from 7-10 and from 11-14 min) in order to measure the 
steady-state levels of .Ang I and Ang II in coronary effluent and interstitial fluid. Coronary 
flow at the time of coronary effluent and interstitial fluid sampling was similar in control 
hearts (6±2 ml/min; mean±SD, n~I5), de-endothelia1ized hearts (6±2 ml/min; n~S), and 
hearts that were exposed to captopril (8±2 m.Vmin; n=-7). The coronary effluent samples were 
collected into BSA-coated 50-ml polystyrene tubes. Samples of interstitial fluid were 
collected into BSA-coated 1.5-mL Eppendorf cups. The Eppendorf cups and polystyrene 
tubes contained a mixture of inhibitors, 10 !!I in the Eppendorf cups and 2,500 !!I in the 
polystyrene tubes, in order to prevent the conversion of Ang I to Ang II and the degradation 
of Ang I and Ang II. The mixture consisted of 125 mM disodiurn EDTA and 25 mM 
1,10-phenanthroline. The Eppendorf cups and polystyrene tubes were kept on ice during the 
per:fusions, so that the samples were rapidly cooled during their collection and remained cold 
(0-4 °C) during the experiment. When the experiment was completed, the samples for Ang I 
and Ang II measurements were frozen at -80 °C. 
Measurements of angiotensin I and angiotensin II 
The Ang I and Ang II concentrations in coronary effluent and interstitial fluid samples were 
measured directly with sensitive radioimmunoassays.29.36·1n Measurements were made in 50 ~1 
of undiluted coronary effluent and in 50 1!1 interstitial fluid diluted with 25 !!I of 0.25 mol/1 
phosphate buffer, pH 7.4, containing 0.15 mol/1 NaCI. The lowest measurable Ang I 
concentration was 15 frnol/ml in coronary effluent and 40 frnollml in interstitial fluid. The 
lowest measurable Ang II concentration was 10 frnollml in coronary effluent and 25 frnollml 
in interstitial flnid. 
The cardiac tissue concentrations of Ang I and Ang II were measured by 
radioimmunoassay, after SepPak extraction and reversed phase-high performance liquid 
chromatography (HPLC) separation."·'"' The lowest levels of Ang I and Ang II that could be 
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measured with the radioimmunoassays after HPLC separation were 2.0 and 1.0 fmol/g cardiac 
tissue, respectively. 
Data analysis 
All data are given as mean±SD. To correct for differences in arterial Ang I delivery, the Ang I 
and Ang ll levels :in coronary effluent, :interstitial fluid and cardiac tissue (Table 1) were 
expressed as a percentage of the arterial levels of Ang I, based upon the assumption that I g 
of tissue equals a volume of I mi." The mean of the coronary effluent and interstitial fluid 
levels in the samples collected from 7-10 min and from 11-14 min after the start of the Ang I 
perfusion was taken as the steady~state concentration. Differences between experimental 
groups were evaluated for statistical significance by Student's unpaired t-test. Differences 
within groups were evaluated for statistical significance by Student's paired 1-test. P<0.05 was 
considered statistically siguificant. 
Table 1. Angiotensin I and angiotensin II levels (mean±SD) in coronary effluent interstitial fluid and 
tissue of rat Langendorff hearts perfused with angiotensin I in the absence (control; n=15) or presence 
of captopril (n=7), or following endothelium removal (n=5). The arterial angiotensin I levels in the three 
groups were 7.1±3.0, 5.1±1.9 and 6.7±1.5 pmol/ml, respectively. 
Control Captopril De-endothelialized 
Angiotensin I (pmol/ml or pmol/g) 
Coronary effluent 3.7±1.5 2.8±0.8 3.6±0.6 
Interstitial fluid 1.1±0.8 1.7±0.6 3.0±0.7 
Tissue 0.27±0.08 0.20±0.06 0.44±0.15 
Angiotensin II (pmol/ml or pmollg) 
Coronary effluent 0.36±0.20 0.03±0.02 0.15±0.02 
Interstitial fluid 0.50±0.30 0.03±0.01 0.24±0.02 
Tissue 0.14±0.06 NO 0.08±0.01 
NO, not detectable 
Results 
Removal of the coronary endothelium 
Triton X-!00 treatment did not affect baseline coronary flow but increased interstitial fluid 
flow to approximately 10% of the coronary flow. Prior to the addition of triton X-100, 
10 nmol bradykinin increased coronary flow from 7.2±1.9 to 18.3±6.1 mllmin (n=7; P<O.Ol), 
whereas 30 pmol endothelin-1 decreased coronary flow from 11.7±7.1 to 5.9±4.8 mllmin 
(n=4; P<0.05). After triton X-100 treatment, bradykinin could no longer induce vasodilation 
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(increase in flow 0.4±0.6 ml/min; l'=NS), whereas the effect of endothelin-1 was unchanged 
(decrease in flow 5.7±1.9 ml/min; P<0.05). These data, obtained in separate hearts that were 
not exposed to Ang I, show that endothelium removal was successful and did not affect the 
viability of the smooth muscle cells. 
Figure 1. Angiotensin I concentrations in coronary effluent (CE), interstitial fluid (ISF) and tissue of rat 
Langendorff hearts perfused with angiotensin I in the absence (control, open bars; n=15) or presence 
of 1 !J.M captopril (hatched bars; n=7), or following endothelium removal (black bars; n=5). Data 
(mean±SD) are expressed as a percentage of the arterial angiotensin r levels (7.1±3.0, 5.1±1.9 and 
6.7±1.5 pmol/ml, respectively)."" P<0.05 or t P<0.01 versus control. 
Angiotensin I and angiotensin If levels during perfusion with angiotensin I 
(Table 1) 
Coronary effluent. Dl.lling perfusion with Ang I, the steady~state Ang I level in coronary 
effluent was 55% of the arterial level (Figure 1). Thus, 45% of arterially delivered Ang I was 
removed from the perfusate by the heart. Part of the removal was caused by Ang I to Ang II 
conversion, since the perfusate contained Ang II levels corresponding to 3% of the arterial 
Ang I levels (Figure 2). Neither captopril, nor endothelium removal affected coronary Ang I 
extraction. In contrast, captopril greatly reduced the Ang II levels in coronary effluent, 
resulting in a 83% reduction of the Ang II/I ratio in coronary effluent (Figure 3). Endothelium 
removal marginally reduced the Ang II levels in coronary effluent, leading to 33% reduction 
(P<0.05) of the Ang IIII ratio in coronary effluent. 
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Figure 2. Angiotensin 1l concentrations in coronary effluent {CE), interstitial fluid (ISF) and tissue of rat 
Langendorff hearts perfused with angiotensin I in the absence (control, open bars; n=15) or presence 
of 1 J.LM captopril (hatched bars; n=7), or following endothelium removal (black bars; n=5). Data 
(mean±SD) are expressed as a percentage of the arterial angiotensin I levels (7.1±3.0, 5.1±1.9 and 
6.7±1.5 pmol/ml, respectively). ""P<0.05 or t P<0.01 versus control. NO, not detectable. 
Interstitial fluid. Under control conditions, the steady-state Ang I levels in interstitial fluid 
were lower than in coronary effluent (Figure 1), whereas the steady-state Ang II levels in this 
compartment were comparable to or higher than in coronary effluent (Figure 2). 
Consequently, the Ang II/I ratio was approximately four- to five-fold higher in interstitial 
fluid than in coronary effluent (Figure 3). In the presence of captopril, the Ang I levels in 
interstitial fluid doubled, and the Ang II levels in interstitial fluid were reduced to levels close 
to the detection limit. The interstitial Ang II/I ratio was 93% lower after captopril. 
Endothelium removal allowed the Ang I levels in interstitial to equal the levels in coronary 
effluent; the interstitial Ang II levels were unchanged following de~endothelialization. 
However, due to the increased Ang I levels, the Ang II/I ratio in interstitial fluid was reduced 
by 71% after endothelium removal. 
Tissue. The tissue level of Ang I in control hearts (per g tissue), innnediately after the 
perfusion had been switched off, was 4% of the arterial level (per ml perfusate) (Figure 1 ). 
This is much lower than expected on the basis of the Ang I levels in coronary effluent and 
interstitial fluid, suggesting that Ang I was rapidly degraded in the short period between the 
moment the Ang I perfusion was stopped and the moment the tissue was transferred into 
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liquid nitrogen. In contrast, the tissue level of Ang ll more closely resembled its level in 
coronary effluent and interstitial fluid (Figure 2). Consequently, the Ang II/I ratio in cardiac 
tissue was >I 0-fold higher than in coronary effluent (Figure 3). Captopril and endothelium 
removal did not siguificantly alter the tissue Ang I levels. Tissue Ang IT was undetectable in 
the presence of captopril, and slightly reduced (P=NS) after endothelium removal. Both 
procedures significantly reduced the tissue Ang ll/1 ratio. 
CE ISF Tissue 
Figure 3. Angiotensin 11/1 ratios in coronary effluent (CE), interstitial fluid (ISF) and tissue of rat 
Langendorff hearts perfused with angiotensin I in the absence (control, open bars; n=15) or presence 
of 1 f..LM captopril (hatched bars; n=7), or following endothelium removal (black bars; n=S). Data are 
mean±SD. "'P<O.OS or t P<0.01 versus control. NO, not detectable. 
Discussion 
The results of this study do not support the concept of Ang I to Ang IT conversion by enzymes 
other than ACE in the intact rat heart, either in the coronary circulation, or in the interstitial 
space, or elsewhere in the heart. Thus, our findings do not confirm studies in heart 
homogenates that suggested that cardiac Ang I to Ang ll conversion is mainly due to 
chymase.28•193 ,2os,237 There may be two reasons for this discrepancy. First, rat chymase, as 
opposed to human and dog chymase, also cleaves Ang IT. It is unlikely that this property 
prevented us from detecting chymase-dependent Ang I to Ang IT conversion in intact hearts, 
since such conversion was readily detectable in rat heart homogenates.28•193 
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Second, chymase might be located at a site that cannot be reached by arterially delivered 
Ang I. Indeed, the majority of chymase is present in the cytosol of mast cells, from where it 
will only be released upon cell disruption (e.g., after tissue homogenization). However, 
chymase is also present in the extracellular matrix.61 Functional evidence for this contention 
was obtainedi.in the dog heart by infusing micromolar concentrations of Ang I with a 
microdialysis probe directly into the interstitial space.64 The Ang II levels measured in the 
interstitial dialysate under the latter circumstances were <5% of the dialysate Ang I levels. In 
the present study, the interstitial Ang II levels, relative to Ang I, were five to l 0-fold higher, 
and yet none of this Ang II appeared to have been generated by chymase, since captopril 
reduced the Ang II/I ratio in interstitial fluid by >90%. Thus, the most likely explanation for 
the discrepancy between the results obtained in intact and homogenized rat hearts is indeed 
that, under normal circumstances, chymase is located at a site that is not accessible to either 
intravascular or interstitial Ang I. 
Unfortunately, we were unable to further substantiate this conclusion by performing Ang I 
perfusion experiments in the presence of a selective chymase inhibitor. Such drugs are 
currently not available, and studies investigating chymase therefore make use of non-selective 
serine protease inhibitors such as soybean trypsin inhibitor and chymostatin.28.29•64•193 .2°~.2 10211 .237 
In our experimental setup, the latter drug, at a concentration required to block chymase 
completely (100 ~,29 as well as at a ten-fold lower concentration, immediately reduced 
coronary flow to zero (n:=3, Danser et al., unpublished observations). 
The accessibility of chymase may be different under pathological conditions, e.g. after 
myocardial infarction. It might also be the case that tissue damage caused by the 
microdialysis technique is the underlying cause of the chymase-dependent Ang IT generation 
in the normal dog heart.'' Chymase-dependent Ang II generation in the intact dog heart 
would offer an explanation for the lack of effect of ACE inhibitor treatment on volume 
overload-induced cardiac hypertrophy.23H Interestingly, and in support of the present study, 
ACE inhibitors do reduce cardiac hypertrophy in rats exposed to volume overload. 239 
The second aim of this study was to investigate Ang I to Ang II conversion by extra-
endothelial converting enzymes. Removal of the endothelium, verified as the absence of a 
vasodilator response to bradykinin,'" reduced, but not abolished Ang II generation. Based on 
the effects of captopril in intact hearts, it appears that such extra-endothelial conversion is due 
to ACE. Thus, our data clearly provide evidence for the presence and functional importance 
of ACE outside the endothelium, although no conclusions can be dra\VIl on the exact location 
of the enzyme. Several cells in the heart and the vessel wall, including myocytes, fibroblasts, 
104 
Angiotensin 1-11 conversion in cardiac interstitial fluid 
valvular interstitial cells and vascular smooth muscle cells have been reported to synthesize 
ACE.43,24()..242 The modest reduction in the coronary effluent levels of Ang II following 
endothelium removal suggests that ACE located on vascular smooth muscle cells is an 
important contributor to circulating Ang IT. Pipili et al.243 demonstrated earlier that the 
majority of vascular ACE in the rat, unlike vascular ACE in humans~44 and pigs,227 is present 
in the media. The low degree of Ang I to Ang IT conversion in the coronary vascular bed in 
the present study, combined with our earlier observation that ACE~mediated conversion is 
flow-independeufl)9, suggests that ACE is rate-limiting with regard to coronary Ang IT 
generation. 
Removal of the endothelium allowed arterial Ang I to reach the same levels in the 
interstitial space as in the coronary circulation. This was not the case in intact hearts, in 
agreement with in-vivo studies demonstrating that circulating Ang I contributes little to the 
levels of interstitial and tissue Ang J.14•196 Thus, either endothelial peptidases prevent 
circulating Ang I from entering the interstitium, or the endothelium is the most important 
physical barrier between the interstitium and the coronary circulation. The former explanation 
is supported by the increased interstitial Ang I levels in the presence of captopril. The latter 
explanation would imply that, in the absence of the endothelium, interstitial fluid and 
coronary effluent are virtually identical. Indeed, the angiotensin content of both fluids after 
triton X -100 treatment was similar. Therefore, although this concept does not alter our 
conclusions on the importance of extra-endothelial ACE, these experiments do not allow us to 
draw definite conclusions on the origin of interstitial Ang IT in hearts lacking endothelium. 
Tissue homogenization resulted in the immediate loss of virtually all cardiac Ang I. This 
was not the case for Ang II, indicating that Ang II, unlike Ang I, is located in a protected 
compartment with less exposure to degrading enzymes. In view of the long half-life of 
internalized Ang II'' and the reduction in cardiac Ang II after pretreatment of the heart with 
the AT 1 receptor antagonist losartan,36 this compartment is most likely the AT 1 receptor, either 
located on the cell surface or internalized. 
In conclusion, in the intact rat heart, ACE is the main, if not the only, contributor to Ang I 
to Ang IT conversion, both in the coronary vascular bed and the interstitium. Cardiac ACE is 
not limited to the coronary vascular endothelium. 
References are presented in the general reference list. 
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Summary and general discussion 
Chapter 9 
Summary 
Introduction 
The beneficial effects of renin-angiotensin system blockers on cardiac structure and function 
are usually explained based on the capacity of these drugs to interfere with angiotensin 
(Ang) II synthesis at cardiac tissue sites. Such local synthesis may occur in the interstitial 
space, on the surface of, or within cardiac cells. Based on the studies reporting high 
intracellular Ang II levels, it seems likely that Ang II is an intracrine hormone. However, it is 
currently uncertain whether all other components required to synthesize Ang II are present in 
the cell. Furthermore, although most effects of Ang II are mediated via angiotensin II type 1 
(ATt) receptors, the effects occurring after angiotensin II type 2 (AT2) receptor stimulation 
are not entirely clear. Therefore, it was the aim of the present thesis to investigate the 
consequences of AT2 receptor stimulation and to unravel whether cardiac Ang II is an para-, 
auto- and/or intracrine hormone. 
Chapters 2 and 3 
To investigate the vasoactive role of the AT2 receptor upon Ang II stimulation and the 
counterbalancing effects ofvasodilatorprostanoids and nitric oxide on AT1 receptor-mediated 
vasoconstriction, normotensive Wistar rats were infused with increasing doses of Ang II after 
pretreatment with saline, antagonists of AT 1 or AT 2 receptors or inhibitors of cyclooxygenase 
or nitric oxide synthase, respectively. Systemic and regional hemodynamics were investigated 
using the radioactive microsphere method. Ang IT increased mean arterial blood pressure and 
heart rate and decreased systemic vascular conductance. The latter was caused by decreases in 
the conductance of gastrointestinal tract, kidney, skeletal muscle, skin, mesentery+pancreas, 
adrenal and spleen. The AT1 receptor antagonist, irbesartan, inhibited all hemodynamic 
responses induced by Ang II, whereas blockade of the AT2 receptor with PD123319 was 
without effect, demonstrating that under normal conditions the Ang II-induced systentic and 
regional hemodynamic effects are mediated via the ATr receptor only. Cyclooxygenase 
inhibition by indomethacin, but not nitric oxide synthase inhibition by N" -nitro-1-arginine 
methyl ester (L-NAME), enhanced. the Ang II-induced vasoconstriction systentically as well 
as regionally, showing that vasodilator prostanoids, but not nitric oxide, are involved in 
counteracting the Ang IT-induced vasoconstrictor effects. 
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Chapters 4 and 5 
To study the functional consequences of AT2 receptor upregulation123•163 and the importance of 
local Ang II generation after myocardial infarction (MI), coronary artery-ligated rats and pigs 
were infused with Ang II and 125I-labeled Ang I, respectively. In sham-operated and MI rats, 
consecutive Ang II infusions did not affect myocardial vascular conductance, whereas the 
conductance during Ang II infusion was decreased in sham-operated rats by PD123319 and 
increased in MI rats by irbesartan, demonstrating first, that stimulation of the AT 2 receptor in 
the heart causes coronary vasodilation and second, that this effect is enhanced after MI. The 
Ang IT-induced systemic effects in the presence or absence ofirbesartan or PD123319 were 
similar in sham-operated and MI rats, suggesting that AT 2 receptors do not contribute 
importantly to systemic hemodynamics after MI. 
The AT 1 receptor antagonist, eprosarta.n, as well as the angiotensin-converting enzyme 
(ACE) inhibitor, captopril, prevented the development ofleft ventricular hypertrophy in pigs 
following MI. Remarkably, however, both drugs increased the Ang II generation at cardiac 
tissue sites, suggesting that not only diminished AT 1 receptor stimulation but also increased 
stimulation of the growth-inhibitory AT, receptor in the myocardium'"·'" might play a role in 
the beneficial effects of these drugs after MI. AT1 receptor-mediated uptake of circulating 
125I-Ang II was increased at 1 and 3 weeks after MI in the noninfarcted LV, and tltis uptake 
was the main cause of the transient elevation in Ang II levels in the noninfarcted LV at 
1 week. These data show that both circulating and locally generated Ang II contribute to the 
remodeling process after MI. 
Chapter 6, 7 and 8 
To determine the site of cardiac Ang II generation, as well as the enzyme(s) (ACE and/or 
chymase) contributing to tltis generation, the circulating and interstitial levels of Ang I and 
Ang II were compared in vivo and in vitro with and without application of exogenous 
( 2'1-)Ang I and Ang II. 
During intracoronary 1251-Ang II infusion in the pig, the aortic A.ng I and A.ng II levels 
were comparable to their levels in coronary venous plasma, while the A.ng I and A.ng II levels 
in the myocardial interstitial fluid were of the same order of magnitude as those in the 
circulation. In untreated pigs, at steady-state, the 1251-A.ng II levels in left ventricular tissue 
were similar to the 1251-Ang II level in coronary venous plasma. Under these circumstances 
the ex-vivo half-life of tissue 1251-Ang II was >30 min. In contrast, after AT1 receptor 
blockade with L-158,809, the 125I-Ang II levels in the left ventricular tissue decreased to <5% 
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of the coronary venous 125I-Ang II levels and tissue 125I-Ang II disappeared within 15 min. 
These data demonstrate that binding to AT 1 receptors protects Ang II against metabolism. 
Since interstitial levels of 1251-Ang II were <3 %of the coronary venous 1251-Ang II levels, it 
appears that circulating Ang II does not contribute importantly to the interstitial levels of 
Angll. 
Measurement of Ang I and Ang II in organ bath fluid during equimolar Ang I and Ang II 
application to isolated porcine arteries, demonstrated that during Ang I application the Ang II 
levels in the bath were ~18 times lower than during Ang II application. Remarkably, however, 
the potencies of both angiotensins differed only ::::::2-fold. Ang II measured in vascular tissue 
was 2.9±1.5% and 12.2±2.4% of the corresponding Ang I and II bath fluid levels. Tissue 
Ang II was not affected by AT, or AT 2 receptor antagonists, suggesting that it was mainly 
located in the interstitial fluid. Since ::::::15% of tissue weight consists of interstitial fluid, it can 
be calculated that the interstitial Ang II levels during Ang II application are similar to the 
Ang II bath fluid levels, whereas during Ang I application, they are 8.8-27 fold higher. 
Consequently, at equimolar application of Ang I and II, the interstitial Ang II levels differ 
only 2-4 fold. Thus, interstitial, rather than circulating, Ang II determines vasoconstriction. 
Furthermore arterial Ang I, which tlrrough regional conversion results in high interstitial 
Ang II levels, may be of greater physiological importance than arterial Ang II. In these 
in-vitro studies, the ACE inhibitor, quinaprilat, fully prevented Ang II generation during 
Ang I administration, suggesting that in porcine vessels ACE is the only converting enzyme. 
Similar observations were made in a modified version of the rat Langendorff heart, which 
allows separate collection of coronary effluent and interstitial fluid. Hearts were perfused with 
Ang I under control conditions, in the presence of captopril or after endothelium removal with 
0.2% triton X-100. In control hearts, at steady-state, the Ang I concentration in interstitial 
fluid was three- to four-fold lower than in the coronary effluent, whereas the Ang II 
concentrations were similar. Captopril or endothelium removal did not alter coronary Ang I 
extraction, but increased the interstitial fluid levels of Ang I two- and three-fold, respectively. 
This demonstrates that ACE as well as the physical presence of the endothelium normally 
prevent the passage of intact arterial Ang I into the interstitial fluid. In the coronary effluent 
as well as the interstitial fluid, captopril, but not endothelium removal, greatly reduced the 
Ang II levels. Thus, ACE is the main contributor to Ang 1-to-Ang II conversion in the intact 
rat heart, and its presence is not limited to the coronary vascular endothelium. 
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General discussion 
Function of the A T2 receptor 
AT 2 receptors are assumed to decrease blood pressure and cardiac cbronotropy and to inhibit 
growth. Inbibition of growth during pathological conditions is in agreement with our 
observations in pigs following MI. ACE inhibition as well as AT1 receptor blockade increased 
Ang II levels in the infarcted myocardium, whereas both treatments prevented the 
development of left ventricular hypertrophy. The vasodilator effects mediated via AT2 
receptors are still highly controversial. For instance, the enhanced blood pressure responses to 
Ang II that were initially reported in AT2 receptor knockout mice103.104 are now attributed to 
the upregulation of AT1 receptors in these animals. 131 We were unable to observe systemic 
vasodilator responses following ATz receptor stimulation in normotensive Wistar rats. All 
systemic hemodynamic effects during Ang II infusion could be attributed to AT1 receptor 
stimulation. We also did not find evidence for Ang II-induced release of nitric oxide, the 
mediator that is assumed to be responsible for the ATz receptor-mediated vasorelaxation. 1 ~4•245 
Remarkably, although not observed in other regional vascular beds, stimulation of the AT2 
receptor resulted in vasorelaxation in the myocardial vascular bed. Interestingly, this 
vasodilatory effect was enhanced after l\.1I, in full agreement with the many studies reporting 
an upregulation of AT 2 receptor under pathological conditions. 123•163 
Tissue Ang II generation 
Cardiac Ang II is largely formed at cardiac tissue sites. Circulating Ang II, which is 
sequestered by the heart via AT 1 receptor-mediated endocytosis, contributes little to the 
cardiac Ang II levels, except perhaps under pathological conditions (e.g. acutely after MI) 
when AT1 receptors are upregulated. Rapid metabolism, most likely in the vascular wall, also 
prevents circulating Ang II from contributing importantly to interstitial Ang II. 
Although several studies have suggested that myocardial Ang II acts as an intracrine 
hormone, our data do not support this concept. We therefore conclude that intracellular Ang II 
generation at cardiac tissue sites is unlikely to occur, except perhaps in transgenic animals 
expressing mutated angiotensinogen variants that cannot be secreted. 55 The impossibility of 
intracellular Ang II generation is mainly related to the fact that normally neither 
angiotensinogen nor ACE are available intracellularly. This conclusion implies that the 
internalization of renin and prorenin and the intracellular activation of prorenin via 
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M6PIIGFII receptors" represent (pro )renin clearance rather than the initial step leading to 
intracellular angiotensin generation. From our studies in isolated porcine vessels246 and in the 
rat Langendorff heart,36 it appears that tissue Ang II generation occurs in the extracellular 
fluid compartment and that Ang I-II conversion depends on ACE rather than chymase. 
Circulation 
Endothelium 
Interstitial fluid 
Myocytes 
Figure 1. Model of cardiac angiotensin II generation. Ang, angiotensin; Aogen, angiotensinogen; AT, 
angiotensin II receptors. 
Extracellular angiotensin generation in the heart may occur on the cell surface of cardiac 
cells and/or in the interstitial space. Cell surface angiotensin generation is particularly 
supported by studies revealing that membrane-bound renin cleaves angiotensinogen much 
more efficiently than soluble renin68 and that Ang IT-mediated effects occur at 100-fold or 
20-fold lower extracellular Ang IT levels during renin+angiotensinogen29·69 or Ang I 
application (chapter 7), respectively, than during Ang II application. Apparently, angiotensin 
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generation on the cell surface results in high Ang II levels in the microenvironment of AT 
receptors, allowing immediate binding of Ang II to its receptors rather than leakage into the 
interstitium. This concept would explain why the modest changes in Ang II generation and/or 
AT receptor density that occur under pathological conditions85·89.91 have functional 
consequences. 
Cardiac Ang II levels, despite the dependency of the heart on circulating (pro )renin, do not 
always run in parallel with circulating Ang II. For instance, in our study in the infarcted pig," 
cardiac, but not plasma, Ang II levels rose during ACE inhibition, and yet ACE inhibitors 
prevented cardiac remodeling following MI. Possibly, this rise in cardiac Ang II represents 
non-functional Ang II, generated by chymase at a site distant from AT receptors. Similarly, 
the hearts of transgenic mice expressing an Ang IT-producing fusion protein in 
cardiomyocytes were virtually normal,~ despite a 20- to 40-fold rise in their Ang II content. 
Taken together the data in this thesis as well as of other investigators stress the importance of 
Ang II generation at the right place (i.e., on the cell surface in the immediate vicinity of AT 
receptors; figure 1) in order to have functional consequences. 
Finally, the lack of intracellular generation of Ang II does not mean that Ang II has no 
intracellular effects. It merely means that Ang II is not an intracrine hormone, i.e. a hormone 
that is synthesized and acts intracellularly. Since most tissue Ang II is cell-associate~67•74 it is 
in fact very well possible that AT1 receptor-mediated internalization of Ang II underlies its 
effects as an autocrine or paracrine hormone. 
Clinical relevance 
AT2 receptor agonists might exert benificial effects in the heart. However, since AT1 receptor 
blockade also results in stimulation of AT2 receptors, it is questionable whether selective AT2 
receptor agonists would add to the treatment of heart failure. Moreover, if tissue Ang II is 
formed on the cell surface and not intracellularly, membrane-permeable ACE inhibitors and 
AT 1 receptor antagonists will not act differently from their nonmembrane-permeable 
counterparts. On the other han~ to not only treat hypertension, but also to improve heart 
structure and function following MI in subjects with heart failure, these RAS blockers do 
need to pass the endothelial layer in order to interfere with the close cascade of reactions of 
angiotensinogen to Ang II and the subsequent binding of Ang II to AT receptors on the 
surface of cardiac cells. 
References are presented in the general reference list. 
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Angiotensine IT, het eindprodukt van het renine-angiotensine systeem, is in het lichaam een 
belangrijk hormoon voor de regulatie van de bloeddruk en de herstrukturering van het 
hartweefsel na een hartinfarct. In de bloedbaan wordt angiotensine II gevormd door het 
angiotensine-converterend enzym 
(ACE) uit angiotensine I. wat op zijn 
beurt door renine gevormd wordt uit 
angiotensinogeen (Figuur 1). Activatie 
van de angiotensine II type I (AT1) 
receptor door angiotensine II Ieidt in 
de bloedvaten tot vaatvemauwing, en 
in het hart tot groei van de 
hartspiercellen en tot een lcrachtiger 
pompfunctie. De effecten veroorzaakt 
door activatie van de angiotensine II 
type 2 (AT,) receptor zijn momenteel 
nag niet helemaal duidelijk. Resu!taten 
van studies naar de werking van de 
Anglotenslnogeen 
~-+enlne -c:o Lever 
Nler 
Anglotenslne 1 
t /<>glotenslne \ 
--------~~ ~~--~va~ctw~a~n~d 
\_Effect) 
AT2 receptor, wijzen voorlopig in de 
Figuur 1. Schematisch weergave van het renine-
richting van effecten tegengesteld aan angiotensine systeem in de bloedbaan. 
die van de AT1 receptor. 
Klinische en experimentele studies met medicijnen die het renine-angiotensine systeem 
blokkeren, Iaten zien dat de gunstige effekten van deze middelen op de struktuur en funktie 
van het hart niet volledig toegeschreven kunnen worden aan hun bloeddrukverlagende effekt. 
Daarom is het algemeen geaccepteerd dat angiotensin II niet alleen in de bloedbaan, maar ook 
lokaal in het hart gevormd wordt. Deze lokale synthese kan plaatsvinden in de vloeistoftussen 
de cellen (interstitiele vloeistof), op het oppervlak van, of in de hartcellen. Gezien studies die 
hoge concentraties van angiotensine IT in de hartspiercellen melden, lijkt het erop dat 
angiotensine II in de eel gemaakt wordt. Het is echter onzeker of alle andere componenten 
betrokken bij de angiotensine II produktie aanwezig zijn in de eel. 
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Aangezien nog niet alle effecten veroorzaakt door angiotensine II~ alsmede de plaats van 
synthese van dit hormoon bekend zijn, is het doe! van dit proefschrift om de functie van de 
AT 2 receptor te onderzoeken en te bepalen op we~e plek in bet bartweefsel angiotensine II 
gevormd wordt 
De functie van de AT2 receptor 
In overeenstemming met een effect tegengesteld aan AT 1 receptoren, worden AT 2 receptoren 
verondersteld de bloeddruk en de bartslag te verlagen evenals de groei van cellen te remmen. 
Een remming van groei door activatie van de AT 2 receptor wordt ondersteund door onze 
studie in varkens met een hartinfarct; tijdens ACE rermning ofblokkade van de AT1 receptor 
waren namelijk de angiotensine II spiegels in bet gelnfarceerde ba.rtvveefsel verboogd. Beide 
bebandelingen voorkwamen ecbter de bypertrofie (vergroting van de bartspiercellen; een 
proces was tijdens hartinfarct optreedt) van de linker hartkamer, terwijl tijdens ACE rermning 
de AT 1 receptor, die juist celgroei stimuleert, gewoon geactiveerd kon worden. Mogelijk werd 
de hypertrofie geremd door activatie van de ATz receptor als gevolg van de verhoogde Ang II 
spiegels. 
Eventuele vaatverv.rijdende effecten veroorzaakt via ATz receptoren zijn nog steeds zeer 
controversieel. Bijvoorbeeld, de verhoogde bloeddruk tijdens angiotensine II toediening in 
muizen waarbij de ATz receptoren genetisch uitgeschakeld waren, werd eerst toegeschreven 
aan de afwezigheid van AT2 receptoren, terwijl tegenwoordig meer wordt gedacht aan een 
vermeerdering van de AT1 receptoren. Tijdens activatie van de AT2 receptoren door 
angiotensine n toediening in ratten, konden wij gemiddeld in bet gehele dier gezien geen 
vaatverwijdende effecten waamemen. Aile gemiddelde effekten tijdens angiotensine II 
toediening, konden worden verklaard door activatie van de AT 1 receptoren. Hiermee in 
overeenstemming, hebben wij ook geen bewijs gevonden voor het vrijkomen van 
stikstofoxide tijdens de angiotensine II toediening. Stikstofoxide zou verantwoordelijk zijn 
voor de vaatverwijding tijdens activatie van de ATz receptor. 
Alhoewel we geen gemiddelde vaatverwijding in de totale rat gevonden hebben en ook niet 
in de meeste afzonderlijke organen, bleek dat activatie van de ATz receptor in de bloedvaten 
van bet hart wel vaatverwijding veroorzaakte en dat dit nog duidelijker aanwezig was na een 
hartinfarct. Dit laatste komt goed overeen met studies die een verhoging van AT 2 receptoren 
in bet hart melden tijdens zulke omstandigheden. 
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Vorming van angiotensin II in weefsel 
Angiotensine n in weefsel van het hart wordt voomamelijk lokaal gevormd. Opname van 
angiotensine n vanuit de bloedbaan door hechting aan AT1 receptoren, blijkt weinig bij te 
dragen aan angiotensine n in het weefsel. Waarschijnlijk wordt de opname verhinderd door 
afbraak van angiotensine II in de vaatw"and. In tegenstelling tot de verschillende studies die 
suggereren dat angiotensine II in de eel gevormd zou worden, bleek in bet varkenshart dat 
angiotensine I aileen aanwezig was in de interstitiCle vloeistof en niet in de hartspiercellen. 
Dit, in combinatie met studies die aantonen dat angiotensinogeen en ACE niet aanwezig zijn 
in de bartspiercellen, maakt het onwaarschijnlijk dat angiotensine n in de hartspiercel 
gevormd wordt. Een logiscber plek voor de vorming van angiotensine II is synthese buiten de 
eel. Dit wordt onderbouwd door het feit dat angiotensine II in geisoleerde varkensbloedvaten 
gevormd werd in de interstitiCle vloeistof en dat in de interstitiele vloeistof van geisoleerde 
rattenharten angiotensine I door ACE omgezet werd in angiotensine II. Ecn andcr cnzym, 
cbymasc, waarvan studies met vermalen hartvveefsel melden dat het angiotensine I kan 
omzetten in angiotensine II, bleek in intacte rattenharten nauwelijks bij te d.ragen aan deze 
omzetting. Voor de volledigheid moet vermeld worden, dat alhoewel angiotensine IT niet in de 
eel gemaak:t wordt, dit niet zonder meer betekent dat angiotensine n daar geen effect zou 
kunnen bebben. Door intemalisatie via de AT 1 receptor kan angiotensine II zeker lei den tot 
effecten in de hartspiercel. 
Vorming van angiotensine II buiten de bartcellen kan plaatsvinden op bet oppervlak van 
deze cellen of in de interstitiele vloeistof. Synthese op het celoppervlak lijkt het meest 
aannemelijk. Ten eerste zet celgebonden renine angiotensinogcen veel effectiever om in 
angiotensine I dan ongebonden renine. Ten tw"eede zijn de concentraties van angiotensine IT, 
bij een gelijk effect, op een afstand van de eel vcle kcren (20-100 x) lager tijdens 
angiotensine I of renine+angiotensinogeen tocdicning dan tijdens angiotensin II toediening. 
Blijkbaar leidt alleen synthese van angiotensin II op het celoppervlak tot boge angiotensine II 
conccntratics in de directe omgeving van de AT 1 en AT 2 receptoren, waardoor deze 
receptoren worden geactivcerd voordat angiotensine II weglekt. Dit concept zou eveneens 
verklaren waarom de geringe veranderingen in angiotensinc II vorming en/of het aantal AT 
receptoren tijdens pathologiscbe om.standigb.eden al functionele gevolgen bebben. 
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Conclusie en klinische re/evantie 
In dit proefscbrift word! aangetoond dat de AT2 receptorvoor vaatverwijding zorgt in bet hart, 
maar niet in andere organen, en dat de rol van de ATz receptor belangrijker wordt na een 
hartinfarct. Verder blijkt dat lokaal angiotcnsine II niet in, maar juist buiten de hartspiercel 
gevormd word! en dat dit zeer waarschijnlijk op bet celoppervlak plaatsvindt (Figuur 2). 
Eveneens benadrukt dit proefschrift het belang van vorming van angiotensinc IT op de juiste 
plek (op bet celoppervlak, dichtbij de AT reccptoren) om effecten te hebben. 
Bloedbaan 
lnterstitiele vloeistof 
Figuur 1. Model van angiotensine II vorming in hartweefsel. Ang, angiotensine; Aogeen, 
angiotensinogeen; AT, angiotensine tt receptoren. 
Gezien de rol van de AT2 receptor in het hart, zou activatie van de AT2 receptoren door 
middel van medicijnen gunstig kunnen zijn voor het hart. Echter~ medicijnen die AT1 
receptoren blokkeren leiden tot lokale verhoging van angiotensine II spiegels, waardoor deze 
AT 1 receptor blokkers automatisch zorgen voor een activatie van AT 2 receptoren. Daarom is 
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bet twijfelachtig of medicijnen die selectief de AT2 receptoren activeren iets zouden 
toevoegen aan de behandeling van hartfalen. 
Tevens kan gesteld worden, als vorming van angiotensine II in bet weefsel niet in de eel 
maar op het celoppervlak plaats vindt, dat ACE remmers en AT1 receptor blokkers die door 
de celwand kunnen dringen niet verschillend zullen zijn van medicijnen die deze eigenschap 
missen, Aan de andere kant, om niet aileen hoge bloeddruk maar ook de struktuur en funktie 
van bet hart na een hartinfarct te verbeteren. zullen deze remmers van bet renine-angiotensine 
systeem wel de endotheellaag van de vaat\vand moeten passeren om in te grijpen in de 
cascade van reacties van angiotensinogeen tot angiotensine II en de daaropvolgende binding 
van angiotensine II aan de receptoren op bet celoppervlak van hartspiercellen. 
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Als laatste dan het dankwoord. Aan de ene kant een erg leuke taak, omdat je nu eindelijk eens 
goed in de gelegenheid wordt gesteld om iedereen te bedanken die (in het klein en bet groot ) 
bijgedragen heeft aan de tot standkoming van dit proefschrift. Aan de andere kant toch ook 
een moeilijke taak, omdat ik me nu langzamerhand pas realizeer hoeveel mensen er eigenlijk 
aan meehelpen om te promoveren. En natuurlijk wil ik niemand te kort doen, maar omdat ik 
mijzelfwel een beetje ken, alvast bij deze mijn excuses. De tekortkoming ligt geheel bij rnij. 
In de tijd dat de universiteit de afdelingen steeds verder laat inkrimpen, was het we! erg luxe 
dat ik een van de weinige AIO was die werkelijk twee bureaus had. Hiervoor moest ik wei 
met mijn rugzakje op en neer pendelen tussen de afdelingen Inwendige Geneeskunde (I) in 
het Dijkzigt en Farmacologie in de EUR, maar dit heb ik er graag voor over gehad. Vooral in 
bet begin was mijn thuisbasis de afdeling Inwendige Geneeskunde waar ik grondig ingewerkt 
werd in de bepaling van de angiotensines. Bedan.k:t Sjors van Kats voor het optreden als 
persoonlijke coach, aile uitleg en geduldl Ook Rene de Bruin en Jeanette van Gool bedan.k:t 
voor alle keren dat jullie klaar stonden als ik weer eens iets nodig had. V erder Gooitzen en 
Angelique voor aile HPLC ondersteuning en Marjolein, Bianca en Evelien voor het 'uitlenen' 
van materiaal van de onderzoekskamer. Frans Derkx, Ton, Frans Boomsma, Jaap, Carla, 
Annemiek, Thomas, Marine! (nog even1jes en dan ben jij aan de beurt), Richard Zuiderent, 
Usha, Nicole en Edith bedan.k:t voor aile gezelligheid en gesprekken!discussies voor, na en 
tijdens de pauzes en tijdens de weekendjes weg. 
Aangezien er al een goede samenwerking was met de Experimentele Cardiologie, was de 
introductie van mij op deze afdeling zo gebeurd en heb ik gebruik mogen maken van hun 
expertise. Dan.kzij bet kundige team, te weten Sandra de Zeeuw, Jan van Meegen, Rene 
Stubeninsky en Rob van Bremen heb ik experimenten in varkens kunnen uitvoeren. In mijn 
dank hiervoor moet ik ook Dirk-Jan Duncker en prof. Pieter Verdouw betrekken, die het met 
een prettig kritische blik begeleid hebben. 
Na de bepalingen van de angiotensines in varkensweefsel, verschoven mijn activiteiten meer 
naar studies in ratten en geYsoleerde bloedvaten waardoor ik de thuisbasis Inwendige 
Genceskunde verruilde voor die van de Farmacologie. Hier heb ik mij gewaagd in het domein 
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van Jan Heiligers (het kra1je bier moet toch nog een keer komen) waar ik samen met Rene de 
Vries en 'mijn' allereerste (en tot nu toe aller!aatste) student Munesh onder het mom van 
wetenschap vele ratten vervroegd aan hun einde heb laten komen. 
Op deze afdeling waren ook de andere RAS-AIO's/postdocs aanwezig. Jasper, Beril, Mark en 
Wendy, ik heb het altijd erg prettig gevonden om sarnen met jullie onderzoek te doen aan 
hetzelfde onderwerp. In ieder geval begreep iemand mijn ideeen (of deed alsof) en daarnaast 
was het reizen naar congressen een stuk aangenamer. 
Na(ast) het werk moet er natuurlijk ook enige afleiding zijn. Dit werd zeker gevonden op de 
verscbillende karners waar ik gezeten heb. Eerst op Interne en daarna vooral in de 
'mannen'karner, met Richard van Veghel, Roeland en Wiro/Mark op Fannacologie. Er was 
altijd een goede mix tussen gezelligheid en werk, alhoewel, vooral door de komst van de 
waterkoker en tosti-ijzer, soms de rest van de Parma's onze kamer vervvarde met de 
koffiekamer. Verder was er natuurlijk de feestcommissie, waarbij de lol vooraf soms groter 
was dan de georganiseerde jaarlijkse labui1jes. Vooral het uitzetten van de fietstocht op de 
heetste dag van ongeveer 30 jaar zal me altijd heugen (of niet Mechteld?). Aile andere 
(ex-)Farma's wil ik niet ongenoernd Iaten: Antoinette, Peter, Ingrid, Sue, Erik, Pankaj, Edwin, 
Ria, Magda, Regien, Remon, Uday, Kapil, Wenxia, Andor, lnge, Hari, Anne, Marion, Larissa, 
Toos, Jeanette, Freek, Mariska, Emine, Saskia en Luc, met z'n allen maken jullie de afdeling 
F armacologie. 
Zonder bezielende begeleiding was dit proefschrift er echter nooit gekomen. Daarom wil ik 
mijn beide promotoren, prof. Schalekarnp en prof. Saxena, hartelijk danken voor aile input die 
ze de laatste jaren hebben geleverd. Maarten, ik was altijd weer verbaasd dat je, terwijl je mij 
niet direct begeleidde, altijd precies wist wat voor experimenten ik had gedaan en altijd de 
beste ideeen had om de resultaten te verklaren. Pramod, ik vond bet altijd erg prettig dat ik zo 
bij je binnen kon lopen om iets te vragen, vooral bij de microsfeermethode was dit erg handig. 
En natuurlijk Jan Danser, als mijn directe begeleider, ben ikje erg dankbaar voor alle tijd die 
je in mij gestoken hebt en het feit dat je het altijd weer positief inzag, zelfs als ik af en toe 
dacht dat een experiment totaal mislukt was. In de afgelopenjaren heb ik veel vanje geleerd, 
maar helaas is bet rood in mijn manuscripts nog steeds niet verdwenen. Verder moet ikje 
altijd erkentelijk blijven dat je meals AIO aangenomen hebt, ondanks dat ik aanvankelijk de 
baan afgeslagen had, maar na 5 minuten van gedachte veranderde. 
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Ook wil ik bij deze mijn ouders bedanken. Pap en roam, ik waardeer bet heel erg dat jullie mij 
altijd gestimuleerd hebben en de vrijheid hebben gegeven om te studeren wat ik wilde. 
Natuurlijk wil ik ook de rest van roijn (scboon)familie en roijn vrienden niet vergeten. Chris, 
in bet bijzonder bedankt voor je stimulerende interesse in roijn publicaties. Vaak bebbenjullie 
je afgevraagd wat ik nu eigenlijk precies voor werk deed. Ik hoop dat jullie na het lezen van 
dit boekje iets wijzer geworden zijn. Arnoud en Richard, alvast bedankt dat jullie mij als 
paranimfen moreel willen steunen tijdens roijn verdediging. 
Lieve Marinke, de ruimte is eigenlijk veel te klein om jou te bedanken. Zonder jouw steun en 
liefde op tijden dat ik bet promoveren zat was, zou het een stuk moeilijker geweest zijn. 
Daarom hier alvast een kus en de rest houd je tegoed. Een promotie wordt weleens vergeleken 
met een bevalling. Alhoewel ik denk dat bet laatste een stuk zwaarder is, zou ik niet weten 
wanneer ik zenuwachtiger ben. We zullen bet de volgende maand wei zien, wanneer we met 
z'n drietjes zijn. 
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